Ignite Creation Date:
2025-12-25 @ 2:12 AM
Ignite Modification Date:
2025-12-27 @ 7:55 AM
Study NCT ID:
NCT00413660
Status:
COMPLETED
Last Update Posted:
2013-01-18
First Post:
2006-12-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001172', 'term': 'Arthritis, Rheumatoid'}], 'ancestors': [{'id': 'D001168', 'term': 'Arthritis'}, {'id': 'D007592', 'term': 'Joint Diseases'}, {'id': 'D009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D012216', 'term': 'Rheumatic Diseases'}, {'id': 'D003240', 'term': 'Connective Tissue Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C479163', 'term': 'tofacitinib'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ClinicalTrials.gov_Inquiries@pfizer.com', 'phone': '1-800-718-1021', 'title': 'Pfizer ClinicalTrials.gov Call Center', 'organization': 'Pfizer, Inc.'}, 'certainAgreement': {'otherDetails': 'Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'description': 'The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.', 'eventGroups': [{'id': 'EG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily up to Week 24.', 'otherNumAtRisk': 49, 'otherNumAffected': 28, 'seriousNumAtRisk': 49, 'seriousNumAffected': 1}, {'id': 'EG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'CP-690,550 1 mg tablet orally twice daily up to Week 12 followed by CP-690,550 5 mg tablet orally twice up to Week 24.', 'otherNumAtRisk': 21, 'otherNumAffected': 14, 'seriousNumAtRisk': 21, 'seriousNumAffected': 1}, {'id': 'EG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily up to Week 24.', 'otherNumAtRisk': 55, 'otherNumAffected': 30, 'seriousNumAtRisk': 55, 'seriousNumAffected': 4}, {'id': 'EG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'CP-690,550 3 mg tablet orally twice daily up to Week 12 followed by CP-690,550 5 mg tablet orally twice up to Week 24.', 'otherNumAtRisk': 13, 'otherNumAffected': 10, 'seriousNumAtRisk': 13, 'seriousNumAffected': 0}, {'id': 'EG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily up to Week 24.', 'otherNumAtRisk': 71, 'otherNumAffected': 40, 'seriousNumAtRisk': 71, 'seriousNumAffected': 4}, {'id': 'EG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily up to Week 24.', 'otherNumAtRisk': 74, 'otherNumAffected': 45, 'seriousNumAtRisk': 74, 'seriousNumAffected': 1}, {'id': 'EG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily up to Week 24.', 'otherNumAtRisk': 75, 'otherNumAffected': 46, 'seriousNumAtRisk': 75, 'seriousNumAffected': 6}, {'id': 'EG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose up to Week 24.', 'otherNumAtRisk': 67, 'otherNumAffected': 37, 'seriousNumAtRisk': 67, 'seriousNumAffected': 4}, {'id': 'EG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose up to Week 12 followed by CP-690,550 5 mg tablet orally twice daily up to Week 24.', 'otherNumAtRisk': 13, 'otherNumAffected': 6, 'seriousNumAtRisk': 13, 'seriousNumAffected': 0}, {'id': 'EG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily up to Week 24.', 'otherNumAtRisk': 51, 'otherNumAffected': 29, 'seriousNumAtRisk': 51, 'seriousNumAffected': 0}, {'id': 'EG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Matching placebo tablet orally twice daily up to Week 12 followed by CP-690,550 5 mg tablet orally twice up to Week 24.', 'otherNumAtRisk': 18, 'otherNumAffected': 12, 'seriousNumAtRisk': 18, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Lymphadenitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Bradycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Extrasystoles', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Palpitations', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Supraventricular extrasystoles', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Tachycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Tinnitus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Vertigo', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Cataract', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Conjunctivitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Vision blurred', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Visual disturbance', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Xerophthalmia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Abdominal discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Abdominal distension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Abdominal pain upper', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 3}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Abdominal tenderness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Breath odour', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 9}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Dry mouth', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Dyspepsia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Flatulence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Gastritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Gastrooesophageal reflux disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 5}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 4}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Rectal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Stomach discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Toothache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 4}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Chest discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Irritability', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Mucosal inflammation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Oedema peripheral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Allergy to arthropod bite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 1}], 'organSystem': 'Immune system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Bronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Ear infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Erysipelas', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 4}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Gastroenteritis viral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Herpes simplex', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Herpes zoster', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Influenza', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 5}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Laryngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 5}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 6}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 4}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 3}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Onychomycosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Oral fungal infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Oral herpes', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Parainfluenzae virus infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Pharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Pharyngitis streptococcal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Pharyngotonsillitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Pulpitis dental', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Rhinitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Sinusitis bacterial', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Tinea cruris', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Tinea pedis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Tonsillitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Tracheitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 5}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 5}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 4}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 5}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 4}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 5}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 6}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Viral infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Vulvovaginal mycotic infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Animal bite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Excoriation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Fall', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Fibula fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Foot fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Joint sprain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Muscle strain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Alanine aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 5}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Aspartate aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 5}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Blood cholesterol increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Blood creatinine increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Electrocardiogram ST-T change', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Electrocardiogram T wave abnormal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Electrocardiogram abnormal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Haematocrit decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Haemoglobin decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Hepatic enzyme increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Transaminases increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Weight decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Weight increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Anorexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Glucose tolerance impaired', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Hypercholesterolaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 4}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Hyperlipidaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Hypertriglyceridaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Hyperuricaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Bone pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Fibromyalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Muscle spasms', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Musculoskeletal chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Osteochondrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Osteopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Pain in extremity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Rheumatoid arthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Synovial cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Tendonitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Burning sensation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Cluster headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 4}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 9}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 3}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Hypersomnia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Hypoaesthesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Paraesthesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Sciatica', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Sinus headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Somnolence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Tension headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Anxiety', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Emotional disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Insomnia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Nervousness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Nightmare', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Sleep disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Leukocyturia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Nephrolithiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Pyuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Genital discharge', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Ovarian cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Allergic sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Asthma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 6}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Dyspnoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Epistaxis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Nasal congestion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Nasal mucosal disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Pharyngeal inflammation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Pharyngolaryngeal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Pulmonary congestion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Respiratory disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Rhinitis allergic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Rhinorrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Sinus congestion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Wheezing', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Acne', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Alopecia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Angioedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Dermatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Ecchymosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Eczema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Erythema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Intertrigo', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Palpable purpura', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Rash', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 4}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Rash generalised', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Rash papular', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Urticaria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Hot flush', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Venous stasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}], 'seriousEvents': [{'term': 'Atrial fibrillation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Cardiac failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Cardiac failure congestive', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Blindness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Food poisoning', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Gastric ulcer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Gastrooesophageal reflux disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Stomatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Chest discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Lower respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Ankle fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Melanocytic naevus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Migraine', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Dissociative disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Uterine haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Respiratory failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Implantable defibrillator insertion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Surgical and medical procedures', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}, {'term': 'Circulatory collapse', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 51, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.0'}], 'frequencyThreshold': '2'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '68', 'groupId': 'OG001'}, {'value': '71', 'groupId': 'OG002'}, {'value': '74', 'groupId': 'OG003'}, {'value': '75', 'groupId': 'OG004'}, {'value': '80', 'groupId': 'OG005'}, {'value': '69', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG006', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '47.14', 'groupId': 'OG000'}, {'value': '55.88', 'groupId': 'OG001'}, {'value': '56.34', 'groupId': 'OG002'}, {'value': '58.11', 'groupId': 'OG003'}, {'value': '56.00', 'groupId': 'OG004'}, {'value': '56.25', 'groupId': 'OG005'}, {'value': '36.23', 'groupId': 'OG006'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 12', 'description': 'ACR20 response: \\>= 20% improvement in tender joints count (TJC); \\>= 20% improvement in swollen joints count (SJC); and \\>= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-Reactive Protein (CRP).', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study treatment. Missing values were imputed using Baseline Observation Carried Forward (BOCF).'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '68', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '71', 'groupId': 'OG004'}, {'value': '74', 'groupId': 'OG005'}, {'value': '75', 'groupId': 'OG006'}, {'value': '80', 'groupId': 'OG007'}, {'value': '13', 'groupId': 'OG008'}, {'value': '69', 'groupId': 'OG009'}, {'value': '18', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Week 2 (n=70,0,68,0,71,74,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '21.43', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '36.76', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '30.99', 'groupId': 'OG004'}, {'value': '31.08', 'groupId': 'OG005'}, {'value': '40.00', 'groupId': 'OG006'}, {'value': '33.75', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '15.94', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 4 (n=70,0,68,0,71,74,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '37.14', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '45.59', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '46.48', 'groupId': 'OG004'}, {'value': '45.95', 'groupId': 'OG005'}, {'value': '54.67', 'groupId': 'OG006'}, {'value': '51.25', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '24.64', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 6 (n=70,0,68,0,71,74,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '44.29', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '54.41', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '57.75', 'groupId': 'OG004'}, {'value': '55.41', 'groupId': 'OG005'}, {'value': '56.00', 'groupId': 'OG006'}, {'value': '50.00', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '37.68', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 8 (n=70,0,68,0,71,74,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '50.00', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '54.41', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '54.93', 'groupId': 'OG004'}, {'value': '56.76', 'groupId': 'OG005'}, {'value': '64.00', 'groupId': 'OG006'}, {'value': '56.25', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '33.33', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 16 (n=49,21,55,13,71,74,75,67,13,51,18)', 'categories': [{'measurements': [{'value': '63.3', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '60.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '53.5', 'groupId': 'OG004'}, {'value': '64.9', 'groupId': 'OG005'}, {'value': '62.7', 'groupId': 'OG006'}, {'value': '64.2', 'groupId': 'OG007'}, {'value': '0.0', 'groupId': 'OG008'}, {'value': '43.1', 'groupId': 'OG009'}, {'value': '0.0', 'groupId': 'OG010'}]}]}, {'title': 'Week 20 (n=49,21,55,13,71,74,75,67,13,51,18)', 'categories': [{'measurements': [{'value': '59.2', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '67.3', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '57.7', 'groupId': 'OG004'}, {'value': '62.2', 'groupId': 'OG005'}, {'value': '61.3', 'groupId': 'OG006'}, {'value': '64.2', 'groupId': 'OG007'}, {'value': '0.0', 'groupId': 'OG008'}, {'value': '47.1', 'groupId': 'OG009'}, {'value': '0.0', 'groupId': 'OG010'}]}]}, {'title': 'Week 24 (n=49,21,55,13,71,74,75,67,13,51,18)', 'categories': [{'measurements': [{'value': '59.2', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '65.5', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '59.2', 'groupId': 'OG004'}, {'value': '66.2', 'groupId': 'OG005'}, {'value': '65.3', 'groupId': 'OG006'}, {'value': '62.7', 'groupId': 'OG007'}, {'value': '0.0', 'groupId': 'OG008'}, {'value': '47.1', 'groupId': 'OG009'}, {'value': '0.0', 'groupId': 'OG010'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 2, 4, 6, 8, 16, 20, 24/Early Termination (ET)', 'description': 'ACR20 response: \\>= 20% improvement in TJC; \\>= 20% improvement in SJC; and \\>= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Missing values were imputed using BOCF. Here "n" is number of participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '68', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '71', 'groupId': 'OG004'}, {'value': '74', 'groupId': 'OG005'}, {'value': '75', 'groupId': 'OG006'}, {'value': '80', 'groupId': 'OG007'}, {'value': '13', 'groupId': 'OG008'}, {'value': '69', 'groupId': 'OG009'}, {'value': '18', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Week 2 (n=70,0,68,0,71,74,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '1.43', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '5.88', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '5.63', 'groupId': 'OG004'}, {'value': '4.05', 'groupId': 'OG005'}, {'value': '17.33', 'groupId': 'OG006'}, {'value': '15.00', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '2.90', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 4 (n=70,0,68,0,71,74,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '4.29', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '16.18', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '11.27', 'groupId': 'OG004'}, {'value': '20.27', 'groupId': 'OG005'}, {'value': '26.67', 'groupId': 'OG006'}, {'value': '25.00', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '2.90', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 6 (n=70,0,68,0,71,74,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '10.00', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '29.41', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '30.99', 'groupId': 'OG004'}, {'value': '27.03', 'groupId': 'OG005'}, {'value': '32.00', 'groupId': 'OG006'}, {'value': '27.50', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '8.70', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 8 (n=70,0,68,0,71,74,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '17.14', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '32.35', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '32.39', 'groupId': 'OG004'}, {'value': '28.38', 'groupId': 'OG005'}, {'value': '41.33', 'groupId': 'OG006'}, {'value': '32.50', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '17.39', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12 (n=70,0,68,0,71,74,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '22.86', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '29.41', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '36.62', 'groupId': 'OG004'}, {'value': '28.38', 'groupId': 'OG005'}, {'value': '44.00', 'groupId': 'OG006'}, {'value': '36.25', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '17.39', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 16 (n=49,21,55,13,71,74,75,67,13,51,18)', 'categories': [{'measurements': [{'value': '38.8', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '43.6', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '38.0', 'groupId': 'OG004'}, {'value': '36.5', 'groupId': 'OG005'}, {'value': '40.0', 'groupId': 'OG006'}, {'value': '41.8', 'groupId': 'OG007'}, {'value': '0.0', 'groupId': 'OG008'}, {'value': '21.6', 'groupId': 'OG009'}, {'value': '0.0', 'groupId': 'OG010'}]}]}, {'title': 'Week 20 (n=49,21,55,13,71,74,75,67,13,51,18)', 'categories': [{'measurements': [{'value': '38.8', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '45.5', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '38.0', 'groupId': 'OG004'}, {'value': '40.5', 'groupId': 'OG005'}, {'value': '48.0', 'groupId': 'OG006'}, {'value': '47.8', 'groupId': 'OG007'}, {'value': '0.0', 'groupId': 'OG008'}, {'value': '31.4', 'groupId': 'OG009'}, {'value': '0.0', 'groupId': 'OG010'}]}]}, {'title': 'Week 24 (n=49,21,55,13,71,74,75,67,13,51,18)', 'categories': [{'measurements': [{'value': '44.9', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '34.5', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '39.4', 'groupId': 'OG004'}, {'value': '39.2', 'groupId': 'OG005'}, {'value': '46.7', 'groupId': 'OG006'}, {'value': '46.3', 'groupId': 'OG007'}, {'value': '0.0', 'groupId': 'OG008'}, {'value': '31.4', 'groupId': 'OG009'}, {'value': '0.0', 'groupId': 'OG010'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'ACR50 response: \\>= 50% improvement in TJC or SJC and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Missing values were imputed using BOCF. Here "n" is number of participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '68', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '71', 'groupId': 'OG004'}, {'value': '74', 'groupId': 'OG005'}, {'value': '75', 'groupId': 'OG006'}, {'value': '80', 'groupId': 'OG007'}, {'value': '13', 'groupId': 'OG008'}, {'value': '69', 'groupId': 'OG009'}, {'value': '18', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Week 2 (n=70,0,68,0,71,74,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '1.43', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '1.47', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '1.41', 'groupId': 'OG004'}, {'value': '1.35', 'groupId': 'OG005'}, {'value': '6.67', 'groupId': 'OG006'}, {'value': '2.50', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '0.00', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 4 (n=70,0,68,0,71,74,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '2.86', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '7.35', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '0.00', 'groupId': 'OG004'}, {'value': '14.86', 'groupId': 'OG005'}, {'value': '13.33', 'groupId': 'OG006'}, {'value': '12.50', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '1.45', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 6 (n=70,0,68,0,71,74,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '1.43', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '13.24', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '16.90', 'groupId': 'OG004'}, {'value': '9.46', 'groupId': 'OG005'}, {'value': '16.00', 'groupId': 'OG006'}, {'value': '12.50', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '4.35', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 8 (n=70,0,68,0,71,74,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '8.57', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '14.71', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '11.27', 'groupId': 'OG004'}, {'value': '16.22', 'groupId': 'OG005'}, {'value': '16.00', 'groupId': 'OG006'}, {'value': '17.50', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '5.80', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12 (n=70,0,68,0,71,74,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '4.29', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '20.59', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '18.31', 'groupId': 'OG004'}, {'value': '12.16', 'groupId': 'OG005'}, {'value': '24.00', 'groupId': 'OG006'}, {'value': '23.75', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '5.80', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 16 (n=49,21,55,13,71,74,75,67,13,51,18)', 'categories': [{'measurements': [{'value': '16.3', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '21.8', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '18.3', 'groupId': 'OG004'}, {'value': '18.9', 'groupId': 'OG005'}, {'value': '24.0', 'groupId': 'OG006'}, {'value': '22.4', 'groupId': 'OG007'}, {'value': '0.0', 'groupId': 'OG008'}, {'value': '9.8', 'groupId': 'OG009'}, {'value': '0.0', 'groupId': 'OG010'}]}]}, {'title': 'Week 20 (n=49,21,55,13,71,74,75,67,13,51,18)', 'categories': [{'measurements': [{'value': '20.4', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '29.1', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '23.9', 'groupId': 'OG004'}, {'value': '24.3', 'groupId': 'OG005'}, {'value': '28.0', 'groupId': 'OG006'}, {'value': '28.4', 'groupId': 'OG007'}, {'value': '0.0', 'groupId': 'OG008'}, {'value': '13.7', 'groupId': 'OG009'}, {'value': '0.0', 'groupId': 'OG010'}]}]}, {'title': 'Week 24 (n=49,21,55,13,71,74,75,67,13,51,18)', 'categories': [{'measurements': [{'value': '28.6', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '23.6', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '21.1', 'groupId': 'OG004'}, {'value': '18.9', 'groupId': 'OG005'}, {'value': '32.0', 'groupId': 'OG006'}, {'value': '28.4', 'groupId': 'OG007'}, {'value': '0.0', 'groupId': 'OG008'}, {'value': '9.8', 'groupId': 'OG009'}, {'value': '0.0', 'groupId': 'OG010'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'ACR70 response: \\>= 70% improvement in TJC or SJC and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Missing values were imputed using BOCF. Here "n" is number of participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '68', 'groupId': 'OG001'}, {'value': '71', 'groupId': 'OG002'}, {'value': '74', 'groupId': 'OG003'}, {'value': '75', 'groupId': 'OG004'}, {'value': '80', 'groupId': 'OG005'}, {'value': '69', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG006', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}], 'classes': [{'title': 'Week 2', 'categories': [{'measurements': [{'value': '-14.07', 'spread': '247.36', 'groupId': 'OG000'}, {'value': '22.16', 'spread': '243.19', 'groupId': 'OG001'}, {'value': '4.47', 'spread': '319.92', 'groupId': 'OG002'}, {'value': '-21.34', 'spread': '661.05', 'groupId': 'OG003'}, {'value': '88.72', 'spread': '287.91', 'groupId': 'OG004'}, {'value': '36.55', 'spread': '267.26', 'groupId': 'OG005'}, {'value': '-113.31', 'spread': '429.17', 'groupId': 'OG006'}]}]}, {'title': 'Week 4', 'categories': [{'measurements': [{'value': '61.66', 'spread': '622.43', 'groupId': 'OG000'}, {'value': '163.40', 'spread': '659.05', 'groupId': 'OG001'}, {'value': '92.24', 'spread': '919.49', 'groupId': 'OG002'}, {'value': '7.29', 'spread': '2038.26', 'groupId': 'OG003'}, {'value': '341.52', 'spread': '820.16', 'groupId': 'OG004'}, {'value': '170.23', 'spread': '825.49', 'groupId': 'OG005'}, {'value': '-296.38', 'spread': '1270.69', 'groupId': 'OG006'}]}]}, {'title': 'Week 6', 'categories': [{'measurements': [{'value': '244.11', 'spread': '948.25', 'groupId': 'OG000'}, {'value': '442.29', 'spread': '1087.57', 'groupId': 'OG001'}, {'value': '348.96', 'spread': '1446.07', 'groupId': 'OG002'}, {'value': '111.83', 'spread': '3626.48', 'groupId': 'OG003'}, {'value': '716.69', 'spread': '1285.36', 'groupId': 'OG004'}, {'value': '402.21', 'spread': '1428.69', 'groupId': 'OG005'}, {'value': '-453.18', 'spread': '2265.12', 'groupId': 'OG006'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '464.42', 'spread': '1424.59', 'groupId': 'OG000'}, {'value': '772.65', 'spread': '1594.84', 'groupId': 'OG001'}, {'value': '693.90', 'spread': '1952.07', 'groupId': 'OG002'}, {'value': '239.54', 'spread': '5389.58', 'groupId': 'OG003'}, {'value': '1154.14', 'spread': '1733.13', 'groupId': 'OG004'}, {'value': '725.67', 'spread': '1954.96', 'groupId': 'OG005'}, {'value': '-571.99', 'spread': '3310.17', 'groupId': 'OG006'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '995.34', 'spread': '2349.99', 'groupId': 'OG000'}, {'value': '1511.40', 'spread': '2711.76', 'groupId': 'OG001'}, {'value': '1420.20', 'spread': '3284.51', 'groupId': 'OG002'}, {'value': '588.45', 'spread': '8969.29', 'groupId': 'OG003'}, {'value': '1974.18', 'spread': '3231.70', 'groupId': 'OG004'}, {'value': '1504.58', 'spread': '2979.75', 'groupId': 'OG005'}, {'value': '-755.22', 'spread': '5107.45', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline up to Week 2, 4, 6, 8, 12', 'description': "ACR-n: calculated for each participant by taking the lowest percentage improvement in (1) SJC or (2) TJC or (3) the median of the remaining 5 components of the ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening. The area under the curve (AUC) for ACR-n is the measure of the area under the curve of the mean change from baseline in ACR-n. The trapezoidal rule was used to compute the AUC.", 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Missing values were imputed using Last Observation Carried Forward (LOCF).'}, {'type': 'SECONDARY', 'title': 'Tender Joints Count (TJC)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '68', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '71', 'groupId': 'OG004'}, {'value': '74', 'groupId': 'OG005'}, {'value': '75', 'groupId': 'OG006'}, {'value': '80', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '69', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Baseline (n=70,0,68,0,71,74,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '23.64', 'spread': '11.60', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '22.79', 'spread': '10.57', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '21.46', 'spread': '12.95', 'groupId': 'OG004'}, {'value': '24.84', 'spread': '12.51', 'groupId': 'OG005'}, {'value': '23.68', 'spread': '12.71', 'groupId': 'OG006'}, {'value': '23.11', 'spread': '12.67', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '21.59', 'spread': '13.18', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2 (n=68,0,68,0,68,73,73,79,0,66,0)', 'categories': [{'measurements': [{'value': '18.62', 'spread': '12.09', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '17.71', 'spread': '11.87', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '15.56', 'spread': '10.44', 'groupId': 'OG004'}, {'value': '17.34', 'spread': '12.13', 'groupId': 'OG005'}, {'value': '16.32', 'spread': '13.18', 'groupId': 'OG006'}, {'value': '15.33', 'spread': '12.59', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '18.86', 'spread': '13.00', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 4 (n=68,0,65,0,67,70,72,76,0,66,0)', 'categories': [{'measurements': [{'value': '15.01', 'spread': '11.19', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '12.80', 'spread': '10.36', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '13.06', 'spread': '11.59', 'groupId': 'OG004'}, {'value': '14.01', 'spread': '14.73', 'groupId': 'OG005'}, {'value': '13.00', 'spread': '12.48', 'groupId': 'OG006'}, {'value': '13.75', 'spread': '13.08', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '16.17', 'spread': '12.36', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 6 (n=66,0,65,0,69,71,72,74,0,62,0)', 'categories': [{'measurements': [{'value': '14.48', 'spread': '12.18', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '11.12', 'spread': '9.56', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '10.23', 'spread': '10.44', 'groupId': 'OG004'}, {'value': '13.55', 'spread': '14.38', 'groupId': 'OG005'}, {'value': '11.51', 'spread': '12.67', 'groupId': 'OG006'}, {'value': '13.22', 'spread': '13.25', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '14.74', 'spread': '13.86', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 8 (n=66,0,62,0,66,67,70,73,0,61,0)', 'categories': [{'measurements': [{'value': '14.24', 'spread': '12.50', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '10.18', 'spread': '10.30', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '9.82', 'spread': '11.08', 'groupId': 'OG004'}, {'value': '12.22', 'spread': '13.75', 'groupId': 'OG005'}, {'value': '9.49', 'spread': '11.71', 'groupId': 'OG006'}, {'value': '11.15', 'spread': '13.76', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '13.57', 'spread': '14.16', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12 (n=64,0,59,0,64,66,66,70,0,61,0)', 'categories': [{'measurements': [{'value': '12.84', 'spread': '12.79', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '8.83', 'spread': '9.61', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '10.09', 'spread': '11.65', 'groupId': 'OG004'}, {'value': '10.88', 'spread': '12.79', 'groupId': 'OG005'}, {'value': '10.18', 'spread': '12.65', 'groupId': 'OG006'}, {'value': '11.27', 'spread': '13.68', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '13.77', 'spread': '14.84', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 16 (n=42,21,45,13,58,66,61,55,12,37,16)', 'categories': [{'measurements': [{'value': '8.07', 'spread': '9.11', 'groupId': 'OG000'}, {'value': '19.33', 'spread': '15.70', 'groupId': 'OG001'}, {'value': '6.02', 'spread': '7.97', 'groupId': 'OG002'}, {'value': '19.15', 'spread': '16.42', 'groupId': 'OG003'}, {'value': '8.64', 'spread': '12.25', 'groupId': 'OG004'}, {'value': '9.77', 'spread': '12.49', 'groupId': 'OG005'}, {'value': '8.39', 'spread': '11.32', 'groupId': 'OG006'}, {'value': '7.07', 'spread': '8.86', 'groupId': 'OG007'}, {'value': '26.25', 'spread': '19.07', 'groupId': 'OG008'}, {'value': '8.51', 'spread': '7.25', 'groupId': 'OG009'}, {'value': '15.56', 'spread': '18.52', 'groupId': 'OG010'}]}]}, {'title': 'Week 20 (n=39,21,44,13,57,66,59,55,12,37,17)', 'categories': [{'measurements': [{'value': '8.08', 'spread': '11.06', 'groupId': 'OG000'}, {'value': '13.76', 'spread': '12.02', 'groupId': 'OG001'}, {'value': '5.32', 'spread': '6.35', 'groupId': 'OG002'}, {'value': '15.00', 'spread': '11.47', 'groupId': 'OG003'}, {'value': '7.16', 'spread': '9.91', 'groupId': 'OG004'}, {'value': '8.27', 'spread': '11.32', 'groupId': 'OG005'}, {'value': '6.98', 'spread': '9.96', 'groupId': 'OG006'}, {'value': '6.51', 'spread': '10.55', 'groupId': 'OG007'}, {'value': '23.00', 'spread': '16.59', 'groupId': 'OG008'}, {'value': '7.62', 'spread': '7.26', 'groupId': 'OG009'}, {'value': '15.24', 'spread': '17.68', 'groupId': 'OG010'}]}]}, {'title': 'Week 24 (n=40,20,44,13,55,64,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '7.45', 'spread': '10.88', 'groupId': 'OG000'}, {'value': '14.80', 'spread': '14.09', 'groupId': 'OG001'}, {'value': '5.52', 'spread': '5.65', 'groupId': 'OG002'}, {'value': '13.92', 'spread': '9.93', 'groupId': 'OG003'}, {'value': '6.85', 'spread': '9.51', 'groupId': 'OG004'}, {'value': '8.20', 'spread': '9.94', 'groupId': 'OG005'}, {'value': '6.37', 'spread': '8.72', 'groupId': 'OG006'}, {'value': '5.87', 'spread': '7.68', 'groupId': 'OG007'}, {'value': '21.67', 'spread': '13.69', 'groupId': 'OG008'}, {'value': '5.33', 'spread': '5.74', 'groupId': 'OG009'}, {'value': '15.88', 'spread': '17.46', 'groupId': 'OG010'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.', 'unitOfMeasure': 'tender joints', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET', 'denoms': [{'units': 'Participants', 'counts': [{'value': '68', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '68', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '68', 'groupId': 'OG004'}, {'value': '73', 'groupId': 'OG005'}, {'value': '73', 'groupId': 'OG006'}, {'value': '79', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '66', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Week 2 (n=68,0,68,0,68,73,73,79,0,66,0)', 'categories': [{'measurements': [{'value': '-4.68', 'spread': '7.26', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-5.09', 'spread': '9.91', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-6.06', 'spread': '9.36', 'groupId': 'OG004'}, {'value': '-7.62', 'spread': '8.48', 'groupId': 'OG005'}, {'value': '-7.68', 'spread': '10.20', 'groupId': 'OG006'}, {'value': '-7.78', 'spread': '9.67', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-2.27', 'spread': '7.50', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 4 (n=68,0,65,0,67,70,72,76,0,66,0)', 'categories': [{'measurements': [{'value': '-8.28', 'spread': '8.68', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-10.26', 'spread': '9.63', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-8.42', 'spread': '9.73', 'groupId': 'OG004'}, {'value': '-10.77', 'spread': '10.25', 'groupId': 'OG005'}, {'value': '-10.90', 'spread': '11.13', 'groupId': 'OG006'}, {'value': '-9.59', 'spread': '10.42', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-5.03', 'spread': '10.05', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 6 (n=66,0,65,0,69,71,72,74,0,62,0)', 'categories': [{'measurements': [{'value': '-8.86', 'spread': '10.26', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-11.78', 'spread': '10.82', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-11.01', 'spread': '9.64', 'groupId': 'OG004'}, {'value': '-11.07', 'spread': '9.94', 'groupId': 'OG005'}, {'value': '-12.14', 'spread': '10.07', 'groupId': 'OG006'}, {'value': '-10.58', 'spread': '9.60', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-6.69', 'spread': '11.68', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 8 (n=66,0,62,0,66,67,70,73,0,61,0)', 'categories': [{'measurements': [{'value': '-9.08', 'spread': '10.79', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-12.69', 'spread': '11.57', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-11.50', 'spread': '9.06', 'groupId': 'OG004'}, {'value': '-11.93', 'spread': '10.92', 'groupId': 'OG005'}, {'value': '-13.76', 'spread': '11.73', 'groupId': 'OG006'}, {'value': '-12.26', 'spread': '9.96', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-7.03', 'spread': '13.26', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12 (n=64,0,59,0,64,66,66,70,0,61,0)', 'categories': [{'measurements': [{'value': '-10.67', 'spread': '10.73', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-14.00', 'spread': '12.56', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-10.88', 'spread': '11.01', 'groupId': 'OG004'}, {'value': '-13.47', 'spread': '9.96', 'groupId': 'OG005'}, {'value': '-14.24', 'spread': '11.80', 'groupId': 'OG006'}, {'value': '-12.77', 'spread': '10.92', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-6.84', 'spread': '12.84', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 16 (n=42,21,45,13,58,66,61,55,12,37,16)', 'categories': [{'measurements': [{'value': '-14.05', 'spread': '9.97', 'groupId': 'OG000'}, {'value': '-6.81', 'spread': '7.90', 'groupId': 'OG001'}, {'value': '-17.44', 'spread': '10.54', 'groupId': 'OG002'}, {'value': '-1.00', 'spread': '14.29', 'groupId': 'OG003'}, {'value': '-12.93', 'spread': '12.63', 'groupId': 'OG004'}, {'value': '-14.58', 'spread': '11.19', 'groupId': 'OG005'}, {'value': '-15.05', 'spread': '11.31', 'groupId': 'OG006'}, {'value': '-15.65', 'spread': '9.29', 'groupId': 'OG007'}, {'value': '-2.33', 'spread': '15.69', 'groupId': 'OG008'}, {'value': '-10.16', 'spread': '9.92', 'groupId': 'OG009'}, {'value': '-8.06', 'spread': '10.88', 'groupId': 'OG010'}]}]}, {'title': 'Week 20 (n=39,21,44,13,57,66,59,55,12,37,17)', 'categories': [{'measurements': [{'value': '-13.64', 'spread': '10.63', 'groupId': 'OG000'}, {'value': '-12.38', 'spread': '10.61', 'groupId': 'OG001'}, {'value': '-18.36', 'spread': '9.52', 'groupId': 'OG002'}, {'value': '-5.15', 'spread': '11.07', 'groupId': 'OG003'}, {'value': '-14.58', 'spread': '11.94', 'groupId': 'OG004'}, {'value': '-16.08', 'spread': '10.43', 'groupId': 'OG005'}, {'value': '-16.64', 'spread': '10.73', 'groupId': 'OG006'}, {'value': '-15.67', 'spread': '9.33', 'groupId': 'OG007'}, {'value': '-5.58', 'spread': '11.32', 'groupId': 'OG008'}, {'value': '-11.05', 'spread': '11.86', 'groupId': 'OG009'}, {'value': '-8.24', 'spread': '11.19', 'groupId': 'OG010'}]}]}, {'title': 'Week 24 (n=40,21,44,13,55,64,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '-14.53', 'spread': '10.83', 'groupId': 'OG000'}, {'value': '-10.40', 'spread': '11.27', 'groupId': 'OG001'}, {'value': '-18.16', 'spread': '9.82', 'groupId': 'OG002'}, {'value': '-6.23', 'spread': '10.54', 'groupId': 'OG003'}, {'value': '-14.93', 'spread': '11.72', 'groupId': 'OG004'}, {'value': '-16.36', 'spread': '9.39', 'groupId': 'OG005'}, {'value': '-17.03', 'spread': '10.39', 'groupId': 'OG006'}, {'value': '-16.36', 'spread': '10.60', 'groupId': 'OG007'}, {'value': '-6.92', 'spread': '12.62', 'groupId': 'OG008'}, {'value': '-13.17', 'spread': '9.90', 'groupId': 'OG009'}, {'value': '-7.59', 'spread': '12.39', 'groupId': 'OG010'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from baseline indicates an improvement.', 'unitOfMeasure': 'tender joints', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Swollen Joints Count (SJC)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '68', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '71', 'groupId': 'OG004'}, {'value': '74', 'groupId': 'OG005'}, {'value': '75', 'groupId': 'OG006'}, {'value': '80', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '69', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Baseline (n=70,0,68,0,71,74,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '16.51', 'spread': '8.24', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '15.68', 'spread': '8.56', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '14.06', 'spread': '7.44', 'groupId': 'OG004'}, {'value': '14.74', 'spread': '7.46', 'groupId': 'OG005'}, {'value': '15.33', 'spread': '7.02', 'groupId': 'OG006'}, {'value': '15.21', 'spread': '8.04', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '15.72', 'spread': '8.83', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2 (n=68,0,68,0,68,73,73,79,0,66,0)', 'categories': [{'measurements': [{'value': '12.62', 'spread': '7.81', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '10.97', 'spread': '9.02', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '9.51', 'spread': '6.30', 'groupId': 'OG004'}, {'value': '10.14', 'spread': '7.92', 'groupId': 'OG005'}, {'value': '10.07', 'spread': '7.29', 'groupId': 'OG006'}, {'value': '10.14', 'spread': '6.26', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '13.41', 'spread': '9.47', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 4 (n=68,0,65,0,67,70,72,76,0,66,0)', 'categories': [{'measurements': [{'value': '9.85', 'spread': '7.74', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '8.58', 'spread': '8.20', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '8.01', 'spread': '7.45', 'groupId': 'OG004'}, {'value': '7.53', 'spread': '6.98', 'groupId': 'OG005'}, {'value': '7.85', 'spread': '6.70', 'groupId': 'OG006'}, {'value': '8.61', 'spread': '7.16', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '11.11', 'spread': '8.58', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 6 (n=66,0,65,0,69,71,72,74,0,62,0)', 'categories': [{'measurements': [{'value': '8.77', 'spread': '6.34', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '7.23', 'spread': '7.28', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '6.22', 'spread': '6.00', 'groupId': 'OG004'}, {'value': '7.10', 'spread': '7.62', 'groupId': 'OG005'}, {'value': '6.60', 'spread': '6.31', 'groupId': 'OG006'}, {'value': '7.66', 'spread': '7.43', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '10.39', 'spread': '9.24', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 8 (n=66,0,62,0,66,67,70,73,0,61,0)', 'categories': [{'measurements': [{'value': '8.20', 'spread': '7.84', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '6.63', 'spread': '7.63', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '5.35', 'spread': '5.03', 'groupId': 'OG004'}, {'value': '6.78', 'spread': '7.43', 'groupId': 'OG005'}, {'value': '6.01', 'spread': '6.22', 'groupId': 'OG006'}, {'value': '7.22', 'spread': '8.60', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '8.16', 'spread': '8.02', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12 (n=64,0,59,0,64,66,66,70,0,61,0)', 'categories': [{'measurements': [{'value': '8.31', 'spread': '8.41', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '5.36', 'spread': '6.64', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '6.13', 'spread': '6.82', 'groupId': 'OG004'}, {'value': '5.50', 'spread': '5.84', 'groupId': 'OG005'}, {'value': '4.85', 'spread': '6.04', 'groupId': 'OG006'}, {'value': '6.80', 'spread': '8.87', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '8.79', 'spread': '9.10', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 16 (n=42,21,45,13,58,66,61,55,12,37,16)', 'categories': [{'measurements': [{'value': '5.83', 'spread': '7.43', 'groupId': 'OG000'}, {'value': '8.90', 'spread': '7.55', 'groupId': 'OG001'}, {'value': '3.49', 'spread': '3.78', 'groupId': 'OG002'}, {'value': '10.00', 'spread': '10.51', 'groupId': 'OG003'}, {'value': '3.84', 'spread': '4.40', 'groupId': 'OG004'}, {'value': '4.74', 'spread': '5.64', 'groupId': 'OG005'}, {'value': '4.26', 'spread': '5.40', 'groupId': 'OG006'}, {'value': '3.58', 'spread': '3.54', 'groupId': 'OG007'}, {'value': '14.50', 'spread': '12.99', 'groupId': 'OG008'}, {'value': '5.97', 'spread': '5.98', 'groupId': 'OG009'}, {'value': '8.63', 'spread': '7.70', 'groupId': 'OG010'}]}]}, {'title': 'Week 20 (n=39,21,44,13,57,66,59,55,12,37,17)', 'categories': [{'measurements': [{'value': '4.95', 'spread': '7.82', 'groupId': 'OG000'}, {'value': '7.33', 'spread': '8.75', 'groupId': 'OG001'}, {'value': '3.36', 'spread': '5.19', 'groupId': 'OG002'}, {'value': '8.54', 'spread': '9.85', 'groupId': 'OG003'}, {'value': '3.95', 'spread': '5.80', 'groupId': 'OG004'}, {'value': '4.21', 'spread': '5.59', 'groupId': 'OG005'}, {'value': '3.27', 'spread': '4.02', 'groupId': 'OG006'}, {'value': '3.31', 'spread': '4.19', 'groupId': 'OG007'}, {'value': '12.25', 'spread': '8.25', 'groupId': 'OG008'}, {'value': '5.00', 'spread': '6.65', 'groupId': 'OG009'}, {'value': '7.41', 'spread': '9.27', 'groupId': 'OG010'}]}]}, {'title': 'Week 24 (n=40,20,44,13,55,64,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '4.10', 'spread': '4.83', 'groupId': 'OG000'}, {'value': '8.65', 'spread': '8.77', 'groupId': 'OG001'}, {'value': '3.73', 'spread': '5.35', 'groupId': 'OG002'}, {'value': '7.00', 'spread': '7.14', 'groupId': 'OG003'}, {'value': '3.71', 'spread': '4.33', 'groupId': 'OG004'}, {'value': '4.41', 'spread': '6.86', 'groupId': 'OG005'}, {'value': '3.03', 'spread': '3.75', 'groupId': 'OG006'}, {'value': '2.89', 'spread': '2.97', 'groupId': 'OG007'}, {'value': '11.25', 'spread': '9.81', 'groupId': 'OG008'}, {'value': '4.11', 'spread': '3.90', 'groupId': 'OG009'}, {'value': '7.94', 'spread': '8.90', 'groupId': 'OG010'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.', 'unitOfMeasure': 'swollen joints', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET', 'denoms': [{'units': 'Participants', 'counts': [{'value': '68', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '68', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '68', 'groupId': 'OG004'}, {'value': '73', 'groupId': 'OG005'}, {'value': '73', 'groupId': 'OG006'}, {'value': '79', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '66', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Week 2 (n=68,0,68,0,68,73,73,79,0,66,0)', 'categories': [{'measurements': [{'value': '-3.43', 'spread': '5.98', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-4.71', 'spread': '7.40', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-4.24', 'spread': '6.33', 'groupId': 'OG004'}, {'value': '-4.75', 'spread': '5.57', 'groupId': 'OG005'}, {'value': '-5.45', 'spread': '7.74', 'groupId': 'OG006'}, {'value': '-5.04', 'spread': '7.45', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-2.12', 'spread': '5.00', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 4 (n=68,0,65,0,67,70,72,76,0,66,0)', 'categories': [{'measurements': [{'value': '-6.19', 'spread': '6.50', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-7.25', 'spread': '8.80', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-5.97', 'spread': '5.44', 'groupId': 'OG004'}, {'value': '-7.34', 'spread': '6.27', 'groupId': 'OG005'}, {'value': '-7.64', 'spread': '6.77', 'groupId': 'OG006'}, {'value': '-6.74', 'spread': '8.13', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-4.56', 'spread': '5.61', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 6 (n=66,0,65,0,69,71,72,74,0,62,0)', 'categories': [{'measurements': [{'value': '-7.41', 'spread': '6.58', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-8.42', 'spread': '9.28', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-7.68', 'spread': '6.30', 'groupId': 'OG004'}, {'value': '-7.68', 'spread': '7.35', 'groupId': 'OG005'}, {'value': '-8.68', 'spread': '6.73', 'groupId': 'OG006'}, {'value': '-7.97', 'spread': '7.54', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-5.48', 'spread': '6.91', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 8 (n=66,0,62,0,66,67,70,73,0,61,0)', 'categories': [{'measurements': [{'value': '-7.80', 'spread': '8.13', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-9.03', 'spread': '9.79', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-8.74', 'spread': '6.94', 'groupId': 'OG004'}, {'value': '-8.06', 'spread': '7.40', 'groupId': 'OG005'}, {'value': '-9.31', 'spread': '7.51', 'groupId': 'OG006'}, {'value': '-8.26', 'spread': '8.30', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-7.15', 'spread': '6.82', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12 (n=64,0,59,0,64,66,66,70,0,61,0)', 'categories': [{'measurements': [{'value': '-7.61', 'spread': '9.15', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-10.47', 'spread': '9.71', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-8.13', 'spread': '8.00', 'groupId': 'OG004'}, {'value': '-9.20', 'spread': '7.16', 'groupId': 'OG005'}, {'value': '-10.68', 'spread': '7.37', 'groupId': 'OG006'}, {'value': '-8.84', 'spread': '8.48', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-6.52', 'spread': '8.28', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 16 (n=42,21,45,13,58,66,61,55,12,37,16)', 'categories': [{'measurements': [{'value': '-10.67', 'spread': '8.78', 'groupId': 'OG000'}, {'value': '-5.95', 'spread': '6.99', 'groupId': 'OG001'}, {'value': '-13.00', 'spread': '8.90', 'groupId': 'OG002'}, {'value': '-2.46', 'spread': '5.77', 'groupId': 'OG003'}, {'value': '-10.60', 'spread': '7.43', 'groupId': 'OG004'}, {'value': '-9.95', 'spread': '6.97', 'groupId': 'OG005'}, {'value': '-10.66', 'spread': '6.75', 'groupId': 'OG006'}, {'value': '-10.65', 'spread': '7.09', 'groupId': 'OG007'}, {'value': '-5.83', 'spread': '13.62', 'groupId': 'OG008'}, {'value': '-8.65', 'spread': '6.58', 'groupId': 'OG009'}, {'value': '-6.88', 'spread': '6.51', 'groupId': 'OG010'}]}]}, {'title': 'Week 20 (n=39,21,44,13,57,66,59,55,12,37,17)', 'categories': [{'measurements': [{'value': '-10.95', 'spread': '8.32', 'groupId': 'OG000'}, {'value': '-7.52', 'spread': '8.20', 'groupId': 'OG001'}, {'value': '-13.36', 'spread': '8.25', 'groupId': 'OG002'}, {'value': '-3.92', 'spread': '5.72', 'groupId': 'OG003'}, {'value': '-10.39', 'spread': '6.98', 'groupId': 'OG004'}, {'value': '-10.48', 'spread': '7.21', 'groupId': 'OG005'}, {'value': '-11.61', 'spread': '6.35', 'groupId': 'OG006'}, {'value': '-11.00', 'spread': '6.99', 'groupId': 'OG007'}, {'value': '-8.08', 'spread': '9.89', 'groupId': 'OG008'}, {'value': '-9.62', 'spread': '7.31', 'groupId': 'OG009'}, {'value': '-7.88', 'spread': '9.21', 'groupId': 'OG010'}]}]}, {'title': 'Week 24 (n=40,20,44,13,55,64,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '-12.15', 'spread': '7.83', 'groupId': 'OG000'}, {'value': '-6.60', 'spread': '7.50', 'groupId': 'OG001'}, {'value': '-13.00', 'spread': '8.52', 'groupId': 'OG002'}, {'value': '-5.46', 'spread': '6.77', 'groupId': 'OG003'}, {'value': '-10.25', 'spread': '6.70', 'groupId': 'OG004'}, {'value': '-10.48', 'spread': '6.33', 'groupId': 'OG005'}, {'value': '-11.70', 'spread': '6.38', 'groupId': 'OG006'}, {'value': '-11.57', 'spread': '7.50', 'groupId': 'OG007'}, {'value': '-9.08', 'spread': '11.99', 'groupId': 'OG008'}, {'value': '-10.28', 'spread': '7.46', 'groupId': 'OG009'}, {'value': '-7.35', 'spread': '6.47', 'groupId': 'OG010'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. A negative value in change from baseline indicates an improvement.', 'unitOfMeasure': 'swollen joints', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Patient Assessment of Arthritis Pain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '67', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '71', 'groupId': 'OG004'}, {'value': '74', 'groupId': 'OG005'}, {'value': '75', 'groupId': 'OG006'}, {'value': '80', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '69', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Baseline (n=70,0,66,0,71,74,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '59.96', 'spread': '25.67', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '55.05', 'spread': '24.81', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '54.87', 'spread': '26.68', 'groupId': 'OG004'}, {'value': '56.66', 'spread': '25.42', 'groupId': 'OG005'}, {'value': '55.83', 'spread': '22.85', 'groupId': 'OG006'}, {'value': '59.61', 'spread': '23.61', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '51.19', 'spread': '27.72', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2 (n=68,0,67,0,68,73,73,79,0,66,0)', 'categories': [{'measurements': [{'value': '49.53', 'spread': '24.99', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '43.33', 'spread': '23.26', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '44.35', 'spread': '24.31', 'groupId': 'OG004'}, {'value': '41.26', 'spread': '22.18', 'groupId': 'OG005'}, {'value': '37.82', 'spread': '22.17', 'groupId': 'OG006'}, {'value': '40.57', 'spread': '27.24', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '46.91', 'spread': '25.39', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 4 (n=68,0,65,0,67,70,72,76,0,66,0)', 'categories': [{'measurements': [{'value': '45.57', 'spread': '24.99', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '37.83', 'spread': '22.77', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '40.03', 'spread': '24.25', 'groupId': 'OG004'}, {'value': '39.34', 'spread': '25.09', 'groupId': 'OG005'}, {'value': '35.81', 'spread': '23.88', 'groupId': 'OG006'}, {'value': '34.39', 'spread': '24.29', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '42.02', 'spread': '24.40', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 6 (n=66,0,65,0,69,71,72,74,0,61,0)', 'categories': [{'measurements': [{'value': '38.74', 'spread': '24.31', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '33.75', 'spread': '25.06', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '33.33', 'spread': '24.18', 'groupId': 'OG004'}, {'value': '34.38', 'spread': '23.15', 'groupId': 'OG005'}, {'value': '32.97', 'spread': '23.50', 'groupId': 'OG006'}, {'value': '33.65', 'spread': '25.47', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '42.21', 'spread': '27.12', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 8 (n=66,0,62,0,66,67,70,73,0,61,0)', 'categories': [{'measurements': [{'value': '38.97', 'spread': '23.33', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '28.81', 'spread': '23.86', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '36.55', 'spread': '25.00', 'groupId': 'OG004'}, {'value': '34.60', 'spread': '24.04', 'groupId': 'OG005'}, {'value': '30.26', 'spread': '22.20', 'groupId': 'OG006'}, {'value': '31.16', 'spread': '24.86', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '41.34', 'spread': '26.45', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12 (n=64,0,59,0,64,65,66,70,0,61,0)', 'categories': [{'measurements': [{'value': '35.92', 'spread': '22.49', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '30.90', 'spread': '24.44', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '28.88', 'spread': '22.80', 'groupId': 'OG004'}, {'value': '33.78', 'spread': '25.50', 'groupId': 'OG005'}, {'value': '31.48', 'spread': '24.86', 'groupId': 'OG006'}, {'value': '31.09', 'spread': '26.57', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '41.02', 'spread': '26.13', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 16 (n=42,21,45,13,58,66,61,54,12,37,16)', 'categories': [{'measurements': [{'value': '27.83', 'spread': '18.65', 'groupId': 'OG000'}, {'value': '40.38', 'spread': '21.81', 'groupId': 'OG001'}, {'value': '29.67', 'spread': '24.13', 'groupId': 'OG002'}, {'value': '39.31', 'spread': '24.13', 'groupId': 'OG003'}, {'value': '28.98', 'spread': '22.15', 'groupId': 'OG004'}, {'value': '30.33', 'spread': '22.04', 'groupId': 'OG005'}, {'value': '27.07', 'spread': '20.76', 'groupId': 'OG006'}, {'value': '24.56', 'spread': '23.46', 'groupId': 'OG007'}, {'value': '51.25', 'spread': '21.95', 'groupId': 'OG008'}, {'value': '30.08', 'spread': '22.81', 'groupId': 'OG009'}, {'value': '38.38', 'spread': '24.52', 'groupId': 'OG010'}]}]}, {'title': 'Week 20 (n=39,21,43,13,57,65,59,55,12,37,17)', 'categories': [{'measurements': [{'value': '29.28', 'spread': '22.75', 'groupId': 'OG000'}, {'value': '35.71', 'spread': '22.42', 'groupId': 'OG001'}, {'value': '26.63', 'spread': '23.48', 'groupId': 'OG002'}, {'value': '42.31', 'spread': '28.61', 'groupId': 'OG003'}, {'value': '25.91', 'spread': '23.10', 'groupId': 'OG004'}, {'value': '33.66', 'spread': '24.02', 'groupId': 'OG005'}, {'value': '24.69', 'spread': '20.98', 'groupId': 'OG006'}, {'value': '24.58', 'spread': '26.24', 'groupId': 'OG007'}, {'value': '43.92', 'spread': '27.07', 'groupId': 'OG008'}, {'value': '25.08', 'spread': '21.19', 'groupId': 'OG009'}, {'value': '33.00', 'spread': '27.70', 'groupId': 'OG010'}]}]}, {'title': 'Week 24 (n=40,20,44,13,55,63,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '25.53', 'spread': '21.05', 'groupId': 'OG000'}, {'value': '38.15', 'spread': '26.27', 'groupId': 'OG001'}, {'value': '25.98', 'spread': '20.61', 'groupId': 'OG002'}, {'value': '35.62', 'spread': '28.27', 'groupId': 'OG003'}, {'value': '24.45', 'spread': '20.24', 'groupId': 'OG004'}, {'value': '28.65', 'spread': '21.11', 'groupId': 'OG005'}, {'value': '24.47', 'spread': '22.23', 'groupId': 'OG006'}, {'value': '19.92', 'spread': '18.27', 'groupId': 'OG007'}, {'value': '35.33', 'spread': '27.17', 'groupId': 'OG008'}, {'value': '27.14', 'spread': '21.17', 'groupId': 'OG009'}, {'value': '33.65', 'spread': '26.15', 'groupId': 'OG010'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.', 'unitOfMeasure': 'mm', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET', 'denoms': [{'units': 'Participants', 'counts': [{'value': '68', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '65', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '68', 'groupId': 'OG004'}, {'value': '73', 'groupId': 'OG005'}, {'value': '73', 'groupId': 'OG006'}, {'value': '79', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '66', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Week 2 (n=65,0,68,0,68,73,73,79,0,66,0)', 'categories': [{'measurements': [{'value': '-9.49', 'spread': '24.31', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-11.00', 'spread': '20.82', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-10.76', 'spread': '26.22', 'groupId': 'OG004'}, {'value': '-15.30', 'spread': '25.46', 'groupId': 'OG005'}, {'value': '-17.67', 'spread': '24.58', 'groupId': 'OG006'}, {'value': '-18.84', 'spread': '25.59', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-4.55', 'spread': '25.28', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 4 (n=68,0,63,0,67,70,72,76,0,66,0)', 'categories': [{'measurements': [{'value': '-13.44', 'spread': '26.39', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-17.11', 'spread': '23.98', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-14.76', 'spread': '24.06', 'groupId': 'OG004'}, {'value': '-17.80', 'spread': '30.25', 'groupId': 'OG005'}, {'value': '-20.39', 'spread': '28.95', 'groupId': 'OG006'}, {'value': '-24.74', 'spread': '26.39', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-9.26', 'spread': '28.24', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 6 (n=66,0,63,0,69,71,72,74,0,61,0)', 'categories': [{'measurements': [{'value': '-19.56', 'spread': '31.29', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-22.71', 'spread': '28.84', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-21.07', 'spread': '29.07', 'groupId': 'OG004'}, {'value': '-22.94', 'spread': '29.71', 'groupId': 'OG005'}, {'value': '-22.61', 'spread': '28.87', 'groupId': 'OG006'}, {'value': '-26.97', 'spread': '26.15', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-8.61', 'spread': '29.03', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 8 (n=66,0,60,0,66,67,70,73,0,61,0)', 'categories': [{'measurements': [{'value': '-19.91', 'spread': '26.68', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-26.23', 'spread': '29.28', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-18.11', 'spread': '29.71', 'groupId': 'OG004'}, {'value': '-21.84', 'spread': '30.42', 'groupId': 'OG005'}, {'value': '-24.66', 'spread': '30.16', 'groupId': 'OG006'}, {'value': '-29.08', 'spread': '27.13', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-9.97', 'spread': '28.48', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12 (n=64,0,57,0,64,65,66,70,0,61,0)', 'categories': [{'measurements': [{'value': '-23.16', 'spread': '28.49', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-24.39', 'spread': '30.89', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-25.75', 'spread': '29.47', 'groupId': 'OG004'}, {'value': '-24.02', 'spread': '27.96', 'groupId': 'OG005'}, {'value': '-23.95', 'spread': '29.90', 'groupId': 'OG006'}, {'value': '-29.67', 'spread': '28.25', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-10.30', 'spread': '30.14', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 16 (n=42,21,45,13,58,66,61,54,12,37,16)', 'categories': [{'measurements': [{'value': '-34.02', 'spread': '31.75', 'groupId': 'OG000'}, {'value': '-13.48', 'spread': '25.66', 'groupId': 'OG001'}, {'value': '-27.19', 'spread': '24.93', 'groupId': 'OG002'}, {'value': '-15.15', 'spread': '21.97', 'groupId': 'OG003'}, {'value': '-26.50', 'spread': '28.81', 'groupId': 'OG004'}, {'value': '-26.64', 'spread': '25.04', 'groupId': 'OG005'}, {'value': '-27.97', 'spread': '29.32', 'groupId': 'OG006'}, {'value': '-32.09', 'spread': '24.84', 'groupId': 'OG007'}, {'value': '-19.00', 'spread': '29.73', 'groupId': 'OG008'}, {'value': '-17.22', 'spread': '35.13', 'groupId': 'OG009'}, {'value': '-18.19', 'spread': '21.36', 'groupId': 'OG010'}]}]}, {'title': 'Week 20 (n=39,21,41,13,57,65,59,55,12,37,17)', 'categories': [{'measurements': [{'value': '-31.54', 'spread': '36.96', 'groupId': 'OG000'}, {'value': '-18.14', 'spread': '25.06', 'groupId': 'OG001'}, {'value': '-32.37', 'spread': '26.83', 'groupId': 'OG002'}, {'value': '-12.15', 'spread': '25.36', 'groupId': 'OG003'}, {'value': '-29.54', 'spread': '30.99', 'groupId': 'OG004'}, {'value': '-22.78', 'spread': '30.27', 'groupId': 'OG005'}, {'value': '-30.97', 'spread': '31.28', 'groupId': 'OG006'}, {'value': '-32.95', 'spread': '27.48', 'groupId': 'OG007'}, {'value': '-26.33', 'spread': '33.15', 'groupId': 'OG008'}, {'value': '-22.22', 'spread': '30.68', 'groupId': 'OG009'}, {'value': '-21.82', 'spread': '21.49', 'groupId': 'OG010'}]}]}, {'title': 'Week 24 (n=40,20,42,13,55,63,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '-36.08', 'spread': '32.62', 'groupId': 'OG000'}, {'value': '-15.40', 'spread': '24.78', 'groupId': 'OG001'}, {'value': '-33.19', 'spread': '25.68', 'groupId': 'OG002'}, {'value': '-18.85', 'spread': '24.73', 'groupId': 'OG003'}, {'value': '-29.89', 'spread': '30.87', 'groupId': 'OG004'}, {'value': '-28.51', 'spread': '28.01', 'groupId': 'OG005'}, {'value': '-31.00', 'spread': '31.88', 'groupId': 'OG006'}, {'value': '-36.98', 'spread': '27.86', 'groupId': 'OG007'}, {'value': '-34.92', 'spread': '31.74', 'groupId': 'OG008'}, {'value': '-21.08', 'spread': '32.99', 'groupId': 'OG009'}, {'value': '-21.18', 'spread': '26.30', 'groupId': 'OG010'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.', 'unitOfMeasure': 'mm', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Patient Global Assessment (PtGA) of Arthritis', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '68', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '71', 'groupId': 'OG004'}, {'value': '74', 'groupId': 'OG005'}, {'value': '75', 'groupId': 'OG006'}, {'value': '79', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '69', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Baseline (n=70,0,68,0,71,74,75,79,0,69,0)', 'categories': [{'measurements': [{'value': '62.47', 'spread': '24.77', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '58.91', 'spread': '22.94', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '54.62', 'spread': '23.71', 'groupId': 'OG004'}, {'value': '58.35', 'spread': '23.14', 'groupId': 'OG005'}, {'value': '56.09', 'spread': '21.42', 'groupId': 'OG006'}, {'value': '57.24', 'spread': '25.64', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '51.88', 'spread': '26.44', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2 (n=68,0,68,0,68,73,73,79,0,66,0)', 'categories': [{'measurements': [{'value': '53.19', 'spread': '22.93', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '41.96', 'spread': '23.12', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '42.56', 'spread': '22.89', 'groupId': 'OG004'}, {'value': '42.32', 'spread': '21.98', 'groupId': 'OG005'}, {'value': '35.73', 'spread': '21.46', 'groupId': 'OG006'}, {'value': '41.80', 'spread': '26.25', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '46.33', 'spread': '25.02', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 4 (n=68,0,65,0,67,70,72,76,0,66,0)', 'categories': [{'measurements': [{'value': '47.87', 'spread': '23.21', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '39.78', 'spread': '22.47', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '38.94', 'spread': '22.27', 'groupId': 'OG004'}, {'value': '38.53', 'spread': '24.49', 'groupId': 'OG005'}, {'value': '34.76', 'spread': '21.33', 'groupId': 'OG006'}, {'value': '37.47', 'spread': '25.17', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '41.21', 'spread': '24.46', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 6 (n=66,0,65,0,69,71,72,74,0,61,0)', 'categories': [{'measurements': [{'value': '42.30', 'spread': '22.34', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '36.08', 'spread': '23.56', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '33.01', 'spread': '24.06', 'groupId': 'OG004'}, {'value': '35.41', 'spread': '22.68', 'groupId': 'OG005'}, {'value': '30.56', 'spread': '21.87', 'groupId': 'OG006'}, {'value': '34.86', 'spread': '25.24', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '43.02', 'spread': '25.14', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 8 (n=66,0,62,0,66,67,70,73,0,61,0)', 'categories': [{'measurements': [{'value': '41.06', 'spread': '21.76', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '30.11', 'spread': '22.38', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '36.50', 'spread': '25.29', 'groupId': 'OG004'}, {'value': '36.09', 'spread': '24.38', 'groupId': 'OG005'}, {'value': '30.61', 'spread': '21.60', 'groupId': 'OG006'}, {'value': '31.85', 'spread': '25.35', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '40.64', 'spread': '25.32', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12 (n=64,0,59,0,64,65,66,70,0,60,0)', 'categories': [{'measurements': [{'value': '38.78', 'spread': '22.91', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '34.42', 'spread': '25.15', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '29.66', 'spread': '21.69', 'groupId': 'OG004'}, {'value': '35.05', 'spread': '24.65', 'groupId': 'OG005'}, {'value': '32.53', 'spread': '24.48', 'groupId': 'OG006'}, {'value': '30.76', 'spread': '25.59', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '39.85', 'spread': '25.75', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 16 (n=42,21,45,13,58,66,61,54,12,37,16)', 'categories': [{'measurements': [{'value': '30.76', 'spread': '20.40', 'groupId': 'OG000'}, {'value': '38.29', 'spread': '19.76', 'groupId': 'OG001'}, {'value': '29.84', 'spread': '24.12', 'groupId': 'OG002'}, {'value': '39.31', 'spread': '27.48', 'groupId': 'OG003'}, {'value': '30.62', 'spread': '22.56', 'groupId': 'OG004'}, {'value': '30.98', 'spread': '22.06', 'groupId': 'OG005'}, {'value': '26.59', 'spread': '20.19', 'groupId': 'OG006'}, {'value': '24.76', 'spread': '22.53', 'groupId': 'OG007'}, {'value': '50.67', 'spread': '23.10', 'groupId': 'OG008'}, {'value': '28.46', 'spread': '22.69', 'groupId': 'OG009'}, {'value': '37.63', 'spread': '23.11', 'groupId': 'OG010'}]}]}, {'title': 'Week 20 (n=39,21,43,13,57,66,59,55,12,37,17)', 'categories': [{'measurements': [{'value': '29.85', 'spread': '22.86', 'groupId': 'OG000'}, {'value': '37.95', 'spread': '23.62', 'groupId': 'OG001'}, {'value': '28.16', 'spread': '22.36', 'groupId': 'OG002'}, {'value': '42.08', 'spread': '27.48', 'groupId': 'OG003'}, {'value': '26.07', 'spread': '22.75', 'groupId': 'OG004'}, {'value': '35.00', 'spread': '23.51', 'groupId': 'OG005'}, {'value': '24.90', 'spread': '20.57', 'groupId': 'OG006'}, {'value': '25.56', 'spread': '23.20', 'groupId': 'OG007'}, {'value': '44.42', 'spread': '27.38', 'groupId': 'OG008'}, {'value': '26.22', 'spread': '21.09', 'groupId': 'OG009'}, {'value': '36.94', 'spread': '27.13', 'groupId': 'OG010'}]}]}, {'title': 'Week 24 (n=40,20,44,13,55,64,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '28.23', 'spread': '21.42', 'groupId': 'OG000'}, {'value': '38.55', 'spread': '27.08', 'groupId': 'OG001'}, {'value': '25.93', 'spread': '22.22', 'groupId': 'OG002'}, {'value': '38.23', 'spread': '27.28', 'groupId': 'OG003'}, {'value': '23.64', 'spread': '21.82', 'groupId': 'OG004'}, {'value': '29.66', 'spread': '21.58', 'groupId': 'OG005'}, {'value': '25.07', 'spread': '23.20', 'groupId': 'OG006'}, {'value': '21.85', 'spread': '18.07', 'groupId': 'OG007'}, {'value': '34.83', 'spread': '27.04', 'groupId': 'OG008'}, {'value': '28.25', 'spread': '21.49', 'groupId': 'OG009'}, {'value': '34.59', 'spread': '27.87', 'groupId': 'OG010'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.', 'unitOfMeasure': 'mm', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET', 'denoms': [{'units': 'Participants', 'counts': [{'value': '68', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '68', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '68', 'groupId': 'OG004'}, {'value': '73', 'groupId': 'OG005'}, {'value': '73', 'groupId': 'OG006'}, {'value': '78', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '66', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Week 2 (n=68,0,68,0,68,73,73,78,0,66,0)', 'categories': [{'measurements': [{'value': '-8.57', 'spread': '26.12', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-16.96', 'spread': '20.11', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-12.37', 'spread': '21.83', 'groupId': 'OG004'}, {'value': '-16.74', 'spread': '24.15', 'groupId': 'OG005'}, {'value': '-20.25', 'spread': '26.92', 'groupId': 'OG006'}, {'value': '-15.38', 'spread': '30.86', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-5.82', 'spread': '24.96', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 4 (n=68,0,65,0,67,70,72,75,0,66,0)', 'categories': [{'measurements': [{'value': '-13.90', 'spread': '25.53', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-19.40', 'spread': '25.40', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-15.70', 'spread': '22.92', 'groupId': 'OG004'}, {'value': '-20.76', 'spread': '26.76', 'groupId': 'OG005'}, {'value': '-21.82', 'spread': '28.55', 'groupId': 'OG006'}, {'value': '-19.04', 'spread': '29.28', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-10.65', 'spread': '27.81', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 6 (n=66,0,65,0,69,71,72,73,0,61,0)', 'categories': [{'measurements': [{'value': '-18.71', 'spread': '29.02', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-22.02', 'spread': '25.83', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-20.81', 'spread': '24.06', 'groupId': 'OG004'}, {'value': '-24.03', 'spread': '23.89', 'groupId': 'OG005'}, {'value': '-25.26', 'spread': '30.85', 'groupId': 'OG006'}, {'value': '-22.99', 'spread': '29.63', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-9.46', 'spread': '23.90', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 8 (n=66,0,62,0,66,67,70,72,0,61,0)', 'categories': [{'measurements': [{'value': '-20.35', 'spread': '27.84', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-27.48', 'spread': '26.13', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-17.44', 'spread': '28.12', 'groupId': 'OG004'}, {'value': '-22.58', 'spread': '25.37', 'groupId': 'OG005'}, {'value': '-24.81', 'spread': '31.07', 'groupId': 'OG006'}, {'value': '-25.92', 'spread': '30.55', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-11.48', 'spread': '25.89', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12 (n=64,0,59,0,64,65,66,69,0,60,0)', 'categories': [{'measurements': [{'value': '-22.78', 'spread': '28.81', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-23.95', 'spread': '29.82', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-24.30', 'spread': '24.57', 'groupId': 'OG004'}, {'value': '-24.77', 'spread': '26.21', 'groupId': 'OG005'}, {'value': '-23.08', 'spread': '30.87', 'groupId': 'OG006'}, {'value': '-28.09', 'spread': '30.23', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-12.75', 'spread': '28.20', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 16 (n=42,21,45,13,58,66,61,53,12,37,16)', 'categories': [{'measurements': [{'value': '-33.60', 'spread': '31.45', 'groupId': 'OG000'}, {'value': '-15.86', 'spread': '22.28', 'groupId': 'OG001'}, {'value': '-28.00', 'spread': '28.15', 'groupId': 'OG002'}, {'value': '-22.00', 'spread': '26.01', 'groupId': 'OG003'}, {'value': '-24.05', 'spread': '28.00', 'groupId': 'OG004'}, {'value': '-27.97', 'spread': '24.02', 'groupId': 'OG005'}, {'value': '-28.90', 'spread': '29.36', 'groupId': 'OG006'}, {'value': '-29.68', 'spread': '31.20', 'groupId': 'OG007'}, {'value': '-13.67', 'spread': '35.93', 'groupId': 'OG008'}, {'value': '-20.97', 'spread': '31.57', 'groupId': 'OG009'}, {'value': '-14.81', 'spread': '17.72', 'groupId': 'OG010'}]}]}, {'title': 'Week 20 (n=39,21,43,13,57,66,59,54,12,36,17)', 'categories': [{'measurements': [{'value': '-34.56', 'spread': '31.99', 'groupId': 'OG000'}, {'value': '-16.19', 'spread': '24.18', 'groupId': 'OG001'}, {'value': '-30.93', 'spread': '25.67', 'groupId': 'OG002'}, {'value': '-19.23', 'spread': '28.78', 'groupId': 'OG003'}, {'value': '-28.33', 'spread': '26.93', 'groupId': 'OG004'}, {'value': '-23.95', 'spread': '27.82', 'groupId': 'OG005'}, {'value': '-31.12', 'spread': '32.09', 'groupId': 'OG006'}, {'value': '-30.67', 'spread': '31.38', 'groupId': 'OG007'}, {'value': '-19.92', 'spread': '34.52', 'groupId': 'OG008'}, {'value': '-23.22', 'spread': '27.31', 'groupId': 'OG009'}, {'value': '-13.53', 'spread': '22.22', 'groupId': 'OG010'}]}]}, {'title': 'Week 24 (n=40,20,44,13,55,64,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '-36.68', 'spread': '29.89', 'groupId': 'OG000'}, {'value': '-15.30', 'spread': '32.99', 'groupId': 'OG001'}, {'value': '-32.11', 'spread': '25.76', 'groupId': 'OG002'}, {'value': '-23.08', 'spread': '31.06', 'groupId': 'OG003'}, {'value': '-29.84', 'spread': '27.59', 'groupId': 'OG004'}, {'value': '-28.61', 'spread': '25.31', 'groupId': 'OG005'}, {'value': '-30.83', 'spread': '32.96', 'groupId': 'OG006'}, {'value': '-33.04', 'spread': '32.02', 'groupId': 'OG007'}, {'value': '-29.50', 'spread': '32.33', 'groupId': 'OG008'}, {'value': '-21.92', 'spread': '27.51', 'groupId': 'OG009'}, {'value': '-15.88', 'spread': '25.95', 'groupId': 'OG010'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.', 'unitOfMeasure': 'mm', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Physician Global Assessment of Arthritis', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '68', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '71', 'groupId': 'OG004'}, {'value': '74', 'groupId': 'OG005'}, {'value': '75', 'groupId': 'OG006'}, {'value': '80', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '69', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Baseline (n=70,0,68,0,71,74,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '62.66', 'spread': '16.00', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '57.50', 'spread': '18.47', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '56.51', 'spread': '19.00', 'groupId': 'OG004'}, {'value': '60.77', 'spread': '16.75', 'groupId': 'OG005'}, {'value': '60.51', 'spread': '14.26', 'groupId': 'OG006'}, {'value': '58.75', 'spread': '17.90', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '58.30', 'spread': '15.25', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2 (n=67,0,68,0,68,73,73,79,0,66,0)', 'categories': [{'measurements': [{'value': '49.49', 'spread': '21.64', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '41.07', 'spread': '19.88', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '42.29', 'spread': '20.12', 'groupId': 'OG004'}, {'value': '42.85', 'spread': '19.42', 'groupId': 'OG005'}, {'value': '35.99', 'spread': '15.97', 'groupId': 'OG006'}, {'value': '41.92', 'spread': '22.30', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '49.05', 'spread': '18.00', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 4 (n=68,0,65,0,67,70,72,75,0,66,0)', 'categories': [{'measurements': [{'value': '41.69', 'spread': '21.31', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '36.92', 'spread': '21.20', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '34.73', 'spread': '17.40', 'groupId': 'OG004'}, {'value': '33.56', 'spread': '19.77', 'groupId': 'OG005'}, {'value': '33.35', 'spread': '19.24', 'groupId': 'OG006'}, {'value': '32.96', 'spread': '22.38', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '40.23', 'spread': '19.43', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 6 (n=66,0,65,0,69,71,72,74,0,62,0)', 'categories': [{'measurements': [{'value': '37.38', 'spread': '17.11', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '31.51', 'spread': '21.25', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '27.78', 'spread': '18.40', 'groupId': 'OG004'}, {'value': '30.82', 'spread': '19.95', 'groupId': 'OG005'}, {'value': '27.08', 'spread': '17.28', 'groupId': 'OG006'}, {'value': '32.65', 'spread': '23.41', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '37.85', 'spread': '21.03', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 8 (n=66,0,62,0,66,67,70,73,0,61,0)', 'categories': [{'measurements': [{'value': '35.71', 'spread': '21.03', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '26.60', 'spread': '20.34', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '27.26', 'spread': '19.97', 'groupId': 'OG004'}, {'value': '28.01', 'spread': '19.90', 'groupId': 'OG005'}, {'value': '23.06', 'spread': '17.18', 'groupId': 'OG006'}, {'value': '27.70', 'spread': '21.09', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '34.66', 'spread': '21.39', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12 (n=63,0,59,0,64,66,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '33.65', 'spread': '20.06', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '26.17', 'spread': '21.33', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '24.77', 'spread': '18.80', 'groupId': 'OG004'}, {'value': '26.47', 'spread': '19.69', 'groupId': 'OG005'}, {'value': '23.28', 'spread': '17.89', 'groupId': 'OG006'}, {'value': '28.93', 'spread': '23.44', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '35.70', 'spread': '24.86', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 16 (n=42,21,44,13,58,66,61,55,12,37,16)', 'categories': [{'measurements': [{'value': '23.95', 'spread': '16.25', 'groupId': 'OG000'}, {'value': '44.19', 'spread': '24.68', 'groupId': 'OG001'}, {'value': '19.77', 'spread': '19.74', 'groupId': 'OG002'}, {'value': '33.31', 'spread': '22.97', 'groupId': 'OG003'}, {'value': '23.67', 'spread': '21.04', 'groupId': 'OG004'}, {'value': '23.00', 'spread': '18.60', 'groupId': 'OG005'}, {'value': '19.31', 'spread': '15.80', 'groupId': 'OG006'}, {'value': '18.60', 'spread': '15.00', 'groupId': 'OG007'}, {'value': '48.42', 'spread': '30.00', 'groupId': 'OG008'}, {'value': '26.22', 'spread': '18.43', 'groupId': 'OG009'}, {'value': '27.44', 'spread': '16.36', 'groupId': 'OG010'}]}]}, {'title': 'Week 20 (n=39,21,44,13,57,66,59,55,12,37,17)', 'categories': [{'measurements': [{'value': '20.44', 'spread': '18.10', 'groupId': 'OG000'}, {'value': '34.29', 'spread': '16.64', 'groupId': 'OG001'}, {'value': '20.91', 'spread': '18.21', 'groupId': 'OG002'}, {'value': '32.92', 'spread': '25.15', 'groupId': 'OG003'}, {'value': '20.65', 'spread': '18.68', 'groupId': 'OG004'}, {'value': '24.05', 'spread': '18.32', 'groupId': 'OG005'}, {'value': '16.19', 'spread': '12.41', 'groupId': 'OG006'}, {'value': '18.84', 'spread': '18.42', 'groupId': 'OG007'}, {'value': '44.67', 'spread': '25.31', 'groupId': 'OG008'}, {'value': '21.95', 'spread': '18.03', 'groupId': 'OG009'}, {'value': '33.94', 'spread': '22.43', 'groupId': 'OG010'}]}]}, {'title': 'Week 24 (n=40,19,43,13,55,64,60,53,11,36,17)', 'categories': [{'measurements': [{'value': '18.90', 'spread': '16.51', 'groupId': 'OG000'}, {'value': '36.53', 'spread': '21.17', 'groupId': 'OG001'}, {'value': '20.26', 'spread': '18.12', 'groupId': 'OG002'}, {'value': '32.54', 'spread': '24.26', 'groupId': 'OG003'}, {'value': '16.91', 'spread': '14.67', 'groupId': 'OG004'}, {'value': '21.25', 'spread': '17.79', 'groupId': 'OG005'}, {'value': '14.68', 'spread': '13.07', 'groupId': 'OG006'}, {'value': '14.49', 'spread': '11.75', 'groupId': 'OG007'}, {'value': '41.00', 'spread': '31.58', 'groupId': 'OG008'}, {'value': '20.67', 'spread': '15.81', 'groupId': 'OG009'}, {'value': '32.18', 'spread': '19.03', 'groupId': 'OG010'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.', 'unitOfMeasure': 'mm', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET', 'denoms': [{'units': 'Participants', 'counts': [{'value': '67', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '68', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '68', 'groupId': 'OG004'}, {'value': '73', 'groupId': 'OG005'}, {'value': '73', 'groupId': 'OG006'}, {'value': '79', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '68', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Week 2 (n=67,0,68,0,68,73,73,79,0,66,0)', 'categories': [{'measurements': [{'value': '-12.88', 'spread': '17.84', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-16.43', 'spread': '19.20', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-14.60', 'spread': '24.01', 'groupId': 'OG004'}, {'value': '-17.88', 'spread': '17.66', 'groupId': 'OG005'}, {'value': '-24.30', 'spread': '18.32', 'groupId': 'OG006'}, {'value': '-16.61', 'spread': '19.17', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-8.82', 'spread': '13.20', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 4 (n=68,0,65,0,67,70,72,75,0,66,0)', 'categories': [{'measurements': [{'value': '-20.66', 'spread': '19.47', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-20.80', 'spread': '22.47', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-22.00', 'spread': '20.79', 'groupId': 'OG004'}, {'value': '-27.67', 'spread': '20.61', 'groupId': 'OG005'}, {'value': '-27.43', 'spread': '21.04', 'groupId': 'OG006'}, {'value': '-25.31', 'spread': '22.01', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-17.79', 'spread': '18.95', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 6 (n=66,0,65,0,69,71,72,74,0,62,0)', 'categories': [{'measurements': [{'value': '-25.02', 'spread': '20.89', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-26.34', 'spread': '24.05', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-28.80', 'spread': '20.44', 'groupId': 'OG004'}, {'value': '-30.39', 'spread': '20.61', 'groupId': 'OG005'}, {'value': '-33.26', 'spread': '19.40', 'groupId': 'OG006'}, {'value': '-25.93', 'spread': '23.04', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-20.15', 'spread': '22.19', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 8 (n=66,0,62,0,66,67,70,73,0,61,0)', 'categories': [{'measurements': [{'value': '-26.50', 'spread': '22.83', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-30.92', 'spread': '22.85', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-29.67', 'spread': '24.30', 'groupId': 'OG004'}, {'value': '-33.63', 'spread': '21.96', 'groupId': 'OG005'}, {'value': '-37.26', 'spread': '19.37', 'groupId': 'OG006'}, {'value': '-30.66', 'spread': '21.10', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-22.82', 'spread': '22.89', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12 (n=63,0,59,0,64,66,66,70,0,61,0)', 'categories': [{'measurements': [{'value': '-28.76', 'spread': '23.50', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-31.69', 'spread': '24.30', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-31.58', 'spread': '23.09', 'groupId': 'OG004'}, {'value': '-34.98', 'spread': '20.53', 'groupId': 'OG005'}, {'value': '-36.80', 'spread': '20.78', 'groupId': 'OG006'}, {'value': '-30.27', 'spread': '22.44', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-21.77', 'spread': '24.51', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 16 (n=42,21,44,13,58,66,61,55,12,37,16)', 'categories': [{'measurements': [{'value': '-39.33', 'spread': '19.85', 'groupId': 'OG000'}, {'value': '-16.95', 'spread': '26.42', 'groupId': 'OG001'}, {'value': '-39.23', 'spread': '23.11', 'groupId': 'OG002'}, {'value': '-23.85', 'spread': '19.42', 'groupId': 'OG003'}, {'value': '-33.47', 'spread': '26.06', 'groupId': 'OG004'}, {'value': '-38.45', 'spread': '20.53', 'groupId': 'OG005'}, {'value': '-39.70', 'spread': '20.34', 'groupId': 'OG006'}, {'value': '-38.65', 'spread': '17.68', 'groupId': 'OG007'}, {'value': '-19.08', 'spread': '29.20', 'groupId': 'OG008'}, {'value': '-29.89', 'spread': '22.16', 'groupId': 'OG009'}, {'value': '-32.56', 'spread': '15.65', 'groupId': 'OG010'}]}]}, {'title': 'Week 20 (n=39,21,44,13,57,66,59,55,12,37,17)', 'categories': [{'measurements': [{'value': '-42.21', 'spread': '23.73', 'groupId': 'OG000'}, {'value': '-26.86', 'spread': '23.81', 'groupId': 'OG001'}, {'value': '-38.70', 'spread': '20.41', 'groupId': 'OG002'}, {'value': '-24.23', 'spread': '22.29', 'groupId': 'OG003'}, {'value': '-36.81', 'spread': '24.26', 'groupId': 'OG004'}, {'value': '-37.41', 'spread': '18.99', 'groupId': 'OG005'}, {'value': '-43.42', 'spread': '16.85', 'groupId': 'OG006'}, {'value': '-38.16', 'spread': '19.33', 'groupId': 'OG007'}, {'value': '-22.83', 'spread': '26.51', 'groupId': 'OG008'}, {'value': '-34.16', 'spread': '23.25', 'groupId': 'OG009'}, {'value': '-26.29', 'spread': '24.43', 'groupId': 'OG010'}]}]}, {'title': 'Week 24 (n=40,19,43,13,55,64,60,53,11,36,17)', 'categories': [{'measurements': [{'value': '-44.15', 'spread': '22.39', 'groupId': 'OG000'}, {'value': '-24.11', 'spread': '24.91', 'groupId': 'OG001'}, {'value': '-39.98', 'spread': '21.13', 'groupId': 'OG002'}, {'value': '-24.62', 'spread': '19.99', 'groupId': 'OG003'}, {'value': '-39.51', 'spread': '22.83', 'groupId': 'OG004'}, {'value': '-40.61', 'spread': '20.10', 'groupId': 'OG005'}, {'value': '-44.65', 'spread': '16.76', 'groupId': 'OG006'}, {'value': '-41.91', 'spread': '17.09', 'groupId': 'OG007'}, {'value': '-28.64', 'spread': '31.29', 'groupId': 'OG008'}, {'value': '-35.06', 'spread': '21.26', 'groupId': 'OG009'}, {'value': '-28.06', 'spread': '20.84', 'groupId': 'OG010'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.', 'unitOfMeasure': 'mm', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Health Assessment Questionnaire-Disability Index (HAQ-DI)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '66', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '71', 'groupId': 'OG004'}, {'value': '74', 'groupId': 'OG005'}, {'value': '75', 'groupId': 'OG006'}, {'value': '80', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '69', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Baseline (n=70,0,66,0,71,74,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '1.58', 'spread': '0.57', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '1.36', 'spread': '0.75', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '1.44', 'spread': '0.64', 'groupId': 'OG004'}, {'value': '1.33', 'spread': '0.60', 'groupId': 'OG005'}, {'value': '1.41', 'spread': '0.64', 'groupId': 'OG006'}, {'value': '1.46', 'spread': '0.58', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '1.20', 'spread': '0.73', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2 (n=68,0,68,0,68,73,73,79,0,66,0)', 'categories': [{'measurements': [{'value': '1.41', 'spread': '0.61', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '1.14', 'spread': '0.75', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '1.20', 'spread': '0.58', 'groupId': 'OG004'}, {'value': '1.16', 'spread': '0.61', 'groupId': 'OG005'}, {'value': '1.15', 'spread': '0.67', 'groupId': 'OG006'}, {'value': '1.23', 'spread': '0.63', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '1.15', 'spread': '0.64', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 4 (n=68,0,65,0,67,70,72,75,0,66,0)', 'categories': [{'measurements': [{'value': '1.32', 'spread': '0.61', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '1.03', 'spread': '0.69', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '1.13', 'spread': '0.65', 'groupId': 'OG004'}, {'value': '1.08', 'spread': '0.64', 'groupId': 'OG005'}, {'value': '1.12', 'spread': '0.69', 'groupId': 'OG006'}, {'value': '1.14', 'spread': '0.65', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '1.14', 'spread': '0.66', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 6 (n=66,0,64,0,69,71,72,74,0,61,0)', 'categories': [{'measurements': [{'value': '1.23', 'spread': '0.57', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '0.96', 'spread': '0.69', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '1.03', 'spread': '0.61', 'groupId': 'OG004'}, {'value': '1.02', 'spread': '0.65', 'groupId': 'OG005'}, {'value': '1.05', 'spread': '0.69', 'groupId': 'OG006'}, {'value': '1.05', 'spread': '0.65', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '1.07', 'spread': '0.70', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 8 (n=66,0,62,0,66,67,70,71,0,61,0)', 'categories': [{'measurements': [{'value': '1.22', 'spread': '0.59', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '0.93', 'spread': '0.68', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '1.06', 'spread': '0.66', 'groupId': 'OG004'}, {'value': '0.89', 'spread': '0.67', 'groupId': 'OG005'}, {'value': '0.98', 'spread': '0.68', 'groupId': 'OG006'}, {'value': '0.98', 'spread': '0.72', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '1.05', 'spread': '0.71', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12 (n=64,0,59,0,64,65,66,68,0,61,0)', 'categories': [{'measurements': [{'value': '1.19', 'spread': '0.63', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '0.92', 'spread': '0.75', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '0.94', 'spread': '0.65', 'groupId': 'OG004'}, {'value': '0.95', 'spread': '0.68', 'groupId': 'OG005'}, {'value': '0.96', 'spread': '0.69', 'groupId': 'OG006'}, {'value': '0.90', 'spread': '0.67', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '1.08', 'spread': '0.74', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 16 (n=42,21,45,13,58,66,61,55,12,37,16)', 'categories': [{'measurements': [{'value': '1.05', 'spread': '0.59', 'groupId': 'OG000'}, {'value': '1.42', 'spread': '0.64', 'groupId': 'OG001'}, {'value': '0.82', 'spread': '0.72', 'groupId': 'OG002'}, {'value': '1.18', 'spread': '0.77', 'groupId': 'OG003'}, {'value': '0.92', 'spread': '0.60', 'groupId': 'OG004'}, {'value': '0.91', 'spread': '0.68', 'groupId': 'OG005'}, {'value': '0.97', 'spread': '0.75', 'groupId': 'OG006'}, {'value': '0.81', 'spread': '0.67', 'groupId': 'OG007'}, {'value': '1.36', 'spread': '0.67', 'groupId': 'OG008'}, {'value': '0.80', 'spread': '0.64', 'groupId': 'OG009'}, {'value': '1.05', 'spread': '0.80', 'groupId': 'OG010'}]}]}, {'title': 'Week 20 (n=39,21,44,13,57,66,59,55,12,37,17)', 'categories': [{'measurements': [{'value': '0.95', 'spread': '0.58', 'groupId': 'OG000'}, {'value': '1.33', 'spread': '0.72', 'groupId': 'OG001'}, {'value': '0.77', 'spread': '0.68', 'groupId': 'OG002'}, {'value': '1.13', 'spread': '0.78', 'groupId': 'OG003'}, {'value': '0.78', 'spread': '0.57', 'groupId': 'OG004'}, {'value': '0.84', 'spread': '0.65', 'groupId': 'OG005'}, {'value': '0.92', 'spread': '0.72', 'groupId': 'OG006'}, {'value': '0.75', 'spread': '0.63', 'groupId': 'OG007'}, {'value': '1.42', 'spread': '0.62', 'groupId': 'OG008'}, {'value': '0.73', 'spread': '0.65', 'groupId': 'OG009'}, {'value': '0.92', 'spread': '0.75', 'groupId': 'OG010'}]}]}, {'title': 'Week 24 (n=40,20,44,13,54,63,59,53,12,36,17)', 'categories': [{'measurements': [{'value': '0.99', 'spread': '0.57', 'groupId': 'OG000'}, {'value': '1.38', 'spread': '0.74', 'groupId': 'OG001'}, {'value': '0.85', 'spread': '0.68', 'groupId': 'OG002'}, {'value': '1.05', 'spread': '0.84', 'groupId': 'OG003'}, {'value': '0.78', 'spread': '0.62', 'groupId': 'OG004'}, {'value': '0.85', 'spread': '0.66', 'groupId': 'OG005'}, {'value': '0.88', 'spread': '0.69', 'groupId': 'OG006'}, {'value': '0.72', 'spread': '0.61', 'groupId': 'OG007'}, {'value': '1.34', 'spread': '0.78', 'groupId': 'OG008'}, {'value': '0.74', 'spread': '0.66', 'groupId': 'OG009'}, {'value': '0.95', 'spread': '0.68', 'groupId': 'OG010'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET', 'denoms': [{'units': 'Participants', 'counts': [{'value': '68', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '66', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '68', 'groupId': 'OG004'}, {'value': '73', 'groupId': 'OG005'}, {'value': '73', 'groupId': 'OG006'}, {'value': '79', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '66', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Week 2 (n=68,0,68,0,68,73,73,79,0,66,0)', 'categories': [{'measurements': [{'value': '-0.15', 'spread': '0.38', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-0.23', 'spread': '0.49', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-0.23', 'spread': '0.41', 'groupId': 'OG004'}, {'value': '-0.18', 'spread': '0.42', 'groupId': 'OG005'}, {'value': '-0.24', 'spread': '0.40', 'groupId': 'OG006'}, {'value': '-0.23', 'spread': '0.45', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-0.05', 'spread': '0.36', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 4 (n=68,0,63,0,67,70,72,75,0,66,0)', 'categories': [{'measurements': [{'value': '-0.24', 'spread': '0.46', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-0.36', 'spread': '0.52', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-0.32', 'spread': '0.51', 'groupId': 'OG004'}, {'value': '-0.25', 'spread': '0.45', 'groupId': 'OG005'}, {'value': '-0.31', 'spread': '0.44', 'groupId': 'OG006'}, {'value': '-0.34', 'spread': '0.50', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-0.05', 'spread': '0.46', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 6 (n=66,0,62,0,69,71,72,74,0,61,0)', 'categories': [{'measurements': [{'value': '-0.31', 'spread': '0.45', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-0.39', 'spread': '0.53', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-0.42', 'spread': '0.54', 'groupId': 'OG004'}, {'value': '-0.32', 'spread': '0.57', 'groupId': 'OG005'}, {'value': '-0.34', 'spread': '0.47', 'groupId': 'OG006'}, {'value': '-0.42', 'spread': '0.52', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-0.13', 'spread': '0.59', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 8 (n=66,0,61,0,66,67,70,71,0,61,0)', 'categories': [{'measurements': [{'value': '-0.34', 'spread': '0.48', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-0.41', 'spread': '0.63', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-0.40', 'spread': '0.58', 'groupId': 'OG004'}, {'value': '-0.43', 'spread': '0.66', 'groupId': 'OG005'}, {'value': '-0.39', 'spread': '0.49', 'groupId': 'OG006'}, {'value': '-0.50', 'spread': '0.61', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-0.12', 'spread': '0.55', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12 (n=64,0,58,0,64,65,66,68,0,61,0)', 'categories': [{'measurements': [{'value': '-0.37', 'spread': '0.48', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-0.48', 'spread': '0.61', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-0.51', 'spread': '0.61', 'groupId': 'OG004'}, {'value': '-0.37', 'spread': '0.63', 'groupId': 'OG005'}, {'value': '-0.45', 'spread': '0.50', 'groupId': 'OG006'}, {'value': '-0.58', 'spread': '0.61', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-0.10', 'spread': '0.57', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 16 (n=42,21,44,13,58,66,61,55,12,37,16)', 'categories': [{'measurements': [{'value': '-0.52', 'spread': '0.48', 'groupId': 'OG000'}, {'value': '-0.16', 'spread': '0.50', 'groupId': 'OG001'}, {'value': '-0.59', 'spread': '0.64', 'groupId': 'OG002'}, {'value': '-0.08', 'spread': '0.31', 'groupId': 'OG003'}, {'value': '-0.52', 'spread': '0.59', 'groupId': 'OG004'}, {'value': '-0.41', 'spread': '0.63', 'groupId': 'OG005'}, {'value': '-0.45', 'spread': '0.60', 'groupId': 'OG006'}, {'value': '-0.62', 'spread': '0.62', 'groupId': 'OG007'}, {'value': '-0.46', 'spread': '0.58', 'groupId': 'OG008'}, {'value': '-0.30', 'spread': '0.52', 'groupId': 'OG009'}, {'value': '-0.01', 'spread': '0.29', 'groupId': 'OG010'}]}]}, {'title': 'Week 20 (n=39,21,43,13,57,66,59,55,12,37,17)', 'categories': [{'measurements': [{'value': '-0.62', 'spread': '0.47', 'groupId': 'OG000'}, {'value': '-0.24', 'spread': '0.42', 'groupId': 'OG001'}, {'value': '-0.62', 'spread': '0.68', 'groupId': 'OG002'}, {'value': '-0.13', 'spread': '0.41', 'groupId': 'OG003'}, {'value': '-0.64', 'spread': '0.62', 'groupId': 'OG004'}, {'value': '-0.49', 'spread': '0.58', 'groupId': 'OG005'}, {'value': '-0.51', 'spread': '0.59', 'groupId': 'OG006'}, {'value': '-0.67', 'spread': '0.65', 'groupId': 'OG007'}, {'value': '-0.41', 'spread': '0.55', 'groupId': 'OG008'}, {'value': '-0.38', 'spread': '0.54', 'groupId': 'OG009'}, {'value': '-0.11', 'spread': '0.30', 'groupId': 'OG010'}]}]}, {'title': 'Week 24 (n=40,20,42,13,54,63,59,53,12,36,17)', 'categories': [{'measurements': [{'value': '-0.60', 'spread': '0.52', 'groupId': 'OG000'}, {'value': '-0.21', 'spread': '0.58', 'groupId': 'OG001'}, {'value': '-0.53', 'spread': '0.65', 'groupId': 'OG002'}, {'value': '-0.21', 'spread': '0.32', 'groupId': 'OG003'}, {'value': '-0.61', 'spread': '0.65', 'groupId': 'OG004'}, {'value': '-0.47', 'spread': '0.62', 'groupId': 'OG005'}, {'value': '-0.53', 'spread': '0.60', 'groupId': 'OG006'}, {'value': '-0.66', 'spread': '0.72', 'groupId': 'OG007'}, {'value': '-0.48', 'spread': '0.74', 'groupId': 'OG008'}, {'value': '-0.37', 'spread': '0.54', 'groupId': 'OG009'}, {'value': '-0.08', 'spread': '0.29', 'groupId': 'OG010'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Change = scores at observation minus score at Baseline, and total possible score ranged from -3 to 3. A negative value in change from baseline indicates an improvement.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'C-Reactive Protein (CRP)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '68', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '71', 'groupId': 'OG004'}, {'value': '74', 'groupId': 'OG005'}, {'value': '75', 'groupId': 'OG006'}, {'value': '80', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '69', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Baseline (n=70,0,68,0,71,74,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '16.30', 'spread': '18.08', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '15.85', 'spread': '19.34', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '18.03', 'spread': '24.96', 'groupId': 'OG004'}, {'value': '14.42', 'spread': '17.81', 'groupId': 'OG005'}, {'value': '17.21', 'spread': '16.94', 'groupId': 'OG006'}, {'value': '14.68', 'spread': '17.19', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '18.88', 'spread': '19.55', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2 (n=65,0,63,0,63,69,68,74,0,61,0)', 'categories': [{'measurements': [{'value': '14.54', 'spread': '19.53', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '8.20', 'spread': '11.77', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '6.98', 'spread': '10.05', 'groupId': 'OG004'}, {'value': '5.24', 'spread': '9.59', 'groupId': 'OG005'}, {'value': '4.08', 'spread': '4.79', 'groupId': 'OG006'}, {'value': '8.35', 'spread': '13.48', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '18.10', 'spread': '20.41', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 4 (n=65,0,61,0,62,64,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '10.28', 'spread': '11.83', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '10.11', 'spread': '15.29', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '8.63', 'spread': '12.54', 'groupId': 'OG004'}, {'value': '5.46', 'spread': '9.76', 'groupId': 'OG005'}, {'value': '4.63', 'spread': '8.68', 'groupId': 'OG006'}, {'value': '8.67', 'spread': '13.62', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '15.30', 'spread': '16.85', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 6 (n=64,0,61,0,66,67,66,69,0,58,0)', 'categories': [{'measurements': [{'value': '10.55', 'spread': '9.79', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '8.34', 'spread': '13.70', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '8.26', 'spread': '14.30', 'groupId': 'OG004'}, {'value': '5.42', 'spread': '10.04', 'groupId': 'OG005'}, {'value': '5.41', 'spread': '8.63', 'groupId': 'OG006'}, {'value': '10.68', 'spread': '17.49', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '15.18', 'spread': '19.32', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 8 (n=63,0,59,0,62,62,67,67,0,58,0)', 'categories': [{'measurements': [{'value': '9.62', 'spread': '11.78', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '7.64', 'spread': '11.54', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '7.17', 'spread': '11.47', 'groupId': 'OG004'}, {'value': '10.18', 'spread': '24.04', 'groupId': 'OG005'}, {'value': '8.39', 'spread': '11.39', 'groupId': 'OG006'}, {'value': '9.75', 'spread': '18.92', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '20.38', 'spread': '30.37', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12 (n=61,0,57,0,60,63,62,65,0,60,0)', 'categories': [{'measurements': [{'value': '8.53', 'spread': '9.59', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '9.54', 'spread': '13.52', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '6.54', 'spread': '9.68', 'groupId': 'OG004'}, {'value': '9.11', 'spread': '20.08', 'groupId': 'OG005'}, {'value': '5.81', 'spread': '7.25', 'groupId': 'OG006'}, {'value': '9.53', 'spread': '15.08', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '19.69', 'spread': '20.07', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 16 (n=42,21,43,13,54,64,58,55,9,37,16)', 'categories': [{'measurements': [{'value': '7.80', 'spread': '10.30', 'groupId': 'OG000'}, {'value': '7.02', 'spread': '8.51', 'groupId': 'OG001'}, {'value': '10.72', 'spread': '18.93', 'groupId': 'OG002'}, {'value': '5.85', 'spread': '5.47', 'groupId': 'OG003'}, {'value': '5.40', 'spread': '8.06', 'groupId': 'OG004'}, {'value': '6.77', 'spread': '10.27', 'groupId': 'OG005'}, {'value': '9.79', 'spread': '22.24', 'groupId': 'OG006'}, {'value': '6.52', 'spread': '11.33', 'groupId': 'OG007'}, {'value': '6.89', 'spread': '7.06', 'groupId': 'OG008'}, {'value': '13.08', 'spread': '11.49', 'groupId': 'OG009'}, {'value': '6.52', 'spread': '7.30', 'groupId': 'OG010'}]}]}, {'title': 'Week 20 (n=39,21,44,13,57,63,57,55,12,36,17)', 'categories': [{'measurements': [{'value': '8.96', 'spread': '11.64', 'groupId': 'OG000'}, {'value': '8.55', 'spread': '12.87', 'groupId': 'OG001'}, {'value': '7.71', 'spread': '10.88', 'groupId': 'OG002'}, {'value': '11.28', 'spread': '17.83', 'groupId': 'OG003'}, {'value': '7.93', 'spread': '19.22', 'groupId': 'OG004'}, {'value': '5.58', 'spread': '8.69', 'groupId': 'OG005'}, {'value': '3.46', 'spread': '3.17', 'groupId': 'OG006'}, {'value': '4.75', 'spread': '5.28', 'groupId': 'OG007'}, {'value': '7.89', 'spread': '9.08', 'groupId': 'OG008'}, {'value': '16.14', 'spread': '16.63', 'groupId': 'OG009'}, {'value': '12.10', 'spread': '18.21', 'groupId': 'OG010'}]}]}, {'title': 'Week 24 (n=39,20,43,13,53,63,56,52,12,36,17)', 'categories': [{'measurements': [{'value': '7.63', 'spread': '10.26', 'groupId': 'OG000'}, {'value': '6.02', 'spread': '7.31', 'groupId': 'OG001'}, {'value': '10.31', 'spread': '17.43', 'groupId': 'OG002'}, {'value': '12.58', 'spread': '12.19', 'groupId': 'OG003'}, {'value': '5.92', 'spread': '14.78', 'groupId': 'OG004'}, {'value': '6.66', 'spread': '17.03', 'groupId': 'OG005'}, {'value': '6.51', 'spread': '11.04', 'groupId': 'OG006'}, {'value': '4.54', 'spread': '4.69', 'groupId': 'OG007'}, {'value': '7.19', 'spread': '8.18', 'groupId': 'OG008'}, {'value': '13.39', 'spread': '15.05', 'groupId': 'OG009'}, {'value': '16.21', 'spread': '26.51', 'groupId': 'OG010'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 milligram per deciliter (mg/dL) to 10 mg/dL. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET', 'denoms': [{'units': 'Participants', 'counts': [{'value': '65', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '63', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '63', 'groupId': 'OG004'}, {'value': '69', 'groupId': 'OG005'}, {'value': '68', 'groupId': 'OG006'}, {'value': '74', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '61', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Week 2 (n=65,0,63,0,63,69,68,74,0,61,0)', 'categories': [{'measurements': [{'value': '-2.05', 'spread': '18.32', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-6.93', 'spread': '14.85', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-11.38', 'spread': '19.27', 'groupId': 'OG004'}, {'value': '-9.19', 'spread': '19.90', 'groupId': 'OG005'}, {'value': '-11.87', 'spread': '15.22', 'groupId': 'OG006'}, {'value': '-6.56', 'spread': '12.70', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '0.64', 'spread': '14.26', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 4 (n=65,0,61,0,62,64,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '-6.07', 'spread': '14.44', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-5.12', 'spread': '17.24', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-8.54', 'spread': '16.65', 'groupId': 'OG004'}, {'value': '-9.45', 'spread': '16.27', 'groupId': 'OG005'}, {'value': '-11.70', 'spread': '17.89', 'groupId': 'OG006'}, {'value': '-6.69', 'spread': '13.99', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-1.26', 'spread': '12.51', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 6 (n=64,0,61,0,66,67,66,69,0,58,0)', 'categories': [{'measurements': [{'value': '-5.92', 'spread': '16.61', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-6.97', 'spread': '17.77', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-9.81', 'spread': '23.67', 'groupId': 'OG004'}, {'value': '-9.38', 'spread': '16.02', 'groupId': 'OG005'}, {'value': '-10.73', 'spread': '17.63', 'groupId': 'OG006'}, {'value': '-5.03', 'spread': '17.94', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-0.51', 'spread': '12.72', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 8 (n=63,0,59,0,62,62,67,67,0,58,0)', 'categories': [{'measurements': [{'value': '-5.94', 'spread': '16.03', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-7.42', 'spread': '14.21', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-11.35', 'spread': '21.25', 'groupId': 'OG004'}, {'value': '-4.97', 'spread': '24.54', 'groupId': 'OG005'}, {'value': '-8.67', 'spread': '18.05', 'groupId': 'OG006'}, {'value': '-6.11', 'spread': '19.97', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '3.70', 'spread': '25.55', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12 (n=61,0,57,0,60,63,62,65,0,60,0)', 'categories': [{'measurements': [{'value': '-7.56', 'spread': '17.07', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-6.28', 'spread': '14.07', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-12.52', 'spread': '23.93', 'groupId': 'OG004'}, {'value': '-5.96', 'spread': '23.26', 'groupId': 'OG005'}, {'value': '-10.18', 'spread': '16.26', 'groupId': 'OG006'}, {'value': '-5.71', 'spread': '20.18', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '2.07', 'spread': '15.90', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 16 (n=42,21,43,13,54,64,58,55,9,37,16)', 'categories': [{'measurements': [{'value': '-6.96', 'spread': '10.61', 'groupId': 'OG000'}, {'value': '-11.26', 'spread': '21.64', 'groupId': 'OG001'}, {'value': '-7.04', 'spread': '21.18', 'groupId': 'OG002'}, {'value': '-6.33', 'spread': '10.48', 'groupId': 'OG003'}, {'value': '-11.53', 'spread': '22.00', 'groupId': 'OG004'}, {'value': '-8.18', 'spread': '18.99', 'groupId': 'OG005'}, {'value': '-7.01', 'spread': '27.54', 'groupId': 'OG006'}, {'value': '-8.16', 'spread': '17.01', 'groupId': 'OG007'}, {'value': '-7.59', 'spread': '12.45', 'groupId': 'OG008'}, {'value': '-2.59', 'spread': '13.79', 'groupId': 'OG009'}, {'value': '-13.44', 'spread': '12.75', 'groupId': 'OG010'}]}]}, {'title': 'Week 20 (n=39,21,44,13,57,63,57,55,12,36,17)', 'categories': [{'measurements': [{'value': '-6.21', 'spread': '10.94', 'groupId': 'OG000'}, {'value': '-9.73', 'spread': '22.12', 'groupId': 'OG001'}, {'value': '-11.31', 'spread': '16.46', 'groupId': 'OG002'}, {'value': '-0.90', 'spread': '20.08', 'groupId': 'OG003'}, {'value': '-7.80', 'spread': '23.28', 'groupId': 'OG004'}, {'value': '-9.60', 'spread': '19.16', 'groupId': 'OG005'}, {'value': '-14.21', 'spread': '16.73', 'groupId': 'OG006'}, {'value': '-9.65', 'spread': '15.32', 'groupId': 'OG007'}, {'value': '-10.22', 'spread': '13.83', 'groupId': 'OG008'}, {'value': '0.11', 'spread': '15.15', 'groupId': 'OG009'}, {'value': '-7.52', 'spread': '20.34', 'groupId': 'OG010'}]}]}, {'title': 'Week 24 (n=39,20,43,43,53,63,56,52,12,36,17)', 'categories': [{'measurements': [{'value': '-7.61', 'spread': '11.78', 'groupId': 'OG000'}, {'value': '-8.07', 'spread': '10.28', 'groupId': 'OG001'}, {'value': '-7.57', 'spread': '22.26', 'groupId': 'OG002'}, {'value': '0.40', 'spread': '16.50', 'groupId': 'OG003'}, {'value': '-8.18', 'spread': '19.26', 'groupId': 'OG004'}, {'value': '-8.72', 'spread': '22.73', 'groupId': 'OG005'}, {'value': '-10.65', 'spread': '18.76', 'groupId': 'OG006'}, {'value': '-8.75', 'spread': '15.40', 'groupId': 'OG007'}, {'value': '-10.92', 'spread': '15.78', 'groupId': 'OG008'}, {'value': '-2.16', 'spread': '16.06', 'groupId': 'OG009'}, {'value': '-3.41', 'spread': '26.61', 'groupId': 'OG010'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultra-sensitive assay. Normal range of CRP is 0 mg/dL to 10 mg/dL. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '68', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '71', 'groupId': 'OG004'}, {'value': '74', 'groupId': 'OG005'}, {'value': '75', 'groupId': 'OG006'}, {'value': '80', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '69', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Baseline (n=70,0,68,0,71,74,75,79,0,69,0)', 'categories': [{'measurements': [{'value': '5.48', 'spread': '0.80', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '5.31', 'spread': '0.95', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '5.14', 'spread': '0.84', 'groupId': 'OG004'}, {'value': '5.28', 'spread': '0.85', 'groupId': 'OG005'}, {'value': '5.39', 'spread': '0.89', 'groupId': 'OG006'}, {'value': '5.34', 'spread': '0.87', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '5.26', 'spread': '0.96', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2 (n=64,0,63,0,63,69,68,74,0,61,0)', 'categories': [{'measurements': [{'value': '4.88', 'spread': '1.04', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '4.46', 'spread': '1.03', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '4.26', 'spread': '0.90', 'groupId': 'OG004'}, {'value': '4.18', 'spread': '1.04', 'groupId': 'OG005'}, {'value': '4.18', 'spread': '1.16', 'groupId': 'OG006'}, {'value': '4.28', 'spread': '1.07', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '4.91', 'spread': '1.07', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 4 (n=65,0,61,0,62,64,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '4.45', 'spread': '1.08', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '4.03', 'spread': '1.17', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '4.03', 'spread': '0.96', 'groupId': 'OG004'}, {'value': '3.66', 'spread': '1.12', 'groupId': 'OG005'}, {'value': '3.75', 'spread': '1.13', 'groupId': 'OG006'}, {'value': '3.99', 'spread': '1.11', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '4.60', 'spread': '1.01', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 6 (n=63,0,61,0,66,67,66,69,0,58,0)', 'categories': [{'measurements': [{'value': '4.32', 'spread': '1.12', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '3.74', 'spread': '1.30', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '3.68', 'spread': '1.00', 'groupId': 'OG004'}, {'value': '3.59', 'spread': '1.27', 'groupId': 'OG005'}, {'value': '3.60', 'spread': '1.13', 'groupId': 'OG006'}, {'value': '3.94', 'spread': '1.16', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '4.35', 'spread': '1.04', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 8 (n=63,0,59,0,62,62,67,67,0,58,0)', 'categories': [{'measurements': [{'value': '4.21', 'spread': '1.22', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '3.63', 'spread': '1.27', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '3.54', 'spread': '1.01', 'groupId': 'OG004'}, {'value': '3.61', 'spread': '1.23', 'groupId': 'OG005'}, {'value': '3.38', 'spread': '1.10', 'groupId': 'OG006'}, {'value': '3.72', 'spread': '1.35', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '4.30', 'spread': '1.08', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12 (n=61,0,55,0,60,63,62,65,0,60,0)', 'categories': [{'measurements': [{'value': '3.98', 'spread': '1.15', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '3.46', 'spread': '1.38', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '3.57', 'spread': '1.09', 'groupId': 'OG004'}, {'value': '3.40', 'spread': '1.27', 'groupId': 'OG005'}, {'value': '3.28', 'spread': '1.25', 'groupId': 'OG006'}, {'value': '3.61', 'spread': '1.25', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '4.37', 'spread': '1.29', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 16 (n=42,21,43,13,54,64,58,55,9,37,16)', 'categories': [{'measurements': [{'value': '3.59', 'spread': '1.15', 'groupId': 'OG000'}, {'value': '4.33', 'spread': '1.16', 'groupId': 'OG001'}, {'value': '3.11', 'spread': '1.23', 'groupId': 'OG002'}, {'value': '4.19', 'spread': '1.48', 'groupId': 'OG003'}, {'value': '3.19', 'spread': '1.10', 'groupId': 'OG004'}, {'value': '3.34', 'spread': '1.22', 'groupId': 'OG005'}, {'value': '3.12', 'spread': '1.25', 'groupId': 'OG006'}, {'value': '3.14', 'spread': '1.06', 'groupId': 'OG007'}, {'value': '4.65', 'spread': '1.08', 'groupId': 'OG008'}, {'value': '3.93', 'spread': '1.06', 'groupId': 'OG009'}, {'value': '3.91', 'spread': '1.19', 'groupId': 'OG010'}]}]}, {'title': 'Week 20 (n=39,21,44,13,57,63,57,55,12,36,17)', 'categories': [{'measurements': [{'value': '3.48', 'spread': '1.28', 'groupId': 'OG000'}, {'value': '3.83', 'spread': '1.62', 'groupId': 'OG001'}, {'value': '3.06', 'spread': '1.25', 'groupId': 'OG002'}, {'value': '4.24', 'spread': '1.56', 'groupId': 'OG003'}, {'value': '3.09', 'spread': '1.17', 'groupId': 'OG004'}, {'value': '3.14', 'spread': '1.29', 'groupId': 'OG005'}, {'value': '2.94', 'spread': '1.04', 'groupId': 'OG006'}, {'value': '3.08', 'spread': '1.11', 'groupId': 'OG007'}, {'value': '4.82', 'spread': '1.24', 'groupId': 'OG008'}, {'value': '3.81', 'spread': '1.23', 'groupId': 'OG009'}, {'value': '3.86', 'spread': '1.24', 'groupId': 'OG010'}]}]}, {'title': 'Week 24 (n=39,20,42,13,53,63,56,52,12,36,17)', 'categories': [{'measurements': [{'value': '3.39', 'spread': '1.15', 'groupId': 'OG000'}, {'value': '3.88', 'spread': '1.49', 'groupId': 'OG001'}, {'value': '3.14', 'spread': '1.26', 'groupId': 'OG002'}, {'value': '4.08', 'spread': '1.35', 'groupId': 'OG003'}, {'value': '3.03', 'spread': '1.05', 'groupId': 'OG004'}, {'value': '3.15', 'spread': '1.19', 'groupId': 'OG005'}, {'value': '2.91', 'spread': '1.12', 'groupId': 'OG006'}, {'value': '3.07', 'spread': '0.98', 'groupId': 'OG007'}, {'value': '4.51', 'spread': '1.61', 'groupId': 'OG008'}, {'value': '3.48', 'spread': '1.06', 'groupId': 'OG009'}, {'value': '4.08', 'spread': '1.37', 'groupId': 'OG010'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) less than or equal to (\\<=) 3.2 implied low disease activity and more than (\\>) 3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) less than (\\<) 2.6 = remission.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET', 'denoms': [{'units': 'Participants', 'counts': [{'value': '64', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '63', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '63', 'groupId': 'OG004'}, {'value': '69', 'groupId': 'OG005'}, {'value': '68', 'groupId': 'OG006'}, {'value': '73', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '61', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Week 2 (n=64,0,63,0,63,69,68,73,0,61,0)', 'categories': [{'measurements': [{'value': '-0.55', 'spread': '0.76', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-0.78', 'spread': '0.92', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-0.86', 'spread': '0.82', 'groupId': 'OG004'}, {'value': '-1.07', 'spread': '0.84', 'groupId': 'OG005'}, {'value': '-1.22', 'spread': '1.08', 'groupId': 'OG006'}, {'value': '-1.01', 'spread': '0.97', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-0.26', 'spread': '0.78', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 4 (n=65,0,61,0,62,64,65,69,0,61,0)', 'categories': [{'measurements': [{'value': '-0.99', 'spread': '0.91', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-1.23', 'spread': '1.19', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-1.09', 'spread': '0.94', 'groupId': 'OG004'}, {'value': '-1.58', 'spread': '1.09', 'groupId': 'OG005'}, {'value': '-1.71', 'spread': '1.20', 'groupId': 'OG006'}, {'value': '-1.30', 'spread': '1.06', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-0.57', 'spread': '0.88', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 6 (n=63,0,61,0,66,67,66,69,0,58,0)', 'categories': [{'measurements': [{'value': '-1.13', 'spread': '1.03', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-1.52', 'spread': '1.27', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-1.44', 'spread': '0.99', 'groupId': 'OG004'}, {'value': '-1.66', 'spread': '1.18', 'groupId': 'OG005'}, {'value': '-1.81', 'spread': '1.17', 'groupId': 'OG006'}, {'value': '-1.38', 'spread': '1.07', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-0.80', 'spread': '0.93', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 8 (n=63,0,59,0,62,62,67,67,0,58,0)', 'categories': [{'measurements': [{'value': '-1.22', 'spread': '1.14', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-1.61', 'spread': '1.18', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-1.56', 'spread': '0.97', 'groupId': 'OG004'}, {'value': '-1.63', 'spread': '1.25', 'groupId': 'OG005'}, {'value': '-2.02', 'spread': '1.14', 'groupId': 'OG006'}, {'value': '-1.63', 'spread': '1.17', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-0.83', 'spread': '1.11', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12 (n=61,0,55,0,60,63,62,65,0,60,0)', 'categories': [{'measurements': [{'value': '-1.45', 'spread': '1.13', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-1.85', 'spread': '1.27', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-1.59', 'spread': '1.18', 'groupId': 'OG004'}, {'value': '-1.82', 'spread': '1.17', 'groupId': 'OG005'}, {'value': '-2.13', 'spread': '1.32', 'groupId': 'OG006'}, {'value': '-1.72', 'spread': '1.13', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-0.82', 'spread': '1.11', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 16 (n=42,21,43,13,54,64,58,55,9,37,16)', 'categories': [{'measurements': [{'value': '-1.87', 'spread': '1.13', 'groupId': 'OG000'}, {'value': '-1.14', 'spread': '0.99', 'groupId': 'OG001'}, {'value': '-2.27', 'spread': '1.14', 'groupId': 'OG002'}, {'value': '-0.81', 'spread': '1.20', 'groupId': 'OG003'}, {'value': '-1.93', 'spread': '1.12', 'groupId': 'OG004'}, {'value': '-1.89', 'spread': '1.13', 'groupId': 'OG005'}, {'value': '-2.31', 'spread': '1.39', 'groupId': 'OG006'}, {'value': '-2.13', 'spread': '1.04', 'groupId': 'OG007'}, {'value': '-0.88', 'spread': '0.95', 'groupId': 'OG008'}, {'value': '-1.14', 'spread': '1.03', 'groupId': 'OG009'}, {'value': '-1.43', 'spread': '0.70', 'groupId': 'OG010'}]}]}, {'title': 'Week 20 (n=39,21,44,13,57,63,57,55,12,36,17)', 'categories': [{'measurements': [{'value': '-1.94', 'spread': '1.26', 'groupId': 'OG000'}, {'value': '-1.64', 'spread': '1.25', 'groupId': 'OG001'}, {'value': '-2.41', 'spread': '1.26', 'groupId': 'OG002'}, {'value': '-0.76', 'spread': '1.22', 'groupId': 'OG003'}, {'value': '-2.05', 'spread': '1.15', 'groupId': 'OG004'}, {'value': '-2.09', 'spread': '1.28', 'groupId': 'OG005'}, {'value': '-2.49', 'spread': '1.26', 'groupId': 'OG006'}, {'value': '-2.17', 'spread': '0.96', 'groupId': 'OG007'}, {'value': '-0.95', 'spread': '0.81', 'groupId': 'OG008'}, {'value': '-1.27', 'spread': '1.37', 'groupId': 'OG009'}, {'value': '-1.47', 'spread': '1.04', 'groupId': 'OG010'}]}]}, {'title': 'Week 24 (n=39,20,42,13,53,63,56,52,12,36,17)', 'categories': [{'measurements': [{'value': '-2.06', 'spread': '1.22', 'groupId': 'OG000'}, {'value': '-1.55', 'spread': '1.07', 'groupId': 'OG001'}, {'value': '-2.29', 'spread': '1.19', 'groupId': 'OG002'}, {'value': '-0.92', 'spread': '1.17', 'groupId': 'OG003'}, {'value': '-2.06', 'spread': '1.04', 'groupId': 'OG004'}, {'value': '-2.13', 'spread': '1.12', 'groupId': 'OG005'}, {'value': '-2.49', 'spread': '1.27', 'groupId': 'OG006'}, {'value': '-2.19', 'spread': '1.04', 'groupId': 'OG007'}, {'value': '-1.26', 'spread': '1.23', 'groupId': 'OG008'}, {'value': '-1.55', 'spread': '1.25', 'groupId': 'OG009'}, {'value': '-1.25', 'spread': '0.96', 'groupId': 'OG010'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \\<= 3.2 implied low disease activity and \\>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \\<2.6 = remission.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '64', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '63', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '63', 'groupId': 'OG004'}, {'value': '69', 'groupId': 'OG005'}, {'value': '68', 'groupId': 'OG006'}, {'value': '74', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '61', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Week 2: Good (n=64,0,63,0,63,69,68,74,0,61,0)', 'categories': [{'measurements': [{'value': '4.7', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '4.8', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '9.5', 'groupId': 'OG004'}, {'value': '13.0', 'groupId': 'OG005'}, {'value': '16.2', 'groupId': 'OG006'}, {'value': '12.2', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '3.3', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2: Mod (n=64,0,63,0,63,69,68,74,0,61,0)', 'categories': [{'measurements': [{'value': '23.4', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '44.4', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '42.9', 'groupId': 'OG004'}, {'value': '46.4', 'groupId': 'OG005'}, {'value': '50.0', 'groupId': 'OG006'}, {'value': '41.9', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '23.0', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2: None (n=64,0,63,0,63,69,68,74,0,61,0)', 'categories': [{'measurements': [{'value': '71.9', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '50.8', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '47.6', 'groupId': 'OG004'}, {'value': '40.6', 'groupId': 'OG005'}, {'value': '33.8', 'groupId': 'OG006'}, {'value': '44.6', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '73.8', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 4: Good (n=65,0,61,0,62,64,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '10.8', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '21.3', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '16.1', 'groupId': 'OG004'}, {'value': '28.1', 'groupId': 'OG005'}, {'value': '30.8', 'groupId': 'OG006'}, {'value': '21.4', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '8.2', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 4: Mod (n=65,0,61,0,62,64,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '41.5', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '45.9', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '48.4', 'groupId': 'OG004'}, {'value': '53.1', 'groupId': 'OG005'}, {'value': '49.2', 'groupId': 'OG006'}, {'value': '42.9', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '34.4', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 4: None (n=65,0,61,0,62,64,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '47.7', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '32.8', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '35.5', 'groupId': 'OG004'}, {'value': '18.8', 'groupId': 'OG005'}, {'value': '20.0', 'groupId': 'OG006'}, {'value': '34.3', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '57.4', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 6: Good (n=63,0,61,0,66,67,66,69,0,58,0)', 'categories': [{'measurements': [{'value': '11.1', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '29.5', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '31.8', 'groupId': 'OG004'}, {'value': '29.9', 'groupId': 'OG005'}, {'value': '31.8', 'groupId': 'OG006'}, {'value': '23.2', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '12.1', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 6: Mod (n=63,0,61,0,66,67,66,69,0,58,0)', 'categories': [{'measurements': [{'value': '50.8', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '42.6', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '42.4', 'groupId': 'OG004'}, {'value': '50.7', 'groupId': 'OG005'}, {'value': '50.0', 'groupId': 'OG006'}, {'value': '44.9', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '43.1', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 6: None (n=63,0,61,0,66,67,66,69,0,58,0)', 'categories': [{'measurements': [{'value': '38.1', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '27.9', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '25.8', 'groupId': 'OG004'}, {'value': '19.4', 'groupId': 'OG005'}, {'value': '18.2', 'groupId': 'OG006'}, {'value': '31.9', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '44.8', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 8: Good (n=63,0,59,0,62,62,67,67,0,58,0)', 'categories': [{'measurements': [{'value': '19.0', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '30.5', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '37.1', 'groupId': 'OG004'}, {'value': '32.3', 'groupId': 'OG005'}, {'value': '43.3', 'groupId': 'OG006'}, {'value': '37.3', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '13.8', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 8: Mod (n=63,0,59,0,62,62,67,67,0,58,0)', 'categories': [{'measurements': [{'value': '46.0', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '47.5', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '46.8', 'groupId': 'OG004'}, {'value': '45.2', 'groupId': 'OG005'}, {'value': '47.8', 'groupId': 'OG006'}, {'value': '40.3', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '46.6', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 8: None (n=63,0,59,0,62,62,67,67,0,58,0)', 'categories': [{'measurements': [{'value': '34.9', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '22.0', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '16.1', 'groupId': 'OG004'}, {'value': '22.6', 'groupId': 'OG005'}, {'value': '9.0', 'groupId': 'OG006'}, {'value': '22.4', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '39.7', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: Good (n=61,0,55,0,60,63,62,65,0,60,0)', 'categories': [{'measurements': [{'value': '23.0', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '45.5', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '33.3', 'groupId': 'OG004'}, {'value': '41.3', 'groupId': 'OG005'}, {'value': '51.6', 'groupId': 'OG006'}, {'value': '36.9', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '16.7', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: Mod (n=61,0,55,0,60,63,62,65,0,60,0)', 'categories': [{'measurements': [{'value': '49.2', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '32.7', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '50.0', 'groupId': 'OG004'}, {'value': '39.7', 'groupId': 'OG005'}, {'value': '37.1', 'groupId': 'OG006'}, {'value': '44.6', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '36.7', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: None (n=61,0,55,0,60,63,62,65,0,60,0)', 'categories': [{'measurements': [{'value': '27.9', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '21.8', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '16.7', 'groupId': 'OG004'}, {'value': '19.0', 'groupId': 'OG005'}, {'value': '11.3', 'groupId': 'OG006'}, {'value': '18.5', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '46.7', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 16: Good (n=42,21,43,13,54,64,58,55,9,37,16)', 'categories': [{'measurements': [{'value': '40.5', 'groupId': 'OG000'}, {'value': '19.0', 'groupId': 'OG001'}, {'value': '55.8', 'groupId': 'OG002'}, {'value': '30.8', 'groupId': 'OG003'}, {'value': '51.9', 'groupId': 'OG004'}, {'value': '50.0', 'groupId': 'OG005'}, {'value': '48.3', 'groupId': 'OG006'}, {'value': '52.7', 'groupId': 'OG007'}, {'value': '11.1', 'groupId': 'OG008'}, {'value': '27.0', 'groupId': 'OG009'}, {'value': '18.8', 'groupId': 'OG010'}]}]}, {'title': 'Week 16: Mod (n=42,21,43,13,54,64,58,55,9,37,16)', 'categories': [{'measurements': [{'value': '50.0', 'groupId': 'OG000'}, {'value': '38.1', 'groupId': 'OG001'}, {'value': '32.6', 'groupId': 'OG002'}, {'value': '23.1', 'groupId': 'OG003'}, {'value': '37.0', 'groupId': 'OG004'}, {'value': '34.4', 'groupId': 'OG005'}, {'value': '43.1', 'groupId': 'OG006'}, {'value': '43.6', 'groupId': 'OG007'}, {'value': '33.3', 'groupId': 'OG008'}, {'value': '40.5', 'groupId': 'OG009'}, {'value': '62.5', 'groupId': 'OG010'}]}]}, {'title': 'Week 16: None (n=42,21,43,13,54,64,58,55,9,37,16)', 'categories': [{'measurements': [{'value': '9.5', 'groupId': 'OG000'}, {'value': '42.9', 'groupId': 'OG001'}, {'value': '11.6', 'groupId': 'OG002'}, {'value': '46.2', 'groupId': 'OG003'}, {'value': '11.1', 'groupId': 'OG004'}, {'value': '15.6', 'groupId': 'OG005'}, {'value': '8.6', 'groupId': 'OG006'}, {'value': '3.6', 'groupId': 'OG007'}, {'value': '55.6', 'groupId': 'OG008'}, {'value': '32.4', 'groupId': 'OG009'}, {'value': '18.8', 'groupId': 'OG010'}]}]}, {'title': 'Week 20: Good (n=39,21,44,13,57,63,57,55,12,36,17)', 'categories': [{'measurements': [{'value': '46.2', 'groupId': 'OG000'}, {'value': '42.9', 'groupId': 'OG001'}, {'value': '59.1', 'groupId': 'OG002'}, {'value': '15.4', 'groupId': 'OG003'}, {'value': '61.4', 'groupId': 'OG004'}, {'value': '52.4', 'groupId': 'OG005'}, {'value': '57.9', 'groupId': 'OG006'}, {'value': '52.7', 'groupId': 'OG007'}, {'value': '0.0', 'groupId': 'OG008'}, {'value': '30.6', 'groupId': 'OG009'}, {'value': '29.4', 'groupId': 'OG010'}]}]}, {'title': 'Week 20: Mod (n=39,21,44,13,57,63,57,55,12,36,17)', 'categories': [{'measurements': [{'value': '43.6', 'groupId': 'OG000'}, {'value': '28.6', 'groupId': 'OG001'}, {'value': '31.8', 'groupId': 'OG002'}, {'value': '46.2', 'groupId': 'OG003'}, {'value': '28.1', 'groupId': 'OG004'}, {'value': '36.5', 'groupId': 'OG005'}, {'value': '35.1', 'groupId': 'OG006'}, {'value': '40.0', 'groupId': 'OG007'}, {'value': '58.3', 'groupId': 'OG008'}, {'value': '36.1', 'groupId': 'OG009'}, {'value': '47.1', 'groupId': 'OG010'}]}]}, {'title': 'Week 20: None (n=39,21,44,13,57,63,57,55,12,36,17)', 'categories': [{'measurements': [{'value': '10.3', 'groupId': 'OG000'}, {'value': '28.6', 'groupId': 'OG001'}, {'value': '9.1', 'groupId': 'OG002'}, {'value': '38.5', 'groupId': 'OG003'}, {'value': '10.5', 'groupId': 'OG004'}, {'value': '11.1', 'groupId': 'OG005'}, {'value': '7.0', 'groupId': 'OG006'}, {'value': '7.3', 'groupId': 'OG007'}, {'value': '41.7', 'groupId': 'OG008'}, {'value': '33.3', 'groupId': 'OG009'}, {'value': '23.5', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: Good (n=39,20,42,13,53,63,56,52,12,36,17)', 'categories': [{'measurements': [{'value': '43.6', 'groupId': 'OG000'}, {'value': '35.0', 'groupId': 'OG001'}, {'value': '54.8', 'groupId': 'OG002'}, {'value': '23.1', 'groupId': 'OG003'}, {'value': '52.8', 'groupId': 'OG004'}, {'value': '58.7', 'groupId': 'OG005'}, {'value': '66.1', 'groupId': 'OG006'}, {'value': '59.6', 'groupId': 'OG007'}, {'value': '25.0', 'groupId': 'OG008'}, {'value': '33.3', 'groupId': 'OG009'}, {'value': '23.5', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: Mod (n=39,20,42,13,53,63,56,52,12,36,17)', 'categories': [{'measurements': [{'value': '46.2', 'groupId': 'OG000'}, {'value': '35.0', 'groupId': 'OG001'}, {'value': '33.3', 'groupId': 'OG002'}, {'value': '38.5', 'groupId': 'OG003'}, {'value': '37.7', 'groupId': 'OG004'}, {'value': '30.2', 'groupId': 'OG005'}, {'value': '23.2', 'groupId': 'OG006'}, {'value': '34.6', 'groupId': 'OG007'}, {'value': '33.3', 'groupId': 'OG008'}, {'value': '41.7', 'groupId': 'OG009'}, {'value': '47.1', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: None (n=39,20,42,13,53,63,56,52,12,36,17)', 'categories': [{'measurements': [{'value': '10.3', 'groupId': 'OG000'}, {'value': '30.0', 'groupId': 'OG001'}, {'value': '11.9', 'groupId': 'OG002'}, {'value': '38.5', 'groupId': 'OG003'}, {'value': '9.4', 'groupId': 'OG004'}, {'value': '11.1', 'groupId': 'OG005'}, {'value': '10.7', 'groupId': 'OG006'}, {'value': '5.8', 'groupId': 'OG007'}, {'value': '41.7', 'groupId': 'OG008'}, {'value': '25.0', 'groupId': 'OG009'}, {'value': '29.4', 'groupId': 'OG010'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'Disease improvement was classified as good, moderate, and none based on improvement in DAS 28-3 (CRP) from baseline and present DAS 28-3 (CRP) score. Good: an improvement from baseline of \\>1.2 and a present score of \\<=3.2; none: an improvement of \\<=0.6 or \\>0.6 to \\<=1.2 with a present score of \\>5.1; remaining participants were classified as having moderate (Mod) improvement. Scores of good and moderate were considered to have therapeutic response.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Disease Remission Based on DAS28-3 (CRP)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '64', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '63', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '63', 'groupId': 'OG004'}, {'value': '68', 'groupId': 'OG005'}, {'value': '68', 'groupId': 'OG006'}, {'value': '74', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '61', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Week 2 (n=64,0,63,0,63,68,68,74,0,61,0)', 'categories': [{'measurements': [{'value': '1.56', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '3.17', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '1.59', 'groupId': 'OG004'}, {'value': '4.41', 'groupId': 'OG005'}, {'value': '13.24', 'groupId': 'OG006'}, {'value': '4.05', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '3.28', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 4 (n=65,0,61,0,62,63,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '4.62', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '14.75', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '8.06', 'groupId': 'OG004'}, {'value': '19.05', 'groupId': 'OG005'}, {'value': '16.92', 'groupId': 'OG006'}, {'value': '10.00', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '3.28', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 6 (n=63,0,61,0,66,66,66,69,0,58,0)', 'categories': [{'measurements': [{'value': '3.17', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '19.67', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '13.64', 'groupId': 'OG004'}, {'value': '24.24', 'groupId': 'OG005'}, {'value': '22.73', 'groupId': 'OG006'}, {'value': '10.14', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '3.45', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 8 (n=63,0,59,0,62,61,67,67,0,58,0)', 'categories': [{'measurements': [{'value': '7.94', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '22.03', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '19.35', 'groupId': 'OG004'}, {'value': '21.31', 'groupId': 'OG005'}, {'value': '23.88', 'groupId': 'OG006'}, {'value': '20.90', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '6.90', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12 (n=61,0,55,0,60,62,62,65,0,60,0)', 'categories': [{'measurements': [{'value': '6.56', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '30.91', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '16.67', 'groupId': 'OG004'}, {'value': '32.26', 'groupId': 'OG005'}, {'value': '37.10', 'groupId': 'OG006'}, {'value': '24.62', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '6.67', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 16 (n=42,21,43,13,54,63,58,55,9,37,16)', 'categories': [{'measurements': [{'value': '14.3', 'groupId': 'OG000'}, {'value': '9.5', 'groupId': 'OG001'}, {'value': '41.9', 'groupId': 'OG002'}, {'value': '23.1', 'groupId': 'OG003'}, {'value': '24.1', 'groupId': 'OG004'}, {'value': '30.2', 'groupId': 'OG005'}, {'value': '37.9', 'groupId': 'OG006'}, {'value': '29.1', 'groupId': 'OG007'}, {'value': '11.1', 'groupId': 'OG008'}, {'value': '8.1', 'groupId': 'OG009'}, {'value': '12.5', 'groupId': 'OG010'}]}]}, {'title': 'Week 20 (n=39,21,44,13,57,62,57,55,12,36,17)', 'categories': [{'measurements': [{'value': '20.5', 'groupId': 'OG000'}, {'value': '28.6', 'groupId': 'OG001'}, {'value': '43.2', 'groupId': 'OG002'}, {'value': '15.4', 'groupId': 'OG003'}, {'value': '35.1', 'groupId': 'OG004'}, {'value': '37.1', 'groupId': 'OG005'}, {'value': '38.6', 'groupId': 'OG006'}, {'value': '30.9', 'groupId': 'OG007'}, {'value': '0.0', 'groupId': 'OG008'}, {'value': '13.9', 'groupId': 'OG009'}, {'value': '17.6', 'groupId': 'OG010'}]}]}, {'title': 'Week 24 (n=39,20,42,13,53,63,56,52,12,36,17)', 'categories': [{'measurements': [{'value': '23.1', 'groupId': 'OG000'}, {'value': '25.0', 'groupId': 'OG001'}, {'value': '35.7', 'groupId': 'OG002'}, {'value': '15.4', 'groupId': 'OG003'}, {'value': '41.5', 'groupId': 'OG004'}, {'value': '36.5', 'groupId': 'OG005'}, {'value': '39.3', 'groupId': 'OG006'}, {'value': '32.7', 'groupId': 'OG007'}, {'value': '16.7', 'groupId': 'OG008'}, {'value': '19.4', 'groupId': 'OG009'}, {'value': '17.6', 'groupId': 'OG010'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'DAS28-3 (CRP) defined remission was classified as a score of \\<2.6.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': '36-Item Short-Form Health Survey (SF-36)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}, {'value': '68', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '71', 'groupId': 'OG004'}, {'value': '73', 'groupId': 'OG005'}, {'value': '75', 'groupId': 'OG006'}, {'value': '80', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '69', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Baseline: Ph Fn (n=70,0,68,0,71,73,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '31.48', 'spread': '10.33', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '33.20', 'spread': '11.04', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '31.93', 'spread': '9.66', 'groupId': 'OG004'}, {'value': '31.92', 'spread': '9.15', 'groupId': 'OG005'}, {'value': '31.50', 'spread': '9.29', 'groupId': 'OG006'}, {'value': '30.23', 'spread': '9.70', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '34.01', 'spread': '11.06', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Baseline: R-P (n=70,0,68,0,71,73,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '34.53', 'spread': '8.52', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '34.45', 'spread': '10.52', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '35.54', 'spread': '8.69', 'groupId': 'OG004'}, {'value': '34.64', 'spread': '10.72', 'groupId': 'OG005'}, {'value': '33.70', 'spread': '9.85', 'groupId': 'OG006'}, {'value': '33.13', 'spread': '9.32', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '37.23', 'spread': '9.51', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Baseline: BP (n=70,0,68,0,71,73,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '34.14', 'spread': '6.60', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '34.60', 'spread': '8.35', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '35.36', 'spread': '8.23', 'groupId': 'OG004'}, {'value': '35.11', 'spread': '7.85', 'groupId': 'OG005'}, {'value': '34.98', 'spread': '8.19', 'groupId': 'OG006'}, {'value': '34.20', 'spread': '8.18', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '35.93', 'spread': '8.71', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Baseline: GH (n=70,0,68,0,71,73,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '35.08', 'spread': '6.77', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '35.17', 'spread': '8.02', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '35.12', 'spread': '8.90', 'groupId': 'OG004'}, {'value': '36.52', 'spread': '9.28', 'groupId': 'OG005'}, {'value': '35.94', 'spread': '8.44', 'groupId': 'OG006'}, {'value': '36.08', 'spread': '8.48', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '36.50', 'spread': '9.38', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Baseline: Vit (n=70,0,68,0,71,73,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '40.32', 'spread': '9.95', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '42.36', 'spread': '10.07', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '41.54', 'spread': '9.39', 'groupId': 'OG004'}, {'value': '42.60', 'spread': '10.83', 'groupId': 'OG005'}, {'value': '40.81', 'spread': '11.75', 'groupId': 'OG006'}, {'value': '40.97', 'spread': '9.98', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '44.08', 'spread': '11.63', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Baseline: So Fn (n=70,0,68,0,71,73,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '37.76', 'spread': '10.41', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '38.88', 'spread': '11.35', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '37.72', 'spread': '10.38', 'groupId': 'OG004'}, {'value': '38.99', 'spread': '10.80', 'groupId': 'OG005'}, {'value': '38.01', 'spread': '11.06', 'groupId': 'OG006'}, {'value': '38.03', 'spread': '10.70', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '40.09', 'spread': '11.08', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Baseline: R-E (n=70,0,68,0,71,73,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '34.72', 'spread': '11.55', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '35.18', 'spread': '14.16', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '37.21', 'spread': '12.51', 'groupId': 'OG004'}, {'value': '36.23', 'spread': '12.64', 'groupId': 'OG005'}, {'value': '34.73', 'spread': '14.42', 'groupId': 'OG006'}, {'value': '35.13', 'spread': '13.45', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '39.37', 'spread': '13.94', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Baseline: MnH (n=70,0,68,0,71,73,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '38.98', 'spread': '11.58', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '40.07', 'spread': '11.65', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '41.88', 'spread': '12.02', 'groupId': 'OG004'}, {'value': '42.79', 'spread': '10.99', 'groupId': 'OG005'}, {'value': '39.68', 'spread': '12.65', 'groupId': 'OG006'}, {'value': '39.91', 'spread': '12.53', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '42.91', 'spread': '13.08', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Baseline: Ph C (n=70,0,68,0,71,73,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '33.13', 'spread': '6.72', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '33.73', 'spread': '8.33', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '32.99', 'spread': '8.03', 'groupId': 'OG004'}, {'value': '32.96', 'spread': '8.15', 'groupId': 'OG005'}, {'value': '33.19', 'spread': '7.31', 'groupId': 'OG006'}, {'value': '32.11', 'spread': '8.57', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '34.41', 'spread': '8.59', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Baseline: Mn C (n=70,0,68,0,71,73,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '40.39', 'spread': '11.42', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '41.47', 'spread': '12.68', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '42.81', 'spread': '11.80', 'groupId': 'OG004'}, {'value': '43.53', 'spread': '11.00', 'groupId': 'OG005'}, {'value': '40.92', 'spread': '13.00', 'groupId': 'OG006'}, {'value': '41.68', 'spread': '12.17', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '44.72', 'spread': '13.24', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: Ph Fn (n=63,0,59,0,64,65,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '35.05', 'spread': '10.73', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '36.49', 'spread': '11.63', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '36.45', 'spread': '9.78', 'groupId': 'OG004'}, {'value': '36.25', 'spread': '10.75', 'groupId': 'OG005'}, {'value': '37.80', 'spread': '10.76', 'groupId': 'OG006'}, {'value': '37.49', 'spread': '11.48', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '36.23', 'spread': '11.37', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: R-P (n=63,0,59,0,64,65,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '38.47', 'spread': '8.77', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '39.25', 'spread': '10.85', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '38.26', 'spread': '10.21', 'groupId': 'OG004'}, {'value': '39.71', 'spread': '9.69', 'groupId': 'OG005'}, {'value': '39.41', 'spread': '10.03', 'groupId': 'OG006'}, {'value': '40.17', 'spread': '10.41', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '39.79', 'spread': '10.14', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: BP (n=63,0,59,0,64,65,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '41.62', 'spread': '8.02', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '42.76', 'spread': '11.30', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '42.73', 'spread': '9.57', 'groupId': 'OG004'}, {'value': '44.00', 'spread': '10.81', 'groupId': 'OG005'}, {'value': '44.39', 'spread': '9.40', 'groupId': 'OG006'}, {'value': '44.21', 'spread': '9.78', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '39.46', 'spread': '10.15', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: GH (n=63,0,59,0,64,65,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '37.85', 'spread': '8.10', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '39.04', 'spread': '8.74', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '40.11', 'spread': '9.54', 'groupId': 'OG004'}, {'value': '39.15', 'spread': '8.76', 'groupId': 'OG005'}, {'value': '40.05', 'spread': '9.44', 'groupId': 'OG006'}, {'value': '41.10', 'spread': '9.78', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '39.54', 'spread': '10.42', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: Vit (n=63,0,59,0,64,65,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '45.45', 'spread': '9.82', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '46.80', 'spread': '10.08', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '46.33', 'spread': '10.59', 'groupId': 'OG004'}, {'value': '45.99', 'spread': '10.68', 'groupId': 'OG005'}, {'value': '47.82', 'spread': '10.24', 'groupId': 'OG006'}, {'value': '46.03', 'spread': '11.42', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '46.48', 'spread': '12.24', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: So Fn (n=63,0,59,0,64,65,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '41.18', 'spread': '11.32', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '43.54', 'spread': '11.20', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '42.28', 'spread': '10.82', 'groupId': 'OG004'}, {'value': '42.84', 'spread': '10.06', 'groupId': 'OG005'}, {'value': '43.93', 'spread': '9.81', 'groupId': 'OG006'}, {'value': '44.23', 'spread': '10.53', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '41.38', 'spread': '10.87', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: R-E (n=63,0,59,0,64,65,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '39.47', 'spread': '12.12', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '39.14', 'spread': '12.47', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '39.90', 'spread': '12.87', 'groupId': 'OG004'}, {'value': '39.01', 'spread': '12.07', 'groupId': 'OG005'}, {'value': '39.07', 'spread': '11.96', 'groupId': 'OG006'}, {'value': '41.33', 'spread': '13.30', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '40.39', 'spread': '12.49', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: MnH (n=63,0,59,0,64,65,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '43.84', 'spread': '10.95', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '44.57', 'spread': '10.95', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '45.34', 'spread': '13.08', 'groupId': 'OG004'}, {'value': '43.08', 'spread': '9.84', 'groupId': 'OG005'}, {'value': '45.24', 'spread': '10.70', 'groupId': 'OG006'}, {'value': '46.11', 'spread': '11.49', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '43.36', 'spread': '12.67', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: Ph C (n=63,0,59,0,64,65,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '37.24', 'spread': '8.19', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '38.70', 'spread': '9.73', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '38.27', 'spread': '9.31', 'groupId': 'OG004'}, {'value': '39.52', 'spread': '9.30', 'groupId': 'OG005'}, {'value': '39.97', 'spread': '8.98', 'groupId': 'OG006'}, {'value': '39.64', 'spread': '10.20', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '37.89', 'spread': '9.94', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: Mn C (n=63,0,59,0,64,65,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '44.86', 'spread': '11.45', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '45.47', 'spread': '11.10', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '45.84', 'spread': '13.41', 'groupId': 'OG004'}, {'value': '44.18', 'spread': '10.26', 'groupId': 'OG005'}, {'value': '45.61', 'spread': '10.59', 'groupId': 'OG006'}, {'value': '46.65', 'spread': '11.64', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '45.08', 'spread': '12.48', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: Ph Fn(n=40,20,44,13,55,64,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '37.41', 'spread': '10.35', 'groupId': 'OG000'}, {'value': '34.30', 'spread': '10.72', 'groupId': 'OG001'}, {'value': '38.38', 'spread': '11.35', 'groupId': 'OG002'}, {'value': '39.39', 'spread': '11.83', 'groupId': 'OG003'}, {'value': '40.04', 'spread': '10.81', 'groupId': 'OG004'}, {'value': '38.19', 'spread': '10.88', 'groupId': 'OG005'}, {'value': '38.62', 'spread': '11.08', 'groupId': 'OG006'}, {'value': '40.51', 'spread': '12.11', 'groupId': 'OG007'}, {'value': '32.31', 'spread': '11.36', 'groupId': 'OG008'}, {'value': '39.44', 'spread': '10.64', 'groupId': 'OG009'}, {'value': '38.09', 'spread': '10.04', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: R-P (n=40,20,44,13,55,64,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '40.51', 'spread': '8.53', 'groupId': 'OG000'}, {'value': '35.06', 'spread': '9.36', 'groupId': 'OG001'}, {'value': '39.88', 'spread': '11.85', 'groupId': 'OG002'}, {'value': '38.96', 'spread': '10.26', 'groupId': 'OG003'}, {'value': '41.09', 'spread': '9.12', 'groupId': 'OG004'}, {'value': '40.32', 'spread': '10.91', 'groupId': 'OG005'}, {'value': '40.69', 'spread': '9.67', 'groupId': 'OG006'}, {'value': '41.97', 'spread': '10.80', 'groupId': 'OG007'}, {'value': '35.02', 'spread': '10.72', 'groupId': 'OG008'}, {'value': '44.27', 'spread': '9.80', 'groupId': 'OG009'}, {'value': '42.45', 'spread': '9.44', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: BP (n=40,20,44,13,55,64,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '44.17', 'spread': '8.68', 'groupId': 'OG000'}, {'value': '39.57', 'spread': '11.54', 'groupId': 'OG001'}, {'value': '44.15', 'spread': '10.31', 'groupId': 'OG002'}, {'value': '43.07', 'spread': '9.91', 'groupId': 'OG003'}, {'value': '44.96', 'spread': '9.23', 'groupId': 'OG004'}, {'value': '44.52', 'spread': '10.98', 'groupId': 'OG005'}, {'value': '45.76', 'spread': '9.67', 'groupId': 'OG006'}, {'value': '46.89', 'spread': '10.25', 'groupId': 'OG007'}, {'value': '40.32', 'spread': '11.00', 'groupId': 'OG008'}, {'value': '43.11', 'spread': '9.54', 'groupId': 'OG009'}, {'value': '44.24', 'spread': '8.09', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: GH (n=40,20,44,13,55,64,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '40.65', 'spread': '7.40', 'groupId': 'OG000'}, {'value': '36.87', 'spread': '7.75', 'groupId': 'OG001'}, {'value': '41.45', 'spread': '10.05', 'groupId': 'OG002'}, {'value': '37.35', 'spread': '5.95', 'groupId': 'OG003'}, {'value': '41.35', 'spread': '10.23', 'groupId': 'OG004'}, {'value': '41.09', 'spread': '9.27', 'groupId': 'OG005'}, {'value': '41.40', 'spread': '9.24', 'groupId': 'OG006'}, {'value': '44.03', 'spread': '9.52', 'groupId': 'OG007'}, {'value': '35.81', 'spread': '11.52', 'groupId': 'OG008'}, {'value': '43.16', 'spread': '9.70', 'groupId': 'OG009'}, {'value': '40.68', 'spread': '8.34', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: Vit (n=40,20,44,13,55,64,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '49.05', 'spread': '10.69', 'groupId': 'OG000'}, {'value': '39.60', 'spread': '9.23', 'groupId': 'OG001'}, {'value': '48.76', 'spread': '11.25', 'groupId': 'OG002'}, {'value': '47.29', 'spread': '6.58', 'groupId': 'OG003'}, {'value': '48.40', 'spread': '10.41', 'groupId': 'OG004'}, {'value': '47.55', 'spread': '10.18', 'groupId': 'OG005'}, {'value': '50.11', 'spread': '11.68', 'groupId': 'OG006'}, {'value': '50.50', 'spread': '10.98', 'groupId': 'OG007'}, {'value': '41.94', 'spread': '13.65', 'groupId': 'OG008'}, {'value': '49.75', 'spread': '11.83', 'groupId': 'OG009'}, {'value': '48.23', 'spread': '11.92', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: So Fn(n=40,20,44,13,55,64,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '43.62', 'spread': '10.40', 'groupId': 'OG000'}, {'value': '39.40', 'spread': '10.26', 'groupId': 'OG001'}, {'value': '42.84', 'spread': '12.53', 'groupId': 'OG002'}, {'value': '43.84', 'spread': '9.05', 'groupId': 'OG003'}, {'value': '45.25', 'spread': '11.64', 'groupId': 'OG004'}, {'value': '43.56', 'spread': '10.73', 'groupId': 'OG005'}, {'value': '44.67', 'spread': '10.31', 'groupId': 'OG006'}, {'value': '46.35', 'spread': '10.53', 'groupId': 'OG007'}, {'value': '38.67', 'spread': '12.38', 'groupId': 'OG008'}, {'value': '45.18', 'spread': '10.60', 'groupId': 'OG009'}, {'value': '43.05', 'spread': '10.04', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: R-E (n=40,20,44,13,55,64,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '40.23', 'spread': '11.08', 'groupId': 'OG000'}, {'value': '34.30', 'spread': '10.59', 'groupId': 'OG001'}, {'value': '40.59', 'spread': '13.86', 'groupId': 'OG002'}, {'value': '37.94', 'spread': '12.35', 'groupId': 'OG003'}, {'value': '41.46', 'spread': '12.40', 'groupId': 'OG004'}, {'value': '40.15', 'spread': '11.58', 'groupId': 'OG005'}, {'value': '40.39', 'spread': '11.88', 'groupId': 'OG006'}, {'value': '42.31', 'spread': '13.71', 'groupId': 'OG007'}, {'value': '37.09', 'spread': '16.56', 'groupId': 'OG008'}, {'value': '42.27', 'spread': '13.09', 'groupId': 'OG009'}, {'value': '46.28', 'spread': '9.13', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: MnH (n=40,20,44,13,55,64,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '45.92', 'spread': '11.10', 'groupId': 'OG000'}, {'value': '38.74', 'spread': '10.58', 'groupId': 'OG001'}, {'value': '45.66', 'spread': '12.59', 'groupId': 'OG002'}, {'value': '44.59', 'spread': '7.04', 'groupId': 'OG003'}, {'value': '47.29', 'spread': '13.62', 'groupId': 'OG004'}, {'value': '43.89', 'spread': '10.93', 'groupId': 'OG005'}, {'value': '46.86', 'spread': '11.73', 'groupId': 'OG006'}, {'value': '47.24', 'spread': '11.36', 'groupId': 'OG007'}, {'value': '43.44', 'spread': '12.84', 'groupId': 'OG008'}, {'value': '45.63', 'spread': '14.22', 'groupId': 'OG009'}, {'value': '47.52', 'spread': '11.26', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: Ph C (n=40,20,44,13,55,64,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '39.94', 'spread': '8.41', 'groupId': 'OG000'}, {'value': '36.79', 'spread': '9.76', 'groupId': 'OG001'}, {'value': '40.31', 'spread': '9.95', 'groupId': 'OG002'}, {'value': '39.74', 'spread': '9.76', 'groupId': 'OG003'}, {'value': '41.12', 'spread': '9.22', 'groupId': 'OG004'}, {'value': '40.85', 'spread': '9.79', 'groupId': 'OG005'}, {'value': '40.99', 'spread': '9.14', 'groupId': 'OG006'}, {'value': '42.81', 'spread': '10.22', 'groupId': 'OG007'}, {'value': '34.40', 'spread': '10.57', 'groupId': 'OG008'}, {'value': '42.09', 'spread': '9.20', 'groupId': 'OG009'}, {'value': '39.41', 'spread': '9.58', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: Mn C(n=40,20,44,13,55,64,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '46.62', 'spread': '12.04', 'groupId': 'OG000'}, {'value': '39.10', 'spread': '11.18', 'groupId': 'OG001'}, {'value': '46.21', 'spread': '13.26', 'groupId': 'OG002'}, {'value': '44.52', 'spread': '7.18', 'groupId': 'OG003'}, {'value': '47.34', 'spread': '13.41', 'groupId': 'OG004'}, {'value': '45.03', 'spread': '11.20', 'groupId': 'OG005'}, {'value': '47.21', 'spread': '11.71', 'groupId': 'OG006'}, {'value': '48.03', 'spread': '11.81', 'groupId': 'OG007'}, {'value': '43.35', 'spread': '13.89', 'groupId': 'OG008'}, {'value': '47.08', 'spread': '15.31', 'groupId': 'OG009'}, {'value': '49.27', 'spread': '9.52', 'groupId': 'OG010'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 12, 24/ET', 'description': 'SF-36 is a standardized survey evaluating 8 domains (of 2 components \\[C\\]; physical \\[Ph\\] and mental \\[Mn\\]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical \\[R-P\\], role-emotional \\[R-E\\]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}, {'value': '59', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '64', 'groupId': 'OG004'}, {'value': '64', 'groupId': 'OG005'}, {'value': '65', 'groupId': 'OG006'}, {'value': '70', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '61', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Week 12: Ph Fn (n=63,0,59,0,64,64,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '3.98', 'spread': '7.08', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '3.39', 'spread': '9.60', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '4.57', 'spread': '8.25', 'groupId': 'OG004'}, {'value': '4.18', 'spread': '11.13', 'groupId': 'OG005'}, {'value': '5.96', 'spread': '8.21', 'groupId': 'OG006'}, {'value': '7.40', 'spread': '9.15', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '2.24', 'spread': '8.79', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: R-P (n=63,0,59,0,64,64,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '3.77', 'spread': '8.00', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '4.61', 'spread': '11.45', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '2.68', 'spread': '9.44', 'groupId': 'OG004'}, {'value': '4.52', 'spread': '11.62', 'groupId': 'OG005'}, {'value': '5.20', 'spread': '9.27', 'groupId': 'OG006'}, {'value': '6.86', 'spread': '9.69', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '2.01', 'spread': '9.91', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: BP (n=63,0,59,0,64,64,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '7.29', 'spread': '8.12', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '8.80', 'spread': '11.96', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '7.28', 'spread': '10.29', 'groupId': 'OG004'}, {'value': '8.74', 'spread': '10.66', 'groupId': 'OG005'}, {'value': '9.23', 'spread': '9.48', 'groupId': 'OG006'}, {'value': '10.54', 'spread': '9.16', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '3.23', 'spread': '8.98', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: GH (n=63,0,59,0,64,64,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '2.94', 'spread': '7.04', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '3.84', 'spread': '7.61', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '4.78', 'spread': '8.81', 'groupId': 'OG004'}, {'value': '2.73', 'spread': '7.46', 'groupId': 'OG005'}, {'value': '4.32', 'spread': '8.59', 'groupId': 'OG006'}, {'value': '4.97', 'spread': '9.64', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '2.47', 'spread': '10.32', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: Vit (n=63,0,59,0,64,64,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '5.10', 'spread': '8.99', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '4.29', 'spread': '9.92', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '4.68', 'spread': '9.86', 'groupId': 'OG004'}, {'value': '2.29', 'spread': '8.80', 'groupId': 'OG005'}, {'value': '6.87', 'spread': '8.76', 'groupId': 'OG006'}, {'value': '5.22', 'spread': '8.28', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '1.45', 'spread': '11.66', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: So Fn (n=63,0,59,0,64,64,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '3.72', 'spread': '10.54', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '4.99', 'spread': '10.54', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '4.26', 'spread': '9.93', 'groupId': 'OG004'}, {'value': '3.49', 'spread': '11.84', 'groupId': 'OG005'}, {'value': '4.70', 'spread': '10.33', 'groupId': 'OG006'}, {'value': '5.84', 'spread': '12.43', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '0.80', 'spread': '9.70', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: R-E (n=63,0,59,0,64,64,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '4.26', 'spread': '10.65', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '3.69', 'spread': '13.12', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '2.25', 'spread': '11.23', 'groupId': 'OG004'}, {'value': '2.73', 'spread': '13.28', 'groupId': 'OG005'}, {'value': '3.77', 'spread': '13.04', 'groupId': 'OG006'}, {'value': '5.33', 'spread': '12.06', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-0.96', 'spread': '12.04', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: MnH (n=63,0,59,0,64,64,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '4.92', 'spread': '9.27', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '4.63', 'spread': '10.01', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '3.43', 'spread': '10.19', 'groupId': 'OG004'}, {'value': '0.04', 'spread': '9.08', 'groupId': 'OG005'}, {'value': '4.68', 'spread': '8.73', 'groupId': 'OG006'}, {'value': '5.59', 'spread': '9.87', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-0.88', 'spread': '9.76', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: Ph C (n=63,0,59,0,64,64,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '4.27', 'spread': '6.38', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '5.16', 'spread': '8.82', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '5.30', 'spread': '8.03', 'groupId': 'OG004'}, {'value': '6.32', 'spread': '8.72', 'groupId': 'OG005'}, {'value': '6.77', 'spread': '7.29', 'groupId': 'OG006'}, {'value': '7.98', 'spread': '7.95', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '3.71', 'spread': '7.43', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: Mn C (n=63,0,59,0,64,64,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '4.30', 'spread': '9.47', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '3.94', 'spread': '10.38', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '2.72', 'spread': '9.57', 'groupId': 'OG004'}, {'value': '0.28', 'spread': '10.13', 'groupId': 'OG005'}, {'value': '3.81', 'spread': '9.58', 'groupId': 'OG006'}, {'value': '4.18', 'spread': '10.04', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-1.40', 'spread': '9.18', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: Ph Fn(n=40,20,44,13,55,63,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '6.52', 'spread': '8.32', 'groupId': 'OG000'}, {'value': '2.63', 'spread': '9.94', 'groupId': 'OG001'}, {'value': '5.45', 'spread': '8.57', 'groupId': 'OG002'}, {'value': '4.37', 'spread': '8.35', 'groupId': 'OG003'}, {'value': '7.77', 'spread': '9.41', 'groupId': 'OG004'}, {'value': '6.41', 'spread': '11.62', 'groupId': 'OG005'}, {'value': '6.63', 'spread': '10.30', 'groupId': 'OG006'}, {'value': '8.81', 'spread': '10.48', 'groupId': 'OG007'}, {'value': '6.49', 'spread': '8.15', 'groupId': 'OG008'}, {'value': '3.74', 'spread': '9.56', 'groupId': 'OG009'}, {'value': '4.21', 'spread': '9.84', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: R-P (n=40,20,44,13,55,63,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '6.12', 'spread': '8.34', 'groupId': 'OG000'}, {'value': '1.47', 'spread': '7.72', 'groupId': 'OG001'}, {'value': '5.07', 'spread': '11.00', 'groupId': 'OG002'}, {'value': '4.52', 'spread': '6.77', 'groupId': 'OG003'}, {'value': '6.01', 'spread': '10.23', 'groupId': 'OG004'}, {'value': '5.56', 'spread': '9.76', 'groupId': 'OG005'}, {'value': '6.61', 'spread': '9.33', 'groupId': 'OG006'}, {'value': '7.25', 'spread': '11.27', 'groupId': 'OG007'}, {'value': '5.51', 'spread': '10.50', 'groupId': 'OG008'}, {'value': '5.85', 'spread': '11.43', 'groupId': 'OG009'}, {'value': '4.75', 'spread': '8.64', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: BP (n=40,20,44,13,55,63,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '10.65', 'spread': '9.91', 'groupId': 'OG000'}, {'value': '3.85', 'spread': '8.92', 'groupId': 'OG001'}, {'value': '10.16', 'spread': '9.54', 'groupId': 'OG002'}, {'value': '9.75', 'spread': '7.27', 'groupId': 'OG003'}, {'value': '10.09', 'spread': '10.44', 'groupId': 'OG004'}, {'value': '9.21', 'spread': '10.31', 'groupId': 'OG005'}, {'value': '10.44', 'spread': '10.51', 'groupId': 'OG006'}, {'value': '11.86', 'spread': '10.67', 'groupId': 'OG007'}, {'value': '10.67', 'spread': '12.01', 'groupId': 'OG008'}, {'value': '5.92', 'spread': '10.51', 'groupId': 'OG009'}, {'value': '7.73', 'spread': '7.63', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: GH (n=40,20,44,13,55,63,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '5.62', 'spread': '7.70', 'groupId': 'OG000'}, {'value': '3.58', 'spread': '6.97', 'groupId': 'OG001'}, {'value': '5.92', 'spread': '7.09', 'groupId': 'OG002'}, {'value': '4.11', 'spread': '9.07', 'groupId': 'OG003'}, {'value': '6.34', 'spread': '7.85', 'groupId': 'OG004'}, {'value': '4.68', 'spread': '8.77', 'groupId': 'OG005'}, {'value': '5.41', 'spread': '7.88', 'groupId': 'OG006'}, {'value': '6.43', 'spread': '8.93', 'groupId': 'OG007'}, {'value': '5.92', 'spread': '9.84', 'groupId': 'OG008'}, {'value': '4.20', 'spread': '12.05', 'groupId': 'OG009'}, {'value': '4.04', 'spread': '3.82', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: Vit (n=40,20,44,13,55,63,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '8.12', 'spread': '9.94', 'groupId': 'OG000'}, {'value': '1.56', 'spread': '10.79', 'groupId': 'OG001'}, {'value': '5.82', 'spread': '9.30', 'groupId': 'OG002'}, {'value': '5.04', 'spread': '10.16', 'groupId': 'OG003'}, {'value': '6.64', 'spread': '9.03', 'groupId': 'OG004'}, {'value': '3.52', 'spread': '9.27', 'groupId': 'OG005'}, {'value': '8.53', 'spread': '9.99', 'groupId': 'OG006'}, {'value': '7.95', 'spread': '11.17', 'groupId': 'OG007'}, {'value': '6.76', 'spread': '11.52', 'groupId': 'OG008'}, {'value': '2.08', 'spread': '13.86', 'groupId': 'OG009'}, {'value': '6.06', 'spread': '6.19', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: So Fn(n=40,20,44,13,55,63,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '5.86', 'spread': '9.36', 'groupId': 'OG000'}, {'value': '3.27', 'spread': '12.31', 'groupId': 'OG001'}, {'value': '4.09', 'spread': '11.10', 'groupId': 'OG002'}, {'value': '5.87', 'spread': '10.31', 'groupId': 'OG003'}, {'value': '7.54', 'spread': '10.36', 'groupId': 'OG004'}, {'value': '4.16', 'spread': '11.99', 'groupId': 'OG005'}, {'value': '4.91', 'spread': '10.27', 'groupId': 'OG006'}, {'value': '6.79', 'spread': '11.86', 'groupId': 'OG007'}, {'value': '3.64', 'spread': '11.71', 'groupId': 'OG008'}, {'value': '3.33', 'spread': '12.73', 'groupId': 'OG009'}, {'value': '3.85', 'spread': '9.20', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: R-E (n=40,20,44,13,55,63,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '4.28', 'spread': '11.30', 'groupId': 'OG000'}, {'value': '2.33', 'spread': '12.82', 'groupId': 'OG001'}, {'value': '5.48', 'spread': '16.05', 'groupId': 'OG002'}, {'value': '-0.30', 'spread': '13.69', 'groupId': 'OG003'}, {'value': '4.24', 'spread': '11.81', 'groupId': 'OG004'}, {'value': '4.01', 'spread': '13.30', 'groupId': 'OG005'}, {'value': '5.18', 'spread': '11.73', 'groupId': 'OG006'}, {'value': '5.57', 'spread': '14.61', 'groupId': 'OG007'}, {'value': '2.27', 'spread': '16.86', 'groupId': 'OG008'}, {'value': '0.97', 'spread': '13.70', 'groupId': 'OG009'}, {'value': '2.29', 'spread': '11.17', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: MnH (n=40,20,44,13,55,63,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '7.25', 'spread': '12.82', 'groupId': 'OG000'}, {'value': '1.83', 'spread': '8.73', 'groupId': 'OG001'}, {'value': '4.99', 'spread': '11.52', 'groupId': 'OG002'}, {'value': '4.98', 'spread': '11.27', 'groupId': 'OG003'}, {'value': '5.43', 'spread': '11.92', 'groupId': 'OG004'}, {'value': '0.36', 'spread': '10.48', 'groupId': 'OG005'}, {'value': '5.44', 'spread': '8.23', 'groupId': 'OG006'}, {'value': '5.31', 'spread': '12.73', 'groupId': 'OG007'}, {'value': '6.57', 'spread': '12.84', 'groupId': 'OG008'}, {'value': '0.70', 'spread': '9.97', 'groupId': 'OG009'}, {'value': '0.99', 'spread': '10.10', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: Ph C (n=40,20,44,13,55,63,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '7.47', 'spread': '7.90', 'groupId': 'OG000'}, {'value': '2.91', 'spread': '7.31', 'groupId': 'OG001'}, {'value': '6.78', 'spread': '7.17', 'groupId': 'OG002'}, {'value': '6.62', 'spread': '5.93', 'groupId': 'OG003'}, {'value': '8.31', 'spread': '8.48', 'groupId': 'OG004'}, {'value': '7.99', 'spread': '9.21', 'groupId': 'OG005'}, {'value': '7.81', 'spread': '8.84', 'groupId': 'OG006'}, {'value': '9.59', 'spread': '8.67', 'groupId': 'OG007'}, {'value': '7.83', 'spread': '7.89', 'groupId': 'OG008'}, {'value': '6.26', 'spread': '9.97', 'groupId': 'OG009'}, {'value': '6.40', 'spread': '8.08', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: Mn C (n=40,20,44,13,55,63,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '5.48', 'spread': '12.35', 'groupId': 'OG000'}, {'value': '1.93', 'spread': '11.99', 'groupId': 'OG001'}, {'value': '4.31', 'spread': '13.10', 'groupId': 'OG002'}, {'value': '2.48', 'spread': '11.80', 'groupId': 'OG003'}, {'value': '4.46', 'spread': '10.55', 'groupId': 'OG004'}, {'value': '0.73', 'spread': '10.85', 'groupId': 'OG005'}, {'value': '4.78', 'spread': '9.04', 'groupId': 'OG006'}, {'value': '4.52', 'spread': '12.52', 'groupId': 'OG007'}, {'value': '3.44', 'spread': '14.10', 'groupId': 'OG008'}, {'value': '-0.07', 'spread': '12.42', 'groupId': 'OG009'}, {'value': '1.57', 'spread': '8.22', 'groupId': 'OG010'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 12, 24/ET', 'description': 'SF-36 is a standardized survey evaluating 8 domains (of 2 components \\[C\\]; physical \\[Ph\\] and mental \\[Mn\\]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical \\[R-P\\], role-emotional \\[R-E\\]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '68', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '71', 'groupId': 'OG004'}, {'value': '74', 'groupId': 'OG005'}, {'value': '75', 'groupId': 'OG006'}, {'value': '80', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '69', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Baseline (n=70,0,68,0,71,74,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '0.45', 'spread': '0.29', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '0.46', 'spread': '0.33', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '0.50', 'spread': '0.30', 'groupId': 'OG004'}, {'value': '0.48', 'spread': '0.28', 'groupId': 'OG005'}, {'value': '0.46', 'spread': '0.31', 'groupId': 'OG006'}, {'value': '0.49', 'spread': '0.28', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '0.49', 'spread': '0.33', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12 (n=63,0,59,0,64,65,64,70,0,61,0)', 'categories': [{'measurements': [{'value': '0.63', 'spread': '0.20', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '0.59', 'spread': '0.30', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '0.62', 'spread': '0.26', 'groupId': 'OG004'}, {'value': '0.65', 'spread': '0.23', 'groupId': 'OG005'}, {'value': '0.63', 'spread': '0.27', 'groupId': 'OG006'}, {'value': '0.64', 'spread': '0.25', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '0.55', 'spread': '0.31', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 24 (n=40,20,44,13,55,63,60,52,12,36,17)', 'categories': [{'measurements': [{'value': '0.66', 'spread': '0.23', 'groupId': 'OG000'}, {'value': '0.46', 'spread': '0.42', 'groupId': 'OG001'}, {'value': '0.67', 'spread': '0.26', 'groupId': 'OG002'}, {'value': '0.64', 'spread': '0.25', 'groupId': 'OG003'}, {'value': '0.70', 'spread': '0.23', 'groupId': 'OG004'}, {'value': '0.68', 'spread': '0.23', 'groupId': 'OG005'}, {'value': '0.65', 'spread': '0.25', 'groupId': 'OG006'}, {'value': '0.71', 'spread': '0.27', 'groupId': 'OG007'}, {'value': '0.56', 'spread': '0.32', 'groupId': 'OG008'}, {'value': '0.65', 'spread': '0.22', 'groupId': 'OG009'}, {'value': '0.58', 'spread': '0.32', 'groupId': 'OG010'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 12, 24/ET', 'description': 'EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}, {'value': '59', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '64', 'groupId': 'OG004'}, {'value': '65', 'groupId': 'OG005'}, {'value': '64', 'groupId': 'OG006'}, {'value': '70', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '61', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Week 12 (n=63,0,59,0,64,65,64,70,0,61,0)', 'categories': [{'measurements': [{'value': '0.15', 'spread': '0.26', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '0.16', 'spread': '0.37', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '0.11', 'spread': '0.32', 'groupId': 'OG004'}, {'value': '0.17', 'spread': '0.27', 'groupId': 'OG005'}, {'value': '0.18', 'spread': '0.29', 'groupId': 'OG006'}, {'value': '0.16', 'spread': '0.29', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '0.05', 'spread': '0.35', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 24 (n=40,20,44,13,55,63,60,52,12,36,17)', 'categories': [{'measurements': [{'value': '0.20', 'spread': '0.30', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.30', 'groupId': 'OG001'}, {'value': '0.23', 'spread': '0.33', 'groupId': 'OG002'}, {'value': '0.23', 'spread': '0.37', 'groupId': 'OG003'}, {'value': '0.19', 'spread': '0.30', 'groupId': 'OG004'}, {'value': '0.20', 'spread': '0.31', 'groupId': 'OG005'}, {'value': '0.18', 'spread': '0.29', 'groupId': 'OG006'}, {'value': '0.17', 'spread': '0.32', 'groupId': 'OG007'}, {'value': '0.20', 'spread': '0.45', 'groupId': 'OG008'}, {'value': '0.13', 'spread': '0.30', 'groupId': 'OG009'}, {'value': '0.03', 'spread': '0.29', 'groupId': 'OG010'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 12, 24/ET', 'description': 'EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Medical Outcome Study- Sleep Scale (MOS-SS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '68', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '71', 'groupId': 'OG004'}, {'value': '74', 'groupId': 'OG005'}, {'value': '75', 'groupId': 'OG006'}, {'value': '80', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '69', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Baseline: SPS (n=70,0,68,0,71,74,74,80,0,69,0)', 'categories': [{'measurements': [{'value': '40.62', 'spread': '18.87', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '44.46', 'spread': '21.58', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '38.12', 'spread': '18.93', 'groupId': 'OG004'}, {'value': '36.94', 'spread': '18.49', 'groupId': 'OG005'}, {'value': '40.90', 'spread': '22.41', 'groupId': 'OG006'}, {'value': '38.46', 'spread': '21.21', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '38.26', 'spread': '19.58', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Baseline: OSP (n=70,0,68,0,71,74,74,79,0,69,0)', 'categories': [{'measurements': [{'value': '41.94', 'spread': '18.04', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '45.65', 'spread': '20.86', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '40.22', 'spread': '19.00', 'groupId': 'OG004'}, {'value': '39.05', 'spread': '18.56', 'groupId': 'OG005'}, {'value': '42.87', 'spread': '20.62', 'groupId': 'OG006'}, {'value': '40.49', 'spread': '21.33', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '38.86', 'spread': '19.24', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Baseline: Ade (n=70,0,68,0,71,74,74,80,0,69,0)', 'categories': [{'measurements': [{'value': '48.14', 'spread': '25.50', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '43.82', 'spread': '26.99', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '46.20', 'spread': '27.95', 'groupId': 'OG004'}, {'value': '50.27', 'spread': '26.84', 'groupId': 'OG005'}, {'value': '49.19', 'spread': '28.13', 'groupId': 'OG006'}, {'value': '51.00', 'spread': '30.55', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '51.45', 'spread': '28.45', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Baseline: ASOB (n=70,0,68,0,71,74,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '20.00', 'spread': '24.55', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '22.94', 'spread': '24.50', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '17.75', 'spread': '22.82', 'groupId': 'OG004'}, {'value': '17.30', 'spread': '22.29', 'groupId': 'OG005'}, {'value': '21.87', 'spread': '25.93', 'groupId': 'OG006'}, {'value': '20.50', 'spread': '27.55', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '22.61', 'spread': '25.88', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Baseline: SD (n=70,0,68,0,71,74,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '44.43', 'spread': '23.13', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '49.10', 'spread': '27.47', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '42.61', 'spread': '25.40', 'groupId': 'OG004'}, {'value': '41.17', 'spread': '25.36', 'groupId': 'OG005'}, {'value': '48.37', 'spread': '25.66', 'groupId': 'OG006'}, {'value': '44.42', 'spread': '27.37', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '40.34', 'spread': '26.04', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Baseline: Opt (n=70,0,68,0,71,74,75,80,0,69,0)', 'categories': [{'measurements': [{'value': '0.51', 'spread': '0.50', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '0.44', 'spread': '0.50', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '0.46', 'spread': '0.50', 'groupId': 'OG004'}, {'value': '0.45', 'spread': '0.50', 'groupId': 'OG005'}, {'value': '0.47', 'spread': '0.50', 'groupId': 'OG006'}, {'value': '0.50', 'spread': '0.50', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '0.52', 'spread': '0.50', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Baseline: Qua (n=70,0,67,0,71,74,75,78,0,69,0)', 'categories': [{'measurements': [{'value': '6.87', 'spread': '1.73', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '6.72', 'spread': '1.60', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '7.32', 'spread': '7.65', 'groupId': 'OG004'}, {'value': '7.28', 'spread': '3.54', 'groupId': 'OG005'}, {'value': '6.64', 'spread': '1.61', 'groupId': 'OG006'}, {'value': '6.90', 'spread': '1.52', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '6.71', 'spread': '1.47', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Baseline: Sno (n=69,0,68,0,71,74,74,80,0,69,0)', 'categories': [{'measurements': [{'value': '31.59', 'spread': '30.76', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '35.29', 'spread': '32.07', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '44.51', 'spread': '33.16', 'groupId': 'OG004'}, {'value': '39.73', 'spread': '33.19', 'groupId': 'OG005'}, {'value': '36.00', 'spread': '34.01', 'groupId': 'OG006'}, {'value': '35.25', 'spread': '32.49', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '35.94', 'spread': '33.88', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Baseline: Som (n=70,0,68,0,71,74,75,78,0,69,0)', 'categories': [{'measurements': [{'value': '35.14', 'spread': '20.30', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '38.63', 'spread': '23.51', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '32.86', 'spread': '19.17', 'groupId': 'OG004'}, {'value': '34.50', 'spread': '19.03', 'groupId': 'OG005'}, {'value': '35.91', 'spread': '22.08', 'groupId': 'OG006'}, {'value': '35.04', 'spread': '22.93', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '33.04', 'spread': '20.69', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2: SPS (n=67,0,68,0,68,73,73,79,0,65,0)', 'categories': [{'measurements': [{'value': '39.65', 'spread': '21.00', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '37.89', 'spread': '22.17', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '34.22', 'spread': '21.10', 'groupId': 'OG004'}, {'value': '35.25', 'spread': '19.10', 'groupId': 'OG005'}, {'value': '32.97', 'spread': '21.75', 'groupId': 'OG006'}, {'value': '35.78', 'spread': '20.40', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '34.34', 'spread': '20.21', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2: OSP (n=68,0,68,0,68,73,73,79,0,66,0)', 'categories': [{'measurements': [{'value': '39.04', 'spread': '19.70', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '37.88', 'spread': '21.48', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '34.74', 'spread': '20.11', 'groupId': 'OG004'}, {'value': '35.65', 'spread': '19.37', 'groupId': 'OG005'}, {'value': '35.27', 'spread': '20.56', 'groupId': 'OG006'}, {'value': '36.22', 'spread': '19.65', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '35.67', 'spread': '18.79', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2: Ade (n=68,0,68,0,68,73,73,79,0,66,0)', 'categories': [{'measurements': [{'value': '45.15', 'spread': '27.62', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '49.56', 'spread': '28.31', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '53.24', 'spread': '31.64', 'groupId': 'OG004'}, {'value': '53.42', 'spread': '25.40', 'groupId': 'OG005'}, {'value': '57.53', 'spread': '28.81', 'groupId': 'OG006'}, {'value': '50.51', 'spread': '27.68', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '54.24', 'spread': '29.87', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,65,0)', 'categories': [{'measurements': [{'value': '20.29', 'spread': '25.04', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '17.65', 'spread': '22.27', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '17.94', 'spread': '22.70', 'groupId': 'OG004'}, {'value': '22.74', 'spread': '24.11', 'groupId': 'OG005'}, {'value': '15.34', 'spread': '21.74', 'groupId': 'OG006'}, {'value': '20.25', 'spread': '26.11', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '17.88', 'spread': '23.57', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2: SD (n=68,0,68,0,68,73,73,79,0,66,0)', 'categories': [{'measurements': [{'value': '39.15', 'spread': '22.53', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '39.21', 'spread': '27.05', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '35.00', 'spread': '23.80', 'groupId': 'OG004'}, {'value': '34.93', 'spread': '24.83', 'groupId': 'OG005'}, {'value': '38.73', 'spread': '26.23', 'groupId': 'OG006'}, {'value': '35.87', 'spread': '24.33', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '37.33', 'spread': '25.29', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0)', 'categories': [{'measurements': [{'value': '0.41', 'spread': '0.50', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '0.43', 'spread': '0.50', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '0.53', 'spread': '0.50', 'groupId': 'OG004'}, {'value': '0.52', 'spread': '0.50', 'groupId': 'OG005'}, {'value': '0.52', 'spread': '0.50', 'groupId': 'OG006'}, {'value': '0.44', 'spread': '0.50', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '0.59', 'spread': '0.50', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2: Qua (n=68,0,68,0,68,73,73,79,0,66,0)', 'categories': [{'measurements': [{'value': '6.75', 'spread': '1.73', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '6.76', 'spread': '1.40', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '6.72', 'spread': '1.26', 'groupId': 'OG004'}, {'value': '7.05', 'spread': '1.30', 'groupId': 'OG005'}, {'value': '7.10', 'spread': '1.70', 'groupId': 'OG006'}, {'value': '6.78', 'spread': '1.65', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '7.08', 'spread': '1.53', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2: Sno (n=68,0,67,0,68,73,73,79,0,66,0)', 'categories': [{'measurements': [{'value': '32.94', 'spread': '29.88', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '35.59', 'spread': '32.94', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '37.01', 'spread': '31.38', 'groupId': 'OG004'}, {'value': '35.62', 'spread': '33.21', 'groupId': 'OG005'}, {'value': '30.96', 'spread': '33.01', 'groupId': 'OG006'}, {'value': '30.63', 'spread': '30.18', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '35.76', 'spread': '35.17', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2: Som (n=67,0,68,0,68,73,73,79,0,66,0)', 'categories': [{'measurements': [{'value': '32.34', 'spread': '21.03', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '33.63', 'spread': '24.25', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '31.08', 'spread': '21.66', 'groupId': 'OG004'}, {'value': '33.79', 'spread': '20.97', 'groupId': 'OG005'}, {'value': '32.69', 'spread': '21.26', 'groupId': 'OG006'}, {'value': '31.73', 'spread': '22.32', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '30.51', 'spread': '20.56', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: SPS (n=62,0,59,0,63,65,64,70,0,61,0)', 'categories': [{'measurements': [{'value': '35.05', 'spread': '16.56', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '33.62', 'spread': '22.04', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '33.39', 'spread': '20.64', 'groupId': 'OG004'}, {'value': '34.92', 'spread': '18.85', 'groupId': 'OG005'}, {'value': '35.00', 'spread': '19.41', 'groupId': 'OG006'}, {'value': '32.81', 'spread': '21.22', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '34.26', 'spread': '22.07', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: OSP (n=62,0,59,0,63,65,64,70,0,61,0)', 'categories': [{'measurements': [{'value': '34.78', 'spread': '16.37', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '34.23', 'spread': '20.63', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '33.61', 'spread': '19.83', 'groupId': 'OG004'}, {'value': '35.26', 'spread': '19.48', 'groupId': 'OG005'}, {'value': '36.33', 'spread': '19.86', 'groupId': 'OG006'}, {'value': '33.44', 'spread': '21.57', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '34.50', 'spread': '20.96', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: Ade (n=62,0,59,0,63,65,64,70,0,61,0)', 'categories': [{'measurements': [{'value': '49.35', 'spread': '24.69', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '54.92', 'spread': '32.24', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '53.17', 'spread': '29.99', 'groupId': 'OG004'}, {'value': '54.00', 'spread': '26.74', 'groupId': 'OG005'}, {'value': '56.09', 'spread': '28.21', 'groupId': 'OG006'}, {'value': '58.43', 'spread': '27.59', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '54.59', 'spread': '27.72', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0)', 'categories': [{'measurements': [{'value': '15.16', 'spread': '22.52', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '13.90', 'spread': '19.39', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '20.32', 'spread': '27.24', 'groupId': 'OG004'}, {'value': '20.00', 'spread': '23.72', 'groupId': 'OG005'}, {'value': '18.75', 'spread': '22.50', 'groupId': 'OG006'}, {'value': '21.43', 'spread': '26.00', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '20.98', 'spread': '28.85', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0)', 'categories': [{'measurements': [{'value': '34.94', 'spread': '20.00', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '35.66', 'spread': '26.03', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '32.52', 'spread': '23.96', 'groupId': 'OG004'}, {'value': '34.27', 'spread': '25.00', 'groupId': 'OG005'}, {'value': '39.16', 'spread': '25.16', 'groupId': 'OG006'}, {'value': '34.18', 'spread': '27.10', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '35.41', 'spread': '26.22', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '0.52', 'spread': '0.50', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '0.53', 'spread': '0.50', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '0.48', 'spread': '0.50', 'groupId': 'OG004'}, {'value': '0.54', 'spread': '0.50', 'groupId': 'OG005'}, {'value': '0.45', 'spread': '0.50', 'groupId': 'OG006'}, {'value': '0.51', 'spread': '0.50', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '0.48', 'spread': '0.50', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: Qua (n=62,0,58,0,63,65,64,70,0,61,0)', 'categories': [{'measurements': [{'value': '7.08', 'spread': '1.41', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '7.05', 'spread': '1.53', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '6.71', 'spread': '1.49', 'groupId': 'OG004'}, {'value': '6.85', 'spread': '1.33', 'groupId': 'OG005'}, {'value': '6.98', 'spread': '1.74', 'groupId': 'OG006'}, {'value': '7.60', 'spread': '5.37', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '8.10', 'spread': '9.47', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0)', 'categories': [{'measurements': [{'value': '29.18', 'spread': '26.97', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '34.92', 'spread': '32.71', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '41.59', 'spread': '32.19', 'groupId': 'OG004'}, {'value': '35.69', 'spread': '32.11', 'groupId': 'OG005'}, {'value': '34.69', 'spread': '32.71', 'groupId': 'OG006'}, {'value': '33.43', 'spread': '29.63', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '30.82', 'spread': '31.53', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: Som (n=62,0,59,0,63,65,64,70,0,61,0)', 'categories': [{'measurements': [{'value': '28.82', 'spread': '18.61', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '32.20', 'spread': '21.52', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '31.01', 'spread': '23.10', 'groupId': 'OG004'}, {'value': '34.36', 'spread': '23.22', 'groupId': 'OG005'}, {'value': '32.29', 'spread': '20.62', 'groupId': 'OG006'}, {'value': '30.57', 'spread': '25.16', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '28.96', 'spread': '18.77', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: SPS (n=40,20,44,13,55,64,59,52,12,34,17)', 'categories': [{'measurements': [{'value': '32.17', 'spread': '17.35', 'groupId': 'OG000'}, {'value': '43.67', 'spread': '20.23', 'groupId': 'OG001'}, {'value': '30.68', 'spread': '21.02', 'groupId': 'OG002'}, {'value': '38.21', 'spread': '17.46', 'groupId': 'OG003'}, {'value': '32.55', 'spread': '22.35', 'groupId': 'OG004'}, {'value': '32.50', 'spread': '18.22', 'groupId': 'OG005'}, {'value': '29.89', 'spread': '18.91', 'groupId': 'OG006'}, {'value': '25.45', 'spread': '17.75', 'groupId': 'OG007'}, {'value': '44.44', 'spread': '27.09', 'groupId': 'OG008'}, {'value': '29.51', 'spread': '19.04', 'groupId': 'OG009'}, {'value': '32.55', 'spread': '22.31', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: OSP (n=40,20,44,13,55,64,59,52,12,34,17)', 'categories': [{'measurements': [{'value': '31.64', 'spread': '16.38', 'groupId': 'OG000'}, {'value': '42.86', 'spread': '19.06', 'groupId': 'OG001'}, {'value': '31.46', 'spread': '19.54', 'groupId': 'OG002'}, {'value': '38.80', 'spread': '18.07', 'groupId': 'OG003'}, {'value': '32.18', 'spread': '21.24', 'groupId': 'OG004'}, {'value': '32.95', 'spread': '18.88', 'groupId': 'OG005'}, {'value': '31.18', 'spread': '19.77', 'groupId': 'OG006'}, {'value': '26.76', 'spread': '17.75', 'groupId': 'OG007'}, {'value': '47.27', 'spread': '27.08', 'groupId': 'OG008'}, {'value': '30.41', 'spread': '18.52', 'groupId': 'OG009'}, {'value': '33.04', 'spread': '21.93', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: Ade (n=40,20,44,13,55,64,59,52,12,34,17)', 'categories': [{'measurements': [{'value': '57.00', 'spread': '25.74', 'groupId': 'OG000'}, {'value': '39.50', 'spread': '27.81', 'groupId': 'OG001'}, {'value': '58.41', 'spread': '28.69', 'groupId': 'OG002'}, {'value': '46.15', 'spread': '18.05', 'groupId': 'OG003'}, {'value': '55.64', 'spread': '31.61', 'groupId': 'OG004'}, {'value': '57.34', 'spread': '26.32', 'groupId': 'OG005'}, {'value': '57.46', 'spread': '26.43', 'groupId': 'OG006'}, {'value': '66.92', 'spread': '28.60', 'groupId': 'OG007'}, {'value': '44.17', 'spread': '34.50', 'groupId': 'OG008'}, {'value': '57.65', 'spread': '27.64', 'groupId': 'OG009'}, {'value': '55.29', 'spread': '33.56', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17', 'categories': [{'measurements': [{'value': '14.00', 'spread': '17.66', 'groupId': 'OG000'}, {'value': '20.00', 'spread': '26.75', 'groupId': 'OG001'}, {'value': '12.73', 'spread': '18.85', 'groupId': 'OG002'}, {'value': '18.46', 'spread': '17.25', 'groupId': 'OG003'}, {'value': '14.18', 'spread': '20.61', 'groupId': 'OG004'}, {'value': '17.19', 'spread': '23.33', 'groupId': 'OG005'}, {'value': '11.53', 'spread': '19.72', 'groupId': 'OG006'}, {'value': '11.15', 'spread': '18.33', 'groupId': 'OG007'}, {'value': '25.00', 'spread': '32.05', 'groupId': 'OG008'}, {'value': '13.53', 'spread': '15.35', 'groupId': 'OG009'}, {'value': '14.12', 'spread': '25.26', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17)', 'categories': [{'measurements': [{'value': '32.31', 'spread': '19.05', 'groupId': 'OG000'}, {'value': '40.19', 'spread': '21.76', 'groupId': 'OG001'}, {'value': '30.80', 'spread': '24.04', 'groupId': 'OG002'}, {'value': '38.08', 'spread': '28.62', 'groupId': 'OG003'}, {'value': '32.77', 'spread': '25.76', 'groupId': 'OG004'}, {'value': '32.73', 'spread': '26.78', 'groupId': 'OG005'}, {'value': '32.61', 'spread': '26.23', 'groupId': 'OG006'}, {'value': '28.49', 'spread': '23.70', 'groupId': 'OG007'}, {'value': '52.19', 'spread': '29.21', 'groupId': 'OG008'}, {'value': '30.33', 'spread': '24.00', 'groupId': 'OG009'}, {'value': '36.40', 'spread': '27.29', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '0.53', 'spread': '0.51', 'groupId': 'OG000'}, {'value': '0.50', 'spread': '0.51', 'groupId': 'OG001'}, {'value': '0.55', 'spread': '0.50', 'groupId': 'OG002'}, {'value': '0.38', 'spread': '0.51', 'groupId': 'OG003'}, {'value': '0.45', 'spread': '0.50', 'groupId': 'OG004'}, {'value': '0.55', 'spread': '0.50', 'groupId': 'OG005'}, {'value': '0.45', 'spread': '0.50', 'groupId': 'OG006'}, {'value': '0.57', 'spread': '0.50', 'groupId': 'OG007'}, {'value': '0.33', 'spread': '0.49', 'groupId': 'OG008'}, {'value': '0.58', 'spread': '0.50', 'groupId': 'OG009'}, {'value': '0.41', 'spread': '0.51', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: Qua (n=40,20,44,13,55,64,59,52,12,34,17)', 'categories': [{'measurements': [{'value': '6.88', 'spread': '1.44', 'groupId': 'OG000'}, {'value': '6.80', 'spread': '1.40', 'groupId': 'OG001'}, {'value': '7.25', 'spread': '1.31', 'groupId': 'OG002'}, {'value': '6.69', 'spread': '1.65', 'groupId': 'OG003'}, {'value': '7.93', 'spread': '7.26', 'groupId': 'OG004'}, {'value': '6.94', 'spread': '1.23', 'groupId': 'OG005'}, {'value': '7.05', 'spread': '1.85', 'groupId': 'OG006'}, {'value': '7.12', 'spread': '1.20', 'groupId': 'OG007'}, {'value': '9.42', 'spread': '12.87', 'groupId': 'OG008'}, {'value': '7.43', 'spread': '1.09', 'groupId': 'OG009'}, {'value': '6.41', 'spread': '1.42', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: Sno (n=40,20,44,13,54,64,59,52,12,34,17)', 'categories': [{'measurements': [{'value': '26.50', 'spread': '23.70', 'groupId': 'OG000'}, {'value': '38.00', 'spread': '32.38', 'groupId': 'OG001'}, {'value': '35.00', 'spread': '31.73', 'groupId': 'OG002'}, {'value': '44.62', 'spread': '32.82', 'groupId': 'OG003'}, {'value': '37.41', 'spread': '32.05', 'groupId': 'OG004'}, {'value': '38.13', 'spread': '33.37', 'groupId': 'OG005'}, {'value': '35.25', 'spread': '30.25', 'groupId': 'OG006'}, {'value': '38.46', 'spread': '32.62', 'groupId': 'OG007'}, {'value': '35.00', 'spread': '28.44', 'groupId': 'OG008'}, {'value': '27.06', 'spread': '32.62', 'groupId': 'OG009'}, {'value': '34.12', 'spread': '33.74', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: Som (n=40,20,44,13,55,64,59,52,12,34,17)', 'categories': [{'measurements': [{'value': '29.50', 'spread': '19.33', 'groupId': 'OG000'}, {'value': '40.67', 'spread': '20.85', 'groupId': 'OG001'}, {'value': '34.39', 'spread': '25.39', 'groupId': 'OG002'}, {'value': '31.79', 'spread': '18.49', 'groupId': 'OG003'}, {'value': '29.94', 'spread': '20.68', 'groupId': 'OG004'}, {'value': '32.40', 'spread': '24.05', 'groupId': 'OG005'}, {'value': '28.70', 'spread': '19.93', 'groupId': 'OG006'}, {'value': '26.03', 'spread': '21.42', 'groupId': 'OG007'}, {'value': '33.89', 'spread': '25.34', 'groupId': 'OG008'}, {'value': '27.06', 'spread': '17.67', 'groupId': 'OG009'}, {'value': '23.14', 'spread': '18.12', 'groupId': 'OG010'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 12, 24/ET', 'description': 'Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 subscales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range:0-100); sleep quantity (Qua)(range:0-24), and optimal (Opt) sleep (yes: 1, no: 0)and nine item index measures of sleep disturbance were constructed to provide composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range\\* 100); total score range: 0 to 100; higher score = greater intensity of attribute.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET', 'denoms': [{'units': 'Participants', 'counts': [{'value': '67', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}, {'value': '68', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '68', 'groupId': 'OG004'}, {'value': '73', 'groupId': 'OG005'}, {'value': '72', 'groupId': 'OG006'}, {'value': '79', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '66', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Week 2: SPS (n=67,0,68,0,68,73,72,79,0,66,0)', 'categories': [{'measurements': [{'value': '-0.95', 'spread': '11.35', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-6.57', 'spread': '15.20', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-3.43', 'spread': '16.51', 'groupId': 'OG004'}, {'value': '-2.05', 'spread': '14.11', 'groupId': 'OG005'}, {'value': '-7.45', 'spread': '11.74', 'groupId': 'OG006'}, {'value': '-2.36', 'spread': '17.85', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-4.29', 'spread': '13.12', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2: OSP (n=67,0,68,0,68,73,72,78,0,65,0)', 'categories': [{'measurements': [{'value': '-2.94', 'spread': '10.26', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-7.76', 'spread': '14.28', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-4.93', 'spread': '14.92', 'groupId': 'OG004'}, {'value': '-3.75', 'spread': '12.36', 'groupId': 'OG005'}, {'value': '-7.06', 'spread': '10.93', 'groupId': 'OG006'}, {'value': '-4.07', 'spread': '15.98', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-3.30', 'spread': '12.13', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2: Ade (n=68,0,68,0,68,73,72,79,0,66,0)', 'categories': [{'measurements': [{'value': '-3.68', 'spread': '22.72', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '5.74', 'spread': '21.04', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '6.76', 'spread': '25.06', 'groupId': 'OG004'}, {'value': '3.70', 'spread': '26.11', 'groupId': 'OG005'}, {'value': '7.64', 'spread': '16.74', 'groupId': 'OG006'}, {'value': '-0.51', 'spread': '28.68', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '3.18', 'spread': '19.70', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,66,0)', 'categories': [{'measurements': [{'value': '-0.29', 'spread': '19.70', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-5.29', 'spread': '20.62', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '0.29', 'spread': '25.27', 'groupId': 'OG004'}, {'value': '5.48', 'spread': '21.15', 'groupId': 'OG005'}, {'value': '-6.03', 'spread': '21.78', 'groupId': 'OG006'}, {'value': '0.00', 'spread': '20.51', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-5.76', 'spread': '25.24', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2: SD (n=68,0,68,0,68,73,73,79,0,65,0)', 'categories': [{'measurements': [{'value': '-5.64', 'spread': '13.23', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-9.89', 'spread': '17.97', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-6.82', 'spread': '18.04', 'groupId': 'OG004'}, {'value': '-6.73', 'spread': '15.61', 'groupId': 'OG005'}, {'value': '-8.77', 'spread': '15.11', 'groupId': 'OG006'}, {'value': '-7.85', 'spread': '20.80', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-2.81', 'spread': '17.05', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0)', 'categories': [{'measurements': [{'value': '-0.10', 'spread': '0.52', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-0.01', 'spread': '0.47', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '0.04', 'spread': '0.44', 'groupId': 'OG004'}, {'value': '0.07', 'spread': '0.56', 'groupId': 'OG005'}, {'value': '0.04', 'spread': '0.54', 'groupId': 'OG006'}, {'value': '-0.05', 'spread': '0.53', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '0.08', 'spread': '0.36', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2: Qua (n=68,0,67,0,68,73,73,77,0,66,0)', 'categories': [{'measurements': [{'value': '-0.13', 'spread': '1.21', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '0.03', 'spread': '1.07', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-0.69', 'spread': '7.75', 'groupId': 'OG004'}, {'value': '-0.21', 'spread': '3.75', 'groupId': 'OG005'}, {'value': '0.41', 'spread': '1.21', 'groupId': 'OG006'}, {'value': '-0.09', 'spread': '1.16', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '0.36', 'spread': '0.99', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2: Sno (n=67,0,68,0,67,73,73,79,0,66,0)', 'categories': [{'measurements': [{'value': '3.28', 'spread': '22.99', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '0.29', 'spread': '22.26', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-7.46', 'spread': '21.97', 'groupId': 'OG004'}, {'value': '-4.66', 'spread': '23.46', 'groupId': 'OG005'}, {'value': '-4.11', 'spread': '21.33', 'groupId': 'OG006'}, {'value': '-4.05', 'spread': '23.62', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '0.91', 'spread': '23.91', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2: Som (n=67,0,68,0,68,73,73,77,0,66,0)', 'categories': [{'measurements': [{'value': '-3.18', 'spread': '18.47', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-5.00', 'spread': '18.33', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-1.37', 'spread': '18.05', 'groupId': 'OG004'}, {'value': '-0.73', 'spread': '16.20', 'groupId': 'OG005'}, {'value': '-2.74', 'spread': '15.79', 'groupId': 'OG006'}, {'value': '-3.03', 'spread': '17.76', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-2.22', 'spread': '18.47', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: SPS (n=62,0,59,0,63,65,63,70,0,61,0)', 'categories': [{'measurements': [{'value': '-5.54', 'spread': '12.21', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-10.51', 'spread': '20.72', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-3.97', 'spread': '18.57', 'groupId': 'OG004'}, {'value': '-2.00', 'spread': '19.98', 'groupId': 'OG005'}, {'value': '-5.19', 'spread': '19.19', 'groupId': 'OG006'}, {'value': '-4.62', 'spread': '17.24', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-2.95', 'spread': '18.20', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: OSP (n=62,0,59,0,63,65,63,69,0,61,0)', 'categories': [{'measurements': [{'value': '-7.27', 'spread': '11.71', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-11.21', 'spread': '18.59', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-5.59', 'spread': '18.71', 'groupId': 'OG004'}, {'value': '-3.64', 'spread': '18.32', 'groupId': 'OG005'}, {'value': '-5.63', 'spread': '17.18', 'groupId': 'OG006'}, {'value': '-6.42', 'spread': '15.31', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-3.03', 'spread': '17.70', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: Ade (n=62,0,59,0,63,65,63,70,0,61,0)', 'categories': [{'measurements': [{'value': '1.45', 'spread': '22.39', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '11.19', 'spread': '27.55', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '5.87', 'spread': '27.51', 'groupId': 'OG004'}, {'value': '4.77', 'spread': '29.32', 'groupId': 'OG005'}, {'value': '6.51', 'spread': '25.15', 'groupId': 'OG006'}, {'value': '6.57', 'spread': '32.16', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '0.82', 'spread': '23.47', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0)', 'categories': [{'measurements': [{'value': '-3.87', 'spread': '24.52', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-7.46', 'spread': '24.89', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '3.81', 'spread': '28.70', 'groupId': 'OG004'}, {'value': '2.46', 'spread': '26.10', 'groupId': 'OG005'}, {'value': '-2.81', 'spread': '23.87', 'groupId': 'OG006'}, {'value': '1.43', 'spread': '24.15', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-1.97', 'spread': '25.22', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0)', 'categories': [{'measurements': [{'value': '-9.74', 'spread': '16.98', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-13.43', 'spread': '22.93', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-9.25', 'spread': '23.07', 'groupId': 'OG004'}, {'value': '-6.73', 'spread': '22.54', 'groupId': 'OG005'}, {'value': '-8.22', 'spread': '20.59', 'groupId': 'OG006'}, {'value': '-8.45', 'spread': '18.59', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-2.97', 'spread': '21.46', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0)', 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.54', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '0.07', 'spread': '0.61', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '0.03', 'spread': '0.64', 'groupId': 'OG004'}, {'value': '0.08', 'spread': '0.62', 'groupId': 'OG005'}, {'value': '-0.05', 'spread': '0.57', 'groupId': 'OG006'}, {'value': '0.01', 'spread': '0.58', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-0.08', 'spread': '0.53', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: Qua (n=62,0,57,0,63,65,64,68,0,61,0)', 'categories': [{'measurements': [{'value': '0.16', 'spread': '1.43', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '0.40', 'spread': '1.32', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-0.73', 'spread': '8.24', 'groupId': 'OG004'}, {'value': '-0.42', 'spread': '3.80', 'groupId': 'OG005'}, {'value': '0.28', 'spread': '1.52', 'groupId': 'OG006'}, {'value': '0.74', 'spread': '5.57', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '1.33', 'spread': '9.25', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0)', 'categories': [{'measurements': [{'value': '0.66', 'spread': '22.20', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-0.34', 'spread': '27.67', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-2.54', 'spread': '28.85', 'groupId': 'OG004'}, {'value': '-2.15', 'spread': '26.25', 'groupId': 'OG005'}, {'value': '1.56', 'spread': '24.25', 'groupId': 'OG006'}, {'value': '-1.14', 'spread': '22.04', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-3.28', 'spread': '19.38', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12: Som (n=62,0,59,0,63,65,64,68,0,61,0)', 'categories': [{'measurements': [{'value': '-6.56', 'spread': '18.60', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '-6.33', 'spread': '19.08', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '-1.06', 'spread': '19.20', 'groupId': 'OG004'}, {'value': '1.54', 'spread': '23.06', 'groupId': 'OG005'}, {'value': '-2.81', 'spread': '20.33', 'groupId': 'OG006'}, {'value': '-4.90', 'spread': '20.72', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '-4.37', 'spread': '21.56', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: SPS (n=40,20,44,13,55,64,58,52,12,34,17)', 'categories': [{'measurements': [{'value': '-8.25', 'spread': '15.47', 'groupId': 'OG000'}, {'value': '-0.50', 'spread': '15.83', 'groupId': 'OG001'}, {'value': '-11.97', 'spread': '19.23', 'groupId': 'OG002'}, {'value': '-6.92', 'spread': '18.13', 'groupId': 'OG003'}, {'value': '-4.12', 'spread': '20.03', 'groupId': 'OG004'}, {'value': '-3.33', 'spread': '16.38', 'groupId': 'OG005'}, {'value': '-8.62', 'spread': '18.34', 'groupId': 'OG006'}, {'value': '-7.82', 'spread': '18.23', 'groupId': 'OG007'}, {'value': '-3.33', 'spread': '20.84', 'groupId': 'OG008'}, {'value': '-6.27', 'spread': '19.96', 'groupId': 'OG009'}, {'value': '-2.16', 'spread': '16.71', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: OSP (n=40,20,44,13,55,64,58,51,12,34,17)', 'categories': [{'measurements': [{'value': '-10.18', 'spread': '14.38', 'groupId': 'OG000'}, {'value': '-2.81', 'spread': '14.39', 'groupId': 'OG001'}, {'value': '-12.16', 'spread': '17.87', 'groupId': 'OG002'}, {'value': '-8.50', 'spread': '16.00', 'groupId': 'OG003'}, {'value': '-6.04', 'spread': '19.83', 'groupId': 'OG004'}, {'value': '-4.83', 'spread': '16.17', 'groupId': 'OG005'}, {'value': '-9.82', 'spread': '16.06', 'groupId': 'OG006'}, {'value': '-9.24', 'spread': '18.00', 'groupId': 'OG007'}, {'value': '-3.38', 'spread': '18.83', 'groupId': 'OG008'}, {'value': '-6.01', 'spread': '18.67', 'groupId': 'OG009'}, {'value': '-1.96', 'spread': '18.70', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: Ade (n=40,20,44,13,55,64,58,52,12,34,17)', 'categories': [{'measurements': [{'value': '7.75', 'spread': '26.36', 'groupId': 'OG000'}, {'value': '-6.00', 'spread': '25.42', 'groupId': 'OG001'}, {'value': '11.59', 'spread': '24.30', 'groupId': 'OG002'}, {'value': '9.23', 'spread': '23.97', 'groupId': 'OG003'}, {'value': '8.00', 'spread': '28.11', 'groupId': 'OG004'}, {'value': '6.72', 'spread': '29.33', 'groupId': 'OG005'}, {'value': '5.52', 'spread': '26.70', 'groupId': 'OG006'}, {'value': '11.92', 'spread': '32.36', 'groupId': 'OG007'}, {'value': '-1.67', 'spread': '39.73', 'groupId': 'OG008'}, {'value': '-1.18', 'spread': '29.72', 'groupId': 'OG009'}, {'value': '8.82', 'spread': '19.00', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17)', 'categories': [{'measurements': [{'value': '-3.50', 'spread': '20.20', 'groupId': 'OG000'}, {'value': '-7.00', 'spread': '29.22', 'groupId': 'OG001'}, {'value': '-11.36', 'spread': '27.42', 'groupId': 'OG002'}, {'value': '-1.54', 'spread': '26.41', 'groupId': 'OG003'}, {'value': '-3.27', 'spread': '24.27', 'groupId': 'OG004'}, {'value': '0.63', 'spread': '24.94', 'groupId': 'OG005'}, {'value': '-10.17', 'spread': '25.56', 'groupId': 'OG006'}, {'value': '-5.38', 'spread': '19.45', 'groupId': 'OG007'}, {'value': '-6.67', 'spread': '21.46', 'groupId': 'OG008'}, {'value': '-11.18', 'spread': '21.57', 'groupId': 'OG009'}, {'value': '3.53', 'spread': '26.68', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17)', 'categories': [{'measurements': [{'value': '-13.66', 'spread': '18.64', 'groupId': 'OG000'}, {'value': '-6.31', 'spread': '17.76', 'groupId': 'OG001'}, {'value': '-15.88', 'spread': '24.63', 'groupId': 'OG002'}, {'value': '-13.75', 'spread': '21.22', 'groupId': 'OG003'}, {'value': '-6.59', 'spread': '25.51', 'groupId': 'OG004'}, {'value': '-6.64', 'spread': '22.53', 'groupId': 'OG005'}, {'value': '-13.98', 'spread': '18.70', 'groupId': 'OG006'}, {'value': '-8.94', 'spread': '22.39', 'groupId': 'OG007'}, {'value': '-7.19', 'spread': '18.41', 'groupId': 'OG008'}, {'value': '-7.06', 'spread': '23.78', 'groupId': 'OG009'}, {'value': '-1.18', 'spread': '27.63', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17)', 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.51', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.65', 'groupId': 'OG001'}, {'value': '0.07', 'spread': '0.62', 'groupId': 'OG002'}, {'value': '-0.08', 'spread': '0.64', 'groupId': 'OG003'}, {'value': '0.02', 'spread': '0.62', 'groupId': 'OG004'}, {'value': '0.08', 'spread': '0.65', 'groupId': 'OG005'}, {'value': '-0.05', 'spread': '0.53', 'groupId': 'OG006'}, {'value': '0.02', 'spread': '0.54', 'groupId': 'OG007'}, {'value': '0.00', 'spread': '0.74', 'groupId': 'OG008'}, {'value': '-0.08', 'spread': '0.60', 'groupId': 'OG009'}, {'value': '-0.06', 'spread': '0.56', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: Qua (n=40,20,43,13,55,64,59,51,11,35,17)', 'categories': [{'measurements': [{'value': '-0.10', 'spread': '1.26', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '1.65', 'groupId': 'OG001'}, {'value': '0.35', 'spread': '1.56', 'groupId': 'OG002'}, {'value': '0.38', 'spread': '1.66', 'groupId': 'OG003'}, {'value': '0.33', 'spread': '2.13', 'groupId': 'OG004'}, {'value': '-0.42', 'spread': '3.97', 'groupId': 'OG005'}, {'value': '0.31', 'spread': '1.44', 'groupId': 'OG006'}, {'value': '0.08', 'spread': '1.04', 'groupId': 'OG007'}, {'value': '3.36', 'spread': '13.89', 'groupId': 'OG008'}, {'value': '0.29', 'spread': '1.45', 'groupId': 'OG009'}, {'value': '0.24', 'spread': '1.25', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: Sno (n=40,19,44,13,54,64,59,52,12,34,17)', 'categories': [{'measurements': [{'value': '3.50', 'spread': '25.17', 'groupId': 'OG000'}, {'value': '-1.05', 'spread': '23.55', 'groupId': 'OG001'}, {'value': '2.73', 'spread': '28.48', 'groupId': 'OG002'}, {'value': '6.15', 'spread': '18.95', 'groupId': 'OG003'}, {'value': '-7.04', 'spread': '24.92', 'groupId': 'OG004'}, {'value': '0.31', 'spread': '28.84', 'groupId': 'OG005'}, {'value': '2.37', 'spread': '22.92', 'groupId': 'OG006'}, {'value': '1.54', 'spread': '28.79', 'groupId': 'OG007'}, {'value': '5.00', 'spread': '30.90', 'groupId': 'OG008'}, {'value': '-6.47', 'spread': '26.84', 'groupId': 'OG009'}, {'value': '-1.18', 'spread': '11.11', 'groupId': 'OG010'}]}]}, {'title': 'Week 24: Som (n=40,20,44,13,55,64,59,51,11,34,17)', 'categories': [{'measurements': [{'value': '-5.33', 'spread': '21.94', 'groupId': 'OG000'}, {'value': '0.67', 'spread': '18.34', 'groupId': 'OG001'}, {'value': '-2.58', 'spread': '20.29', 'groupId': 'OG002'}, {'value': '-4.10', 'spread': '15.04', 'groupId': 'OG003'}, {'value': '-2.18', 'spread': '21.08', 'groupId': 'OG004'}, {'value': '-1.04', 'spread': '20.03', 'groupId': 'OG005'}, {'value': '-6.55', 'spread': '20.02', 'groupId': 'OG006'}, {'value': '-6.80', 'spread': '21.19', 'groupId': 'OG007'}, {'value': '-4.24', 'spread': '18.68', 'groupId': 'OG008'}, {'value': '-7.06', 'spread': '17.36', 'groupId': 'OG009'}, {'value': '-2.35', 'spread': '15.45', 'groupId': 'OG010'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 12, 24/ET', 'description': 'Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 subscales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range: 0-100); sleep quantity (Qua) (range: 0-24), and optimal (Opt) sleep (yes: 1, no: 0) and 9 item index measures of sleep disturbance were constructed to provide 2 composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range\\*100); total score range: 0 to 100; higher score = greater intensity of attribute.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '68', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '71', 'groupId': 'OG004'}, {'value': '73', 'groupId': 'OG005'}, {'value': '75', 'groupId': 'OG006'}, {'value': '79', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '69', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Baseline (n=70,0,68,0,71,73,75,79,0,69,0)', 'categories': [{'measurements': [{'value': '28.17', 'spread': '10.50', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '29.92', 'spread': '11.98', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '28.76', 'spread': '10.42', 'groupId': 'OG004'}, {'value': '30.06', 'spread': '10.85', 'groupId': 'OG005'}, {'value': '29.48', 'spread': '10.19', 'groupId': 'OG006'}, {'value': '29.76', 'spread': '11.02', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '32.23', 'spread': '11.13', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 2 (n=68,0,68,0,68,73,73,78,0,66,0)', 'categories': [{'measurements': [{'value': '30.41', 'spread': '12.01', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '32.65', 'spread': '10.64', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '32.46', 'spread': '11.78', 'groupId': 'OG004'}, {'value': '32.51', 'spread': '10.58', 'groupId': 'OG005'}, {'value': '33.41', 'spread': '10.10', 'groupId': 'OG006'}, {'value': '33.36', 'spread': '10.93', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '33.88', 'spread': '8.90', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12 (n=61,0,59,0,63,65,64,69,0,61,0)', 'categories': [{'measurements': [{'value': '33.25', 'spread': '10.80', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '35.44', 'spread': '11.16', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '34.30', 'spread': '10.87', 'groupId': 'OG004'}, {'value': '33.17', 'spread': '9.43', 'groupId': 'OG005'}, {'value': '35.05', 'spread': '10.17', 'groupId': 'OG006'}, {'value': '33.99', 'spread': '11.61', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '35.42', 'spread': '10.04', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 24 (n=39,20,44,13,55,64,59,51,12,35,17)', 'categories': [{'measurements': [{'value': '36.69', 'spread': '10.42', 'groupId': 'OG000'}, {'value': '28.08', 'spread': '11.07', 'groupId': 'OG001'}, {'value': '35.48', 'spread': '11.66', 'groupId': 'OG002'}, {'value': '34.92', 'spread': '9.40', 'groupId': 'OG003'}, {'value': '36.78', 'spread': '10.75', 'groupId': 'OG004'}, {'value': '35.36', 'spread': '10.01', 'groupId': 'OG005'}, {'value': '36.80', 'spread': '9.85', 'groupId': 'OG006'}, {'value': '38.24', 'spread': '9.46', 'groupId': 'OG007'}, {'value': '29.50', 'spread': '12.27', 'groupId': 'OG008'}, {'value': '37.17', 'spread': '10.12', 'groupId': 'OG009'}, {'value': '37.47', 'spread': '9.87', 'groupId': 'OG010'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 12, 24/ET', 'description': "FACIT-Fatigue scale (FS) is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-FS score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.", 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET', 'denoms': [{'units': 'Participants', 'counts': [{'value': '68', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '68', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '68', 'groupId': 'OG004'}, {'value': '72', 'groupId': 'OG005'}, {'value': '73', 'groupId': 'OG006'}, {'value': '78', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '66', 'groupId': 'OG009'}, {'value': '17', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG002', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG004', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG005', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG006', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'OG007', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG008', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'OG009', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'OG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'classes': [{'title': 'Week 2 (n=68,0,68,0,68,72,73,78,0,66,0)', 'categories': [{'measurements': [{'value': '1.96', 'spread': '7.99', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '2.74', 'spread': '7.80', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '3.54', 'spread': '7.71', 'groupId': 'OG004'}, {'value': '2.80', 'spread': '7.40', 'groupId': 'OG005'}, {'value': '3.68', 'spread': '7.24', 'groupId': 'OG006'}, {'value': '3.37', 'spread': '6.56', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '1.61', 'spread': '6.21', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 12 (n=61,0,59,0,63,65,64,69,0,61,0)', 'categories': [{'measurements': [{'value': '4.82', 'spread': '8.53', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG001'}, {'value': '5.79', 'spread': '10.95', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG003'}, {'value': '4.90', 'spread': '8.98', 'groupId': 'OG004'}, {'value': '2.18', 'spread': '9.25', 'groupId': 'OG005'}, {'value': '5.41', 'spread': '9.02', 'groupId': 'OG006'}, {'value': '4.51', 'spread': '9.27', 'groupId': 'OG007'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG008'}, {'value': '2.71', 'spread': '9.94', 'groupId': 'OG009'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.', 'groupId': 'OG010'}]}]}, {'title': 'Week 24 (n=39,20,44,13,55,64,59,50,12,35,17)', 'categories': [{'measurements': [{'value': '6.23', 'spread': '9.66', 'groupId': 'OG000'}, {'value': '3.73', 'spread': '10.35', 'groupId': 'OG001'}, {'value': '5.33', 'spread': '9.42', 'groupId': 'OG002'}, {'value': '5.62', 'spread': '11.57', 'groupId': 'OG003'}, {'value': '7.18', 'spread': '9.08', 'groupId': 'OG004'}, {'value': '4.49', 'spread': '9.43', 'groupId': 'OG005'}, {'value': '6.54', 'spread': '8.90', 'groupId': 'OG006'}, {'value': '6.88', 'spread': '9.28', 'groupId': 'OG007'}, {'value': '4.75', 'spread': '10.84', 'groupId': 'OG008'}, {'value': '3.23', 'spread': '12.13', 'groupId': 'OG009'}, {'value': '4.18', 'spread': '6.09', 'groupId': 'OG010'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 12, 24/ET', 'description': "FACIT-FS is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-FS score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.", 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 percent (%) reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'FG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'FG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'FG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'FG004', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'FG005', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'FG006', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'FG007', 'title': 'CP-690,550 1 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'FG008', 'title': 'CP-690,550 3 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'FG009', 'title': 'CP-690,550 20 mg to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}, {'id': 'FG010', 'title': 'Placebo to CP-690,550 5 mg (R)', 'description': 'Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.'}], 'periods': [{'title': 'Up To Week 12', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '71'}, {'groupId': 'FG001', 'numSubjects': '68'}, {'groupId': 'FG002', 'numSubjects': '71'}, {'groupId': 'FG003', 'numSubjects': '75'}, {'groupId': 'FG004', 'numSubjects': '75'}, {'groupId': 'FG005', 'numSubjects': '80'}, {'groupId': 'FG006', 'numSubjects': '69'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}]}, {'type': 'Treated', 'achievements': [{'groupId': 'FG000', 'numSubjects': '70'}, {'groupId': 'FG001', 'numSubjects': '68'}, {'groupId': 'FG002', 'numSubjects': '71'}, {'groupId': 'FG003', 'numSubjects': '74'}, {'groupId': 'FG004', 'numSubjects': '75'}, {'groupId': 'FG005', 'numSubjects': '80'}, {'groupId': 'FG006', 'numSubjects': '69'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '64'}, {'groupId': 'FG001', 'numSubjects': '61'}, {'groupId': 'FG002', 'numSubjects': '64'}, {'groupId': 'FG003', 'numSubjects': '67'}, {'groupId': 'FG004', 'numSubjects': '66'}, {'groupId': 'FG005', 'numSubjects': '70'}, {'groupId': 'FG006', 'numSubjects': '58'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '7'}, {'groupId': 'FG001', 'numSubjects': '7'}, {'groupId': 'FG002', 'numSubjects': '7'}, {'groupId': 'FG003', 'numSubjects': '8'}, {'groupId': 'FG004', 'numSubjects': '9'}, {'groupId': 'FG005', 'numSubjects': '10'}, {'groupId': 'FG006', 'numSubjects': '11'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '4'}, {'groupId': 'FG004', 'numSubjects': '6'}, {'groupId': 'FG005', 'numSubjects': '4'}, {'groupId': 'FG006', 'numSubjects': '1'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}]}, {'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '5'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '2'}, {'groupId': 'FG006', 'numSubjects': '2'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}]}, {'type': 'Randomized, Not Treated', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}]}, {'type': 'Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '6'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '4'}, {'groupId': 'FG006', 'numSubjects': '3'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}]}]}, {'title': 'Post Week 12', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '43'}, {'groupId': 'FG001', 'numSubjects': '48'}, {'groupId': 'FG002', 'numSubjects': '64'}, {'groupId': 'FG003', 'numSubjects': '67'}, {'groupId': 'FG004', 'numSubjects': '66'}, {'groupId': 'FG005', 'numSubjects': '57'}, {'groupId': 'FG006', 'numSubjects': '40'}, {'groupId': 'FG007', 'numSubjects': '21'}, {'groupId': 'FG008', 'numSubjects': '13'}, {'groupId': 'FG009', 'numSubjects': '13'}, {'groupId': 'FG010', 'numSubjects': '18'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '40'}, {'groupId': 'FG001', 'numSubjects': '44'}, {'groupId': 'FG002', 'numSubjects': '56'}, {'groupId': 'FG003', 'numSubjects': '66'}, {'groupId': 'FG004', 'numSubjects': '60'}, {'groupId': 'FG005', 'numSubjects': '54'}, {'groupId': 'FG006', 'numSubjects': '37'}, {'groupId': 'FG007', 'numSubjects': '21'}, {'groupId': 'FG008', 'numSubjects': '13'}, {'groupId': 'FG009', 'numSubjects': '12'}, {'groupId': 'FG010', 'numSubjects': '17'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '8'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '6'}, {'groupId': 'FG005', 'numSubjects': '3'}, {'groupId': 'FG006', 'numSubjects': '3'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '1'}, {'groupId': 'FG010', 'numSubjects': '1'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '4'}, {'groupId': 'FG005', 'numSubjects': '2'}, {'groupId': 'FG006', 'numSubjects': '2'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}]}, {'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '1'}, {'groupId': 'FG010', 'numSubjects': '0'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '1'}]}, {'type': 'Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '3'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '1'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'BG000'}, {'value': '68', 'groupId': 'BG001'}, {'value': '71', 'groupId': 'BG002'}, {'value': '74', 'groupId': 'BG003'}, {'value': '75', 'groupId': 'BG004'}, {'value': '80', 'groupId': 'BG005'}, {'value': '69', 'groupId': 'BG006'}, {'value': '507', 'groupId': 'BG007'}]}], 'groups': [{'id': 'BG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'BG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'BG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 24 weeks.'}, {'id': 'BG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 24 weeks.'}, {'id': 'BG004', 'title': 'CP-690,550 15 mg', 'description': 'CP-690,550 15 mg tablet orally twice daily for 24 weeks.'}, {'id': 'BG005', 'title': 'CP-690,550 20 mg', 'description': 'CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'BG006', 'title': 'Placebo', 'description': 'Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.'}, {'id': 'BG007', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Customized', 'classes': [{'title': '18 to 44 Years', 'categories': [{'measurements': [{'value': '15', 'groupId': 'BG000'}, {'value': '23', 'groupId': 'BG001'}, {'value': '19', 'groupId': 'BG002'}, {'value': '9', 'groupId': 'BG003'}, {'value': '14', 'groupId': 'BG004'}, {'value': '15', 'groupId': 'BG005'}, {'value': '17', 'groupId': 'BG006'}, {'value': '112', 'groupId': 'BG007'}]}]}, {'title': '45 to 64 Years', 'categories': [{'measurements': [{'value': '47', 'groupId': 'BG000'}, {'value': '31', 'groupId': 'BG001'}, {'value': '42', 'groupId': 'BG002'}, {'value': '49', 'groupId': 'BG003'}, {'value': '49', 'groupId': 'BG004'}, {'value': '49', 'groupId': 'BG005'}, {'value': '40', 'groupId': 'BG006'}, {'value': '307', 'groupId': 'BG007'}]}]}, {'title': 'Greater Than or Equal to (>=) 65 Years', 'categories': [{'measurements': [{'value': '8', 'groupId': 'BG000'}, {'value': '14', 'groupId': 'BG001'}, {'value': '10', 'groupId': 'BG002'}, {'value': '16', 'groupId': 'BG003'}, {'value': '12', 'groupId': 'BG004'}, {'value': '16', 'groupId': 'BG005'}, {'value': '12', 'groupId': 'BG006'}, {'value': '88', 'groupId': 'BG007'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '57', 'groupId': 'BG000'}, {'value': '52', 'groupId': 'BG001'}, {'value': '57', 'groupId': 'BG002'}, {'value': '55', 'groupId': 'BG003'}, {'value': '66', 'groupId': 'BG004'}, {'value': '63', 'groupId': 'BG005'}, {'value': '56', 'groupId': 'BG006'}, {'value': '406', 'groupId': 'BG007'}]}, {'title': 'Male', 'measurements': [{'value': '13', 'groupId': 'BG000'}, {'value': '16', 'groupId': 'BG001'}, {'value': '14', 'groupId': 'BG002'}, {'value': '19', 'groupId': 'BG003'}, {'value': '9', 'groupId': 'BG004'}, {'value': '17', 'groupId': 'BG005'}, {'value': '13', 'groupId': 'BG006'}, {'value': '101', 'groupId': 'BG007'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 509}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2007-01'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2013-01', 'dispFirstSubmitDate': '2009-04-06', 'completionDateStruct': {'date': '2008-08', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2013-01-14', 'studyFirstSubmitDate': '2006-12-18', 'dispFirstSubmitQcDate': '2009-10-07', 'resultsFirstSubmitDate': '2012-12-04', 'studyFirstSubmitQcDate': '2006-12-18', 'dispFirstPostDateStruct': {'date': '2009-10-12', 'type': 'ESTIMATED'}, 'lastUpdatePostDateStruct': {'date': '2013-01-18', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2012-12-04', 'studyFirstPostDateStruct': {'date': '2006-12-20', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2013-01-08', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2008-08', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12', 'timeFrame': 'Week 12', 'description': 'ACR20 response: \\>= 20% improvement in tender joints count (TJC); \\>= 20% improvement in swollen joints count (SJC); and \\>= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-Reactive Protein (CRP).'}], 'secondaryOutcomes': [{'measure': 'Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response', 'timeFrame': 'Week 2, 4, 6, 8, 16, 20, 24/Early Termination (ET)', 'description': 'ACR20 response: \\>= 20% improvement in TJC; \\>= 20% improvement in SJC; and \\>= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.'}, {'measure': 'Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response', 'timeFrame': 'Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'ACR50 response: \\>= 50% improvement in TJC or SJC and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.'}, {'measure': 'Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response', 'timeFrame': 'Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'ACR70 response: \\>= 70% improvement in TJC or SJC and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.'}, {'measure': 'Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve', 'timeFrame': 'Baseline up to Week 2, 4, 6, 8, 12', 'description': "ACR-n: calculated for each participant by taking the lowest percentage improvement in (1) SJC or (2) TJC or (3) the median of the remaining 5 components of the ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening. The area under the curve (AUC) for ACR-n is the measure of the area under the curve of the mean change from baseline in ACR-n. The trapezoidal rule was used to compute the AUC."}, {'measure': 'Tender Joints Count (TJC)', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.'}, {'measure': 'Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from baseline indicates an improvement.'}, {'measure': 'Swollen Joints Count (SJC)', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.'}, {'measure': 'Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. A negative value in change from baseline indicates an improvement.'}, {'measure': 'Patient Assessment of Arthritis Pain', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.'}, {'measure': 'Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.'}, {'measure': 'Patient Global Assessment (PtGA) of Arthritis', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.'}, {'measure': 'Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.'}, {'measure': 'Physician Global Assessment of Arthritis', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.'}, {'measure': 'Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.'}, {'measure': 'Health Assessment Questionnaire-Disability Index (HAQ-DI)', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.'}, {'measure': 'Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Change = scores at observation minus score at Baseline, and total possible score ranged from -3 to 3. A negative value in change from baseline indicates an improvement.'}, {'measure': 'C-Reactive Protein (CRP)', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 milligram per deciliter (mg/dL) to 10 mg/dL. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.'}, {'measure': 'Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultra-sensitive assay. Normal range of CRP is 0 mg/dL to 10 mg/dL. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.'}, {'measure': 'Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) less than or equal to (\\<=) 3.2 implied low disease activity and more than (\\>) 3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) less than (\\<) 2.6 = remission.'}, {'measure': 'Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET', 'timeFrame': 'Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \\<= 3.2 implied low disease activity and \\>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \\<2.6 = remission.'}, {'measure': 'Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP)', 'timeFrame': 'Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'Disease improvement was classified as good, moderate, and none based on improvement in DAS 28-3 (CRP) from baseline and present DAS 28-3 (CRP) score. Good: an improvement from baseline of \\>1.2 and a present score of \\<=3.2; none: an improvement of \\<=0.6 or \\>0.6 to \\<=1.2 with a present score of \\>5.1; remaining participants were classified as having moderate (Mod) improvement. Scores of good and moderate were considered to have therapeutic response.'}, {'measure': 'Percentage of Participants With Disease Remission Based on DAS28-3 (CRP)', 'timeFrame': 'Week 2, 4, 6, 8, 12, 16, 20, 24/ET', 'description': 'DAS28-3 (CRP) defined remission was classified as a score of \\<2.6.'}, {'measure': '36-Item Short-Form Health Survey (SF-36)', 'timeFrame': 'Baseline, Week 12, 24/ET', 'description': 'SF-36 is a standardized survey evaluating 8 domains (of 2 components \\[C\\]; physical \\[Ph\\] and mental \\[Mn\\]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical \\[R-P\\], role-emotional \\[R-E\\]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).'}, {'measure': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET', 'timeFrame': 'Baseline, Week 12, 24/ET', 'description': 'SF-36 is a standardized survey evaluating 8 domains (of 2 components \\[C\\]; physical \\[Ph\\] and mental \\[Mn\\]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical \\[R-P\\], role-emotional \\[R-E\\]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).'}, {'measure': 'Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score', 'timeFrame': 'Baseline, Week 12, 24/ET', 'description': 'EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.'}, {'measure': 'Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET', 'timeFrame': 'Baseline, Week 12, 24/ET', 'description': 'EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.'}, {'measure': 'Medical Outcome Study- Sleep Scale (MOS-SS)', 'timeFrame': 'Baseline, Week 2, 12, 24/ET', 'description': 'Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 subscales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range:0-100); sleep quantity (Qua)(range:0-24), and optimal (Opt) sleep (yes: 1, no: 0)and nine item index measures of sleep disturbance were constructed to provide composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range\\* 100); total score range: 0 to 100; higher score = greater intensity of attribute.'}, {'measure': 'Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET', 'timeFrame': 'Baseline, Week 2, 12, 24/ET', 'description': 'Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 subscales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range: 0-100); sleep quantity (Qua) (range: 0-24), and optimal (Opt) sleep (yes: 1, no: 0) and 9 item index measures of sleep disturbance were constructed to provide 2 composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range\\*100); total score range: 0 to 100; higher score = greater intensity of attribute.'}, {'measure': 'Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale', 'timeFrame': 'Baseline, Week 2, 12, 24/ET', 'description': "FACIT-Fatigue scale (FS) is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-FS score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status."}, {'measure': 'Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET', 'timeFrame': 'Baseline, Week 2, 12, 24/ET', 'description': "FACIT-FS is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-FS score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status."}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['DMARD therapy'], 'conditions': ['Arthritis, Rheumatoid']}, 'referencesModule': {'references': [{'pmid': '39192350', 'type': 'DERIVED', 'citation': 'Hetland ML, Strangfeld A, Bonfanti G, Soudis D, Deuring JJ, Edwards RA. Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib. Arthritis Res Ther. 2024 Aug 27;26(1):153. doi: 10.1186/s13075-024-03376-9.'}, {'pmid': '38958913', 'type': 'DERIVED', 'citation': 'Wright GC, Mysler E, Kwok K, Cadatal MJ, Germino R, Yndestad A, Kinch CD, Ogdie A. Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials. Rheumatol Ther. 2024 Oct;11(5):1135-1164. doi: 10.1007/s40744-024-00677-y. Epub 2024 Jul 3.'}, {'pmid': '36931693', 'type': 'DERIVED', 'citation': 'Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17.'}, {'pmid': '36601090', 'type': 'DERIVED', 'citation': 'Hansen KE, Mortezavi M, Nagy E, Wang C, Connell CA, Radi Z, Litman HJ, Adami G, Rossini M. Fracture in clinical studies of tofacitinib in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2022 Dec 27;14:1759720X221142346. doi: 10.1177/1759720X221142346. eCollection 2022.'}, {'pmid': '36600185', 'type': 'DERIVED', 'citation': 'Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, Connell CA, Wang C, Wu J, Menon S, Vranic I, Gomez-Reino JJ. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023 Mar;82(3):331-343. doi: 10.1136/ard-2022-222543. Epub 2022 Dec 5.'}, {'pmid': '36526796', 'type': 'DERIVED', 'citation': 'Winthrop KL, Yndestad A, Henrohn D, Danese S, Marsal S, Galindo M, Woolcott JC, Jo H, Kwok K, Shapiro AB, Jones TV, Diehl A, Su C, Panes J, Cohen SB. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatol Ther. 2023 Apr;10(2):357-373. doi: 10.1007/s40744-022-00507-z. Epub 2022 Dec 17.'}, {'pmid': '34870800', 'type': 'DERIVED', 'citation': 'Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6.'}, {'pmid': '33127856', 'type': 'DERIVED', 'citation': 'Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020 Oct;6(3):e001395. doi: 10.1136/rmdopen-2020-001395.'}, {'pmid': '32816215', 'type': 'DERIVED', 'citation': 'Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20.'}, {'pmid': '28941219', 'type': 'DERIVED', 'citation': 'Mariette X, Chen C, Biswas P, Kwok K, Boy MG. Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program. Arthritis Care Res (Hoboken). 2018 May;70(5):685-694. doi: 10.1002/acr.23421. Epub 2018 Apr 2.'}, {'pmid': '28143815', 'type': 'DERIVED', 'citation': 'Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017 Jul;76(7):1253-1262. doi: 10.1136/annrheumdis-2016-210457. Epub 2017 Jan 31.'}, {'pmid': '27156561', 'type': 'DERIVED', 'citation': 'Wallenstein GV, Kanik KS, Wilkinson B, Cohen S, Cutolo M, Fleischmann RM, Genovese MC, Gomez Reino J, Gruben D, Kremer J, Krishnaswami S, Lee EB, Pascual-Ramos V, Strand V, Zwillich SH. Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials. Clin Exp Rheumatol. 2016 May-Jun;34(3):430-42. Epub 2016 Apr 28.'}, {'pmid': '26275429', 'type': 'DERIVED', 'citation': 'Charles-Schoeman C, Burmester G, Nash P, Zerbini CA, Soma K, Kwok K, Hendrikx T, Bananis E, Fleischmann R. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2016 Jul;75(7):1293-301. doi: 10.1136/annrheumdis-2014-207178. Epub 2015 Aug 14.'}, {'pmid': '25047021', 'type': 'DERIVED', 'citation': 'Cohen S, Radominski SC, Gomez-Reino JJ, Wang L, Krishnaswami S, Wood SP, Soma K, Nduaka CI, Kwok K, Valdez H, Benda B, Riese R. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014 Nov;66(11):2924-37. doi: 10.1002/art.38779.'}, {'pmid': '22006202', 'type': 'DERIVED', 'citation': 'Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, Gruben D, Kanik KS, Krishnaswami S, Pascual-Ramos V, Wallenstein G, Zwillich SH. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 2012 Apr;64(4):970-81. doi: 10.1002/art.33419. Epub 2011 Oct 17.'}], 'seeAlsoLinks': [{'url': 'https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921025&StudyName=Comparison%20Of%206%20CP-690%2C550%20Doses%20Vs.Placebo%2C%20Each%20Combined%20With%20Methotrexate%2C%20For%20The%20Treatment%20Of%20Rheumatoid%20Arthritis', 'label': 'To obtain contact information for a study center near you, click here.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to determine the effectiveness and safety, over 6 months, of 6 dose regimens of CP-690,550, combined with methotrexate, for the treatment of adults with active rheumatoid arthritis.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Active rheumatoid arthritis\n* Inadequate response to stably dosed methotrexate\n\nExclusion Criteria:\n\n* Current therapy with any DMARD or biologic other than methotrexate'}, 'identificationModule': {'nctId': 'NCT00413660', 'briefTitle': 'Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis', 'organization': {'class': 'INDUSTRY', 'fullName': 'Pfizer'}, 'officialTitle': 'A Phase 2B, Randomized, Double Blind, Placebo-Controlled, Multicenter Study To Compare 6 Dose Regimens Of CP-690,550 Vs. Placebo, Each Combined With Methotrexate, Administered For 6 Months In The Treatment Of Subjects With Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate Alone', 'orgStudyIdInfo': {'id': 'A3921025'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'CP 690,550 1 mg BID', 'interventionNames': ['Drug: CP-690,550']}, {'type': 'EXPERIMENTAL', 'label': 'CP 690,550 10 mg BID', 'interventionNames': ['Drug: CP-690,550']}, {'type': 'EXPERIMENTAL', 'label': 'CP 690,550 15 mg', 'interventionNames': ['Drug: CP-690,550']}, {'type': 'EXPERIMENTAL', 'label': 'CP 690,550 3 mg BID', 'interventionNames': ['Drug: CP-690,550']}, {'type': 'EXPERIMENTAL', 'label': 'CP 690,550 5 mg BID', 'interventionNames': ['Drug: CP-690,550']}, {'type': 'EXPERIMENTAL', 'label': 'CP-690,550 20 mg QD', 'interventionNames': ['Drug: CP-690,550']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Dummy tablets', 'interventionNames': ['Other: placebo']}], 'interventions': [{'name': 'CP-690,550', 'type': 'DRUG', 'description': '4 blinded tablets administered BID', 'armGroupLabels': ['CP 690,550 1 mg BID']}, {'name': 'CP-690,550', 'type': 'DRUG', 'description': '4 blinded tablets administered BID', 'armGroupLabels': ['CP 690,550 10 mg BID']}, {'name': 'CP-690,550', 'type': 'DRUG', 'description': '4 blinded tablets administered BID', 'armGroupLabels': ['CP 690,550 15 mg']}, {'name': 'CP-690,550', 'type': 'DRUG', 'description': '4 blinded tablets administered BID', 'armGroupLabels': ['CP 690,550 3 mg BID']}, {'name': 'CP-690,550', 'type': 'DRUG', 'description': '4 blinded tablets administered BID', 'armGroupLabels': ['CP 690,550 5 mg BID']}, {'name': 'CP-690,550', 'type': 'DRUG', 'description': 'Oral tablets', 'armGroupLabels': ['CP-690,550 20 mg QD']}, {'name': 'placebo', 'type': 'OTHER', 'description': 'Placebo', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85234', 'city': 'Gilbert', 'state': 'Arizona', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 33.35283, 'lon': -111.78903}}, {'zip': '71913', 'city': 'Hot Springs', 'state': 'Arkansas', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 34.5037, 'lon': -93.05518}}, {'zip': '91786', 'city': 'Upland', 'state': 'California', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 34.09751, 'lon': -117.64839}}, {'zip': '80204', 'city': 'Denver', 'state': 'Colorado', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 39.73915, 'lon': -104.9847}}, {'zip': '19713', 'city': 'Newark', 'state': 'Delaware', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 39.68372, 'lon': -75.74966}}, {'zip': '32713', 'city': 'DeBary', 'state': 'Florida', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 28.88305, 'lon': -81.30868}}, {'zip': '32746', 'city': 'Lake Mary', 'state': 'Florida', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 28.75888, 'lon': -81.31784}}, {'zip': '34474', 'city': 'Ocala', 'state': 'Florida', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 29.1872, 'lon': -82.14009}}, {'zip': '32804', 'city': 'Orlando', 'state': 'Florida', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '33614', 'city': 'Tampa', 'state': 'Florida', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '33540', 'city': 'Zephyrhills', 'state': 'Florida', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 28.23362, 'lon': -82.18119}}, {'zip': '61103-3692', 'city': 'Rockford', 'state': 'Illinois', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 42.27113, 'lon': -89.094}}, {'zip': '61107', 'city': 'Rockford', 'state': 'Illinois', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 42.27113, 'lon': -89.094}}, {'zip': '52002', 'city': 'Dubuque', 'state': 'Iowa', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 42.50056, 'lon': -90.66457}}, {'zip': '21702', 'city': 'Frederick', 'state': 'Maryland', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 39.41427, 'lon': -77.41054}}, {'zip': '02115', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '12206-1043', 'city': 'Albany', 'state': 'New York', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 42.65258, 'lon': -73.75623}}, {'zip': '13905', 'city': 'Binghamton', 'state': 'New York', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 42.09869, 'lon': -75.91797}}, {'zip': '28210', 'city': 'Charlotte', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'zip': '27609', 'city': 'Raleigh', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 35.7721, 'lon': -78.63861}}, {'zip': '45402', 'city': 'Dayton', 'state': 'Ohio', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 39.75895, 'lon': -84.19161}}, {'zip': '19118', 'city': 'Philladelphia', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Pfizer Investigational Site'}, {'zip': '19611-1124', 'city': 'West Reading', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 40.3337, 'lon': -75.94743}}, {'zip': '29601', 'city': 'Greenville', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 34.85262, 'lon': -82.39401}}, {'zip': '78705', 'city': 'Austin', 'state': 'Texas', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 30.26715, 'lon': -97.74306}}, {'zip': '75231', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '75235', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '75150', 'city': 'Mesquite', 'state': 'Texas', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 32.7668, 'lon': -96.59916}}, {'zip': '98104', 'city': 'Seattle', 'state': 'Washington', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}, {'zip': '98122', 'city': 'Seattle', 'state': 'Washington', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}, {'zip': '98405-2308', 'city': 'Tacoma', 'state': 'Washington', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 47.25288, 'lon': -122.44429}}, {'zip': '98405', 'city': 'Tacoma', 'state': 'Washington', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 47.25288, 'lon': -122.44429}}, {'zip': '54650', 'city': 'Onalaska', 'state': 'Wisconsin', 'country': 'United States', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 43.88441, 'lon': -91.23514}}, {'zip': '(C1117ABH)', 'city': 'Capital Federal', 'state': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Pfizer Investigational Site'}, {'zip': 'C1013AAR', 'city': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': 'C1034ACO', 'city': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': 'C1426ABP', 'city': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': '74043-110', 'city': 'Goiânia', 'state': 'Goiás', 'country': 'Brazil', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': -16.67861, 'lon': -49.25389}}, {'zip': '74110-120', 'city': 'Goiânia', 'state': 'Goiás', 'country': 'Brazil', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': -16.67861, 'lon': -49.25389}}, {'zip': '80060-240', 'city': 'Curitiba', 'state': 'Paraná', 'country': 'Brazil', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': -25.42778, 'lon': -49.27306}}, {'zip': '80060-900', 'city': 'Curitiba', 'state': 'Paraná', 'country': 'Brazil', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': -25.42778, 'lon': -49.27306}}, {'zip': '04230-000', 'city': 'São Paulo', 'state': 'São Paulo', 'country': 'Brazil', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'zip': '05403-010', 'city': 'São Paulo', 'state': 'São Paulo', 'country': 'Brazil', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'zip': '1612', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '1709', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '2570017', 'city': 'Viña del Mar', 'state': 'Región de Valparaíso', 'country': 'Chile', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': -33.02457, 'lon': -71.55183}}, {'city': 'Providencia', 'state': 'RM', 'country': 'Chile', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': -33.43107, 'lon': -70.60454}}, {'zip': '7500922', 'city': 'Santiago', 'state': 'RM', 'country': 'Chile', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'city': 'Santiago', 'state': 'Santiago Metropolitan', 'country': 'Chile', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '656 91', 'city': 'Brno', 'country': 'Czechia', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 49.19522, 'lon': 16.60796}}, {'zip': '370 01', 'city': 'České Budějovice', 'country': 'Czechia', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 48.97447, 'lon': 14.47434}}, {'zip': '128 50', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '140 59', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '148 00', 'city': 'Praha 11 - Chodov', 'country': 'Czechia', 'facility': 'Pfizer Investigational Site'}, {'zip': '760 01', 'city': 'Zlín', 'country': 'Czechia', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 49.22645, 'lon': 17.67065}}, {'zip': 'H-1036', 'city': 'Budapest', 'country': 'Hungary', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': 'H-2921', 'city': 'Komárom', 'country': 'Hungary', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 47.74318, 'lon': 18.11913}}, {'zip': 'H-5000', 'city': 'Szolnok', 'country': 'Hungary', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 47.18066, 'lon': 20.19835}}, {'zip': 'H-8200', 'city': 'Veszprém', 'country': 'Hungary', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 47.09327, 'lon': 17.91149}}, {'zip': '14000', 'city': 'Mexico City', 'state': 'Mexico City', 'country': 'Mexico', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 19.42847, 'lon': -99.12766}}, {'zip': '58070', 'city': 'Morelia', 'state': 'Michoacán', 'country': 'Mexico', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 19.70078, 'lon': -101.18443}}, {'zip': '15-461', 'city': 'Bialystok', 'country': 'Poland', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 53.13333, 'lon': 23.16433}}, {'zip': '15-950', 'city': 'Bialystok', 'country': 'Poland', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 53.13333, 'lon': 23.16433}}, {'zip': '86-300', 'city': 'Grudziądz', 'country': 'Poland', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 53.48411, 'lon': 18.75366}}, {'zip': '60-773', 'city': 'Poznan', 'country': 'Poland', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 52.40692, 'lon': 16.92993}}, {'zip': '81-759', 'city': 'Sopot', 'country': 'Poland', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 54.4418, 'lon': 18.56003}}, {'zip': '02-256', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '50-088', 'city': 'Wroclaw', 'country': 'Poland', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}, {'zip': '81109', 'city': 'Bratislava', 'country': 'Slovakia', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 48.14816, 'lon': 17.10674}}, {'zip': '921 01', 'city': 'Piešťany', 'country': 'Slovakia', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 48.59479, 'lon': 17.82591}}, {'zip': '012 07', 'city': 'Žilina', 'country': 'Slovakia', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 49.22315, 'lon': 18.73941}}, {'zip': '15706', 'city': 'Santiago de Compostela', 'state': 'A Coruña', 'country': 'Spain', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 42.88052, 'lon': -8.54569}}, {'zip': '19002', 'city': 'Guadalajara', 'state': 'Guadalajara', 'country': 'Spain', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 40.62862, 'lon': -3.16185}}, {'zip': '28046', 'city': 'Madrid', 'state': 'Madrid', 'country': 'Spain', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '41014', 'city': 'Seville', 'state': 'Sevilla', 'country': 'Spain', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'zip': '551 85', 'city': 'Jönköping', 'country': 'Sweden', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 57.78145, 'lon': 14.15618}}, {'zip': '901 85', 'city': 'Umeå', 'country': 'Sweden', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 63.82842, 'lon': 20.25972}}, {'zip': '06100', 'city': 'Ankara', 'country': 'Turkey (Türkiye)', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 39.91987, 'lon': 32.85427}}, {'zip': '34098', 'city': 'Istanbul', 'country': 'Turkey (Türkiye)', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'zip': '35100', 'city': 'Izmir', 'country': 'Turkey (Türkiye)', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 38.41273, 'lon': 27.13838}}, {'zip': '35340', 'city': 'Izmir', 'country': 'Turkey (Türkiye)', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 38.41273, 'lon': 27.13838}}], 'overallOfficials': [{'name': 'Pfizer CT.gov Call Center', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Pfizer'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Pfizer', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}